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Chapter 1 
GENERAL INTRODUCTION 
/./ The hemolytic uremic syndrome 
The hemolytic uremic syndrome (HUS) is a clinical syndrome characterized by acute 
hemolytic anemia with fragmented erythrocytes, thrombocytopenia and acute renal failure 
[1]. This syndrome was described for the first time in five children by Gasser in 1955 [2]. 
Since then HUS has been reported from many parts of the world and the documentation of 
epidemics and sporadic cases of HUS made it possible to identify distinct subgroups of HUS, 
that differ in their clinical features, epidemiology, prognosis, etiology and pathogenesis. A 
classification based on etiology of HUS is given in Table 1 and further discussed below [3]. 
HUS can occur in children and in adults. In childhood it is one of the leading causes of acute 
renal failure in children in developed countries. HUS in children occurs mostly following an 
infection and can be divided in the so called typical, post diarrheal (D + ) HUS or atypical 
HUS, which is not preceded with acute diarrhea (D-)[4]. HUS in adults is an uncommon and 
heterogenous condition [3,5]. In adults it is mostly seen in association with drugs, such as 
oral anticonceptives [6,7], mitomycin С [8], OKT3 [9] or quinine [10,11]; post-
transplantation-associated in combination with or without cyclosporin A [12-17], or in 
association with pregnancy [18,19]; malignancy-associated in combination with or without 
chemotherapeutics [20,21], or as a complication of systemic diseases like systemic lupus 
erythematosus [22] and HIV infection [23,24]. The kidney is predominantly involved in the 
disease process of HUS. Histo-pathological examination of the kidney by Habib et al [25] 
reveals swollen endothelial cells which are sometimes detached from the glomerular basement 
membrane. Thrombi and fibrin depositions can be found in the lumen of glomerular 
capillaries; fibrin, platelets and amorphous material can accumulate in the subendothelial 
space. The distribution of damaged vessels in the kidney may vary. Several authors have 
reported that the thrombotic microangiopathic lesions are mostly confined to the glomeruli 
in children younger than 2 years [26,27]. In the kidneys of older children and in adults also 
arterioles and even interlobular arteries can be affected, which results in a worse prognosis. 
In the literature, HUS and thrombotic thrombocytopenic purpura (TTP), a disease more 
common in adults, are often discussed [28]. TTP resembles HUS histopathologically and 
clinically, but differs by the fact that fever and neurologic signs are more prominent than in 
HUS [28]. However, the variability of organ dysfunction in TTP and the occasional extra­
renal manifestations in HUS can sometimes make it very difficult to distinguish between the 
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diagnosis TTP or Η US. 
1.1.1 Typical or diarrhea-associated (D+) HUS in childhood 
HUS in childhood is mostly seen after a prodromal phase of acute, often, bloody gastro­
enteritis, the so called diarrhea-associated (D+) HUS [4]. D+ HUS is also called "typical", 
"classical" or "epidemical" form of HUS. This form is mostly diagnosed in children younger 
than 5 years of age (Figure 1). D+ HUS is rare in adults and often confused with TTP. 
However, elderly people may be another susceptible group for D+ HUS [29]. In most 
developed countries, this type of HUS is the leading cause of acute renal failure in children. 
Population-based studies have shown that the incidence of HUS vanes among countries. 
Incidence rates of 0.27-1.74 per 100.000 children < 15 years and 2 65-3.3 per 100.000 
children < 5 years have been reported from studies from Canada, United Kingdom and 
northern part of the United States [30-34]. The highest incidence of HUS, 21.7 per 100,000 
children < 15 years, has been reported from Argentina [35]. HUS is mostly diagnosed in 
the countries Argentina [36], South Africa [37,38], Canada [33], North-Western part of USA 
[30,39,40] and the Western part of Europe; Belgium [41], United Kingdom [42,43] and The 
Netherlands [44]. HUS occurs most frequently during the summer months, roughly from 
May till September (Figure 2). Boys and girls, who were previously healthy, are equally 
affected [36]. However, some studies show a slight increase of HUS in females [33,45]. 
Table 1. The etiology of the hemolytic uremic syndrome 
Infectious agents 
Diarrhea-associated (D + ) HUS Verocytotoxin-producing E coli [168| 
Shigella dy\enteriae [134,143] 
Neuraminidase-associated HUS Streptococcus pneumoniae 1145,146] 
Others HIV infection [23,24] 
Non-mfectious agents 
Idiopathic [5,144] 
Drugs 
Systemic diseases 
Pregnancy-associated [18,19] 
Malignancy-associated [20,21] 
Transplantation-associated [ 12,15-17] 
Inherited 
cyclosporin A [13,14], mitomycin С [8], oral 
anticonceptiva [6,7], OKT3 | 9 ] , quinine [ 11,12] 
systemic lupus erythematosus [22] 
autosomal dominant [147], recessive [151] 
cobalamin С deficiency [148,149] 
prostacyclin deficiency [155] 
complement abnormalities [153,154] 
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Figure 1. The age of patients with HUS, who were admitted to the Pediatric Nephrology department, 
University Hospital Nijmegen from 1974 till 1993. 
Figure 2. The month of admission of HUS patients, who were admitted to the Pediatric Nephrology 
department, University Hospital Nijmegen from 1974 till 1993. 
Clinical features 
Diarrhea precedes the onset of this typical HUS by 3 to 10 days [3]. The diarrhea may be 
watery and is often bloody and associated with vomiting, cramping abdominal pain and 
nausea. In most cases the diarrhea is mild, but in some severe cases patients may present 
with an acute abdomen, severe ileus and even an intestinal perforation. Family-members of 
the patients can have diarrhea as well. In most cases fever is absent. The acute phase of HUS 
develops very rapidly; the child appears to be unwell, pale, restless and irritable. In some 
cases mild jaundice can occur as a consequence of the acute hemolysis. Oliguria is usually 
present, but polyuria has been described as well. Signs of fluid overload, such as edema may 
occur. Thrombocytopenia is seen in the majority of patients on admission, but its duration 
may be brief. Petechiae and bruises are common, but frank bleeding is rare with the 
exception of the bleeding in the gut. On admission of the patient to the hospital, the liver 
may be tenderly enlarged. Somnolence and irritability is often considered as mild 
involvement of the central nervous system. But there are reports which mention severe 
neurological complications as coma, convulsions and cerebral edema in about 20% of the 
patients with HUS [46,47]. Occasionally pancreatic involvement has been reported in HUS 
[48-50]. Dilated cardiomyopathy is a rare but important extra-renal manifestation of HUS 
[51]. 
Laboratory features 
In patients with HUS, hemolytic anemia, i.e. low hemoglobin levels, reticulocytosis and 
decreased levels of free haptoglobin, is present. Depending on the degree of the hemolytic 
process, lactic dehydrogenase and unconjugated bilirubin will be increased. Characteristic are 
the morphological changes in some erythrocytes, the so called burr cells, helmet cells or 
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fragmentocytes The Coomb's test is negative Elevated numbers of leucocytes, mostly found 
in the acute phase, have been reported to correlate with the seventy of the syndrome [52] 
Platelet count is reduced on initial examination in the majority of patients, but occasionally 
it is found to be normal The duration of thrombocytopenia may be short and can be missed 
The thrombocytes show in vitro a low platelet aggregation These in vitro studies and the 
elevation of the platelet proteins /3-thromboglobulin, platelet factor 4 and serotonin in serum 
suggest, that the circulating thrombocytes are 'empty' and therefore functionally exhausted 
[53,54] Most of the patients have normal or minimally altered parameters of coagulation 
Fibnn(ogen) degradation products are reported to be increased in the serum of HUS patients 
as well as the levels of fibnnopeptide A, indicating an activation ot the intravascular 
coagulation [55] Anti-thrombin III levels are usually normal in HUS [56] Studies have 
reported an activation of the alternative complement pathway, causing low levels of C3 and 
the presence of increased degradation products of C3 and factor В [57,58] Usually the 
serum concentrations of urea and creatinine are elevated and may rise rapidly in the acute 
phase of the disease Occasionally, elevated levels of bilirubin and hepatic transaminases are 
found The urine always contains protein and erythrocytes 
Pathology 
In the original cases described by Gasser et al massive bilateral cortical necrosis was seen 
[2] In the majority of the kidneys from diarrhea associated HUS patients the main feature 
is the alteration of the glomerular capillaries thickening of the capillary wall which results 
in narrowing ol the lumen Endothelial cells are swollen and become detached from the 
basement membrane Fibrin deposits are seen in the glomerular capillaries and subendothehal 
spaces [25,59] Often an expanded mesangium has been described [60] IgM and ГЗ can 
occasionally be found in glomerular mesangium [61] Although extra renal manifestations are 
more commonly associated with TTP and D HUS than D+ HUS, microthrombi have been 
be found in a wide distribution of organs other than the kidney after post-mortem 
examination in most cases of HUS [36,62,63] Gianantonio and co-workers reported that non­
renal thrombi in small vessels were found in autopsy materials from 20 out of 47 patients 
[36] In a group of 15 children with HUS reported by Upadhyaya and co-workers autopsy 
was performed in three patients All three patients had severe neurological symptoms, 
including coma and uncontrollable seizures [62] Evidence ot myocard involvement was 
observed in one ot the three patients Microthrombi consisting of fibrin with occasionally 
enmeshed leucocytes were found in kidney, lung, heart, liver, adrenal glands, brain, thyroid, 
pancreas, colon, lymph nodes, thymus, and bladder Focal areas ot infarction with 
surrounding edema and necrosis were seen in the cerebral cortex of all three patients Non­
renal involvement (pancreas, heart, brain, adrenal glands and lungs) has also been described 
in the pathology reports of ten out of sixteen Dutch patients studied by van Wienngen [63] 
Pathogenesis 
Although the exact pathogenesis ot HUS is still unknown, a lot of progress in understanding 
has been made in the past decade Endothelium damage in the kidney plays a central role in 
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the pathogenesis of HUS, leading to a shift in the hemostatic balance of the kidney towards 
thrombosis Microthrombi have also been noted in other organs, such as colon, heart and 
brain [36,62] Elevation of von Willebrand factor (vWF) antigen in the plasma has been 
considered as evidence of endothelial damage Patients with HUS in the acute phase have 
high levels of high molecular weight vWF multimers in their plasma [64-66] These vWF 
forms can react with activated platelets in the circulation, which in turn leads to platelet 
aggregation Rose and co-workers [67] examined the factor VIII-vWF protein and 
demonstrated that vWF in plasma of HUS and in other vasculitides resembled the endothelial 
form of vWF in being resistant to reduction by dithiothreitol (DTT), in contrast to vWF from 
plasma of normal subjects A number of vasoactive substances stimulate the endothelium to 
release these multimers ot vWF from storage granules In vitro studies have shown that 
plasma may be able to correct ultra-large vWF (ULvWF) torms into rather smaller forms of 
vWF multimers by a "ULvWF reductase" or by neutrophil-denved elastase [68,69] 
Recently, Moake hypothesized that in the acute phase in HUS patients, endothelial cell injury 
or intense stimulation of endothelial cells causing ULvWF release may overwhelm the 
"reducing capacity" of the plasma Platelets exposed to the thrombogenic subendothelial 
matrix bind to ULvWF and become activated [70,71] Immune mediated endothelial cell 
damage is important in the pathogenesis of several vasculitides and may contribute to high 
molecular vWF in plasma [67] In both HUS and other vasculitides plasma anti-endothehal 
cell antibodies have been detected [72] Leung et al suggested that these antibodies contribute 
to endothelial damage [72] 
Most HUS patients have an increase in the number of neutrophils A significant 
relationship in HUS exist between the neutrophil count on admission and adverse outcome 
[52,73] Fitzpatnck and co-workers have reported elevated plasma levels of the inactivated 
product of neutrophils, elastase in complex with αϊ antitrypsin, in the acute phase of the 
disease Because it is rapidly bound to cell-surfaces or inhibitors in plasma, free neutrophil 
elastase is, in contrast to al-antitrypsin-complexed elastase, not detectable in plasma [74] 
Using a radio-immuno-assay which measures both free and bound human neutrophil elastase, 
Milford's study has shown that children with a poor outcome had significantly higher plasma 
elastase concentrations than those who had a good outcome [75] Forsyth et al demonstrated 
that neutrophils isolated from plasma of HUS patients taken in the acute phase, adhered more 
stronger to cultured endothelial cells than control neutrophils [76] The involvement of 
neutrophils in the pathogenesis of HUS is also suggested by the elevated plasma levels of the 
cytokine interleukm-8 in HUS [77] Interleukin 8, produced mainly by activated 
macrophages, but also by endothelial cells, is a chemoattractant and activator of neutrophils 
and is a potential mediator of host response to injury and infection [78-80] Activated 
neutrophils and the local release of proteases and peroxides by them may contribute to the 
endothelial injury seen in HUS [77,81,82] 
Several studies have demonstrated abnormal lipid peroxidation in HUS patients [83-85] 
Formation of lipid peroxides may occur when oxygen derived free radicals interact with 
lipids Elevated levels of conjugated diene lipids, a marker for lipid peroxidation, have been 
detected in the plasma of HUS [86] Decreased concentration of phosphoethanolamine and 
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a reduction in arachidonic acid content in erythrocyte membranes in HUS may be the 
consequence of free radical injury [83,87]. In vitro studies have shown that lipid peroxides 
can damage the endothelium and may have procoagulant activity [88,89]. Recently, Turi et 
al demonstrated oxidative damage of erythrocytes in HUS patients [85]. The source of 
oxygen-derived-free radicals is yet not known but a likely candidate is the activated 
neutrophil. 
Normal vascular endothelium has the capacity to prevent thrombosis [90]. This capacity 
resides in the ability of the endothelium to inhibit the coagulation cascade, in particular by 
binding of antithrombin III and thrombomodulin-mediated activation of protein C; to reduce 
platelet activation by the production of prostacyclin, nitric oxide and ADP-degrading 
ectonucleotidases; and to stimulate fibrinolysis by the production of tissue-type plasminogen 
activator (t-PA) [91]. A disturbance in the balance between the coagulation and the 
fibrinolytic system in HUS causes the occurrence of persistent fibrin thrombi in several 
organs, including the glomerular capillaries of the kidneys [25,36,62]. The formation of 
fibrin is yet not clearly understood. Elevated levels of fibrinogen- and fibrin split- and 
degradation products, prothrombin fragments 1+2 and thrombin-antithrombin complexes 
indicate an active thrombin generation in the acute phase of HUS [55,92]. While t-PA 
activates the fibrinolytic system, the plasminogen activator inhibitor type I, (PAI-1), reduces 
its activity. PAI-1 is released from activated blood platelets and newly synthesized PAI-1 can 
be produced by endothelial cells after exposure to the inflammatory cytokines tumor necrosis 
factor a and interleukin-1 [91]. Bergstein et al [93] has reported an increase in plasma levels 
of PAI-1, which could be dramatically reduced by peritoneal dialysis. The removal of the 
inhibitor from the plasma by peritoneal dialysis was associated with improvement in renal 
function [93]. The role of the fibrinolytic system in HUS needs to be further investigated. 
Although there is no experimental model of HUS, rabbit studies of the generalized 
Shwartzman reaction, resulting in a model of glomerular thrombomicroangiopathy, may lead 
to a better understanding of the development of intravascular glomerular fibrin deposits in 
HUS [94,95]. 
Several interesting studies on the pathogenesis of thrombotic thrombocytopenic purpura 
(TTP) may be relevant and important for understanding the pathogenesis of HUS. Lian and 
coworkers have detected and purified a 37kDa platelet agglutinating protein (PAPp37) in the 
plasma of a subset of patients known with thrombotic thrombocytopenic purpura (TTP) 
[96,97]. In vitro studies have shown that this protein can agglutinate platelets without any co-
factor for its agglutinating activity. PAPp37 binds specifically to the membrane glycoprotein 
IV (GpIV), present on platelets and endothelial cells [98]. Another important serological 
factor in the platelet aggregation in TTP may be the presence of calpain activity (calcium-
dependent cysteine protease) in sera taken in the acute phase of TTP patients [99]. This 
calpain, associated with platelet microparticles in plasma from patients with TTP may modify 
the vWF and induce membrane expression of the vWF receptor GPIIb/IIIa on platelets 
leading to platelet aggregation [100]. Although no calpain activity has yet been found in 
patients with HUS (Murphy, personal communication) and no studies so far have looked for 
the presence of PAPp37 in HUS, earlier studies have shown that platelet aggregating factor 
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can be present in the plasma of D + HUS patients [101] 
During the last decade various publications with different, often contradictonary 
conclusions about the role of prostacyclin (PGI2), as platelet anti aggregatory factor, in HUS 
have been published [102] Prostacyclin, a major product of arachidonic acid (the most 
common poly unsaturable fatty acid in the phospholipids of the cell), is produced by the 
vascular endothelium Prostacyclin is an anti-platelet aggregator and a potent vasodilator 
Another lipid factor produced by the endothelium but mainly by platelets, is thromboxane 
A2 Thromboxane A2 is a platelet aggregator and a potent vasoconstrictor Both factors can 
not be measured directly in plasma because of their instability Inactive 6-keto-PGF,„ and 
thromboxane B2 are the measurable stable breakdown products of prostacyclin and 
thromboxane A2, respectively In 1978 Remuzzi's group was the first who reported that a 
plasma prostaclychn-stimulating factor was absent in two patients with HUS [103] This 
prostacychn-regulating plasma factor, acting as a reducing co factor for the cyclo oxygenase 
peroxidase, has been partially purified and identified as a stable and very polar molecule of 
300-400 Da [104] Several studies, including Remuzzi's, have been performed by incubating 
patient's plasma ex vivo on aortic rings or cultured endothelial cells [102] The chosen 
experimental conditions and preparations of cultured endothelial cells make the interpretation 
of these ex vivo experiments difficult [102,105] More recently other studies have reported 
an increased respectively decreased excretion of 6 keto-PGF,„in the urine during the acute 
phase of HUS [106,107] Although, under physiological conditions the presence of the 
metabolite 6-keto-PGF,, in urine may reflect renal prostacyclin synthesis, this may be 
different in renal failure in which the decreased blood-flow may result in an abnormal 
metabohzation and distribution of 6 keto-PGF,„ between the urine and renal venous blood 
[108,109] 
Benigny et al reported significantly elevated urinary levels of platelet aggregating factor 
(PAF) in children with HUS compared to the urinary PAF levels of healthy control children 
(measured in ng/mg creatinine)! 110] Control values of urinary PAF of children with chronic 
renal failure were missing in her study PAF, a phospholipid, is produced in platelets, 
endothelial cells, mesangial cells, and other cells It promotes platelet aggregation, impairs 
renal function and may play a role in the kidney failure in HUS Animal models have shown 
that elevated urinary levels of PAF may reflect increased production in the kidney [111] 
Another factor which may play a role in the renal failure observed in HUS is endothelin 
Endothelin is a protein produced by endothelial cells as well as mesangial and renal epithelial 
cells It is a potent vasocontnctor and may influence renal blood flow, and glomerular 
filtration rate Little circulating endothelin is cleared into the urine and the unnary endothelin 
is likely of renal origin [112] In the acute phase an increase in urinary levels of endothelin 
is observed in HUS patients compared to healthy controls [113] Both elevated urinary levels 
of PAF and endothelin return to normal values at convalescence [110,113] Urinary 
endothehn-1 is also reported to be elevated in patients with renal diseases [114] However, 
in Siegler's study no unnary levels of endothelin have been measured in a control group of 
children with renal diseases [113] Therefore good control values are still necessary to 
interpret the elevated levels of endothelin and PAF in unne of patients with HUS 
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Hemolytic anemia, characterized by fragmented erythrocytes, is generally presumed to 
be the result of mechanical cell injury by passing narrowed, partly occluded capillaries 
However, erythrocytes may also be vulnerable to injury by abnormal compositon of the 
erythrocyte membrane phospholipids [85] 
Treatment 
Since HUS has been reported by Gasser, there has been a reduction in mortality and 
morbidity of patients This is due to the fact that HUS is earlier recognized and supportively 
treated The risk of involvement of the central nervous system is reduced by the early started 
supportive treatment, consisting ot prompt treatment of acute renal failure by peritoneal 
dialysis or hemodialysis, correcting of electrolyte imbalance, and by treatment of 
hypertension To reverse the microangiopathic process in D+ HUS various controlled and 
uncontrolled trials with numerous agents have been undertaken [115] These trials included 
heparin [116-119], fibrinolytic agents [117,120-122], anti-platelet drugs [119,123], vitamin 
E [124], infusion of fresh frozen plasma [125,126], gamma-globulin [127,128] or 
prostacyclin [129,130], and plasmapheresis [131,132] However, the controlled trials have 
failed to demonstrate significant improvement [119,125,126] 
Prognosis 
The clinical course of HUS has been improved, possibly due to a belter management in the 
acute phase of the disease Although recent reports from Poland [133] and India [134] show 
mortality rates of 36 and 60% respectively, most series of follow-up studies in Europe and 
northern America report fatality-rates between 4% and 17% [36,41,135-142] Most cases of 
D+ HUS recover spontaneously by supportive treatment, although in various reports 5 to 
10% of the cases, in two reports even 16 and 21% [140,141] of the cases, there can still be 
some residual injury These abnormalities may be subtile and the long term complications 
may be unclear, but a number of these patients may develop hypertension or even chronic 
renal failure in later life [140] Risk factors for a poor outcome have been reported to be the 
severity of renal damage [36,137] and high levels of polymorphonuclear leucocytes in the 
acute phase [43,52] Nevertheless, the latest published follow-up study in Belgium reported 
that no variable during the acute phase was predictive of the presence of sequelae after 10 
years [142] 
Etiology 
During the years many different organisms have been described as being the infecting agent 
causing D+ HUS Most of the agents suggested as causes have occasionally been implicated 
and many have no causative role There is enough evidence that verocytotoxin-producing 
£ coli (VTEC) also called Shiga like toxin producing E coli (SLT-EC) play the major role 
in causing D+ HUS in childhood in Western Europe, Canada and USA The D+ HUS seen 
in India is mainly due to an infection with Shigella dysentencae type 1 and is usually 
associated with severe renal damage and a high death rate [134,143] 
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1.1.2 Atypical or diarrhea-negative (D-) HUS in childhood 
Hemolytic uremic syndrome has various etiologies (table 1) In children as well as in adults 
atypical or diarrhea-negative (D-) HUS is a heterogenous group D-HUS is rare in childhood 
and affects children of all ages In most cases the D- HUS develops without a prodromal 
illness and has no seasonal variation in time of onset [144] The D HUS, who have 
arteriolar injury have a much worse outcome and prognosis than D + HUS, who have a 
predominantly glomerular injury An infection with Streptococcus pneumonia can lead to the 
neuraminidase associated form of HUS [145,146] Circulating neuraminidase derived from 
the Streptococcus removes N-acetylneuraminic acid form glycoproteins in the cell membrane 
of erythrocytes, thrombocytes and endothelial cells This leads to an exposure of the 
antigenic Thomsen Friedreich antigen, allowing the binding of commonly present IgM 
antibodies to this antigen This may result in endothelial damage, hemolysis and agglutination 
of platelets In contrast to D+ HUS and other forms of D- HUS, the direct Coombs' test is 
positive in these patients, making transfusions with plasma impossible 
The non-inlectious agents in D-HUS in childhood are inherited or idiopathic [3,144] 
Recently, published studies demonstrate that there is an association between HUS and 
cobalamin С deficiency [148,149] This cobalamin С deficiency is a rare autosomal recessive 
disorder Intracellulair cobalamin С is a necessary co-enzyme in the conversion of 
homocysteine to methionine and of melhylmalonyl-CoA to succinyl-CoA Deficiency of 
cobalamin С will result in elevated levels of homocysteine and methylmalonyl CoA in plasma 
and urine Several in vivo and in vitro reports have demonstrated that elevated levels of 
homocysteine can damage the endothelium and induce a disbalance in the hemostatic system 
[150] Most studies of inherited forms of HUS have been done by Kaplan et al [151,152] 
In both children and adults recurrence of HUS may occur in these inherited forms Several 
autosomal recessive and dominant modes have been presumed while studying the families 
with a predisposition of HUS One study reported an association with HLA-haplotype A3.B7 
and hypocomplementemia in a family with predisposition to HUS [153] In another study by 
Jorgensen et al a familial deficiency of prostacyclin production stimulating factor was 
observed [155] In almost all cases the etiology is idiopathic and the pathogenesis is 
unknown HIV associated HUS and other non-infectious agents named in Table 1 occur 
mainly in adults In contrast to D+ HUS which rarely occurs in the neonate or within the 
first few months of lite, D- HUS can occur in these first months of life [144,148] A possible 
explication for D + HUS rarely occurring in neonates or infants might be a result of breast 
feeding. Human milk, containing the verocytotoxin receptor GbOse4cer (see below) which 
binds verocytotoxin to target cells, may contribute lo a protective effect in diarrheal disease 
by competitive binding of the verocytotoxin [156] 
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1.2 Verocytotoxin-producing Escherichia coli (VTEC) infection in the hemolytic 
uremic syndrome 
1.2.1 Epidemiology of VTEC-associated HUS 
It was Konowalchuk, who found, while looking tor a cell-assay for heat-labile E coli toxins, 
that some culture filtrates of E ioli strains produced a strange irreversible cytotoxic effect 
on vero-cells (a cell line derived from the kidney of the African Green monkey) [157]. These 
E.coh strains which produced this cytotoxic effect were isolated trom faeces of infants with 
diarrhea, faeces of a weaning pig and from cheese The toxin was named after this vero cell-
line, verocytotoxin The major breakthroughs occurred in 1982-1981 with the publication of 
studies from the United States and Canada which linked VTEC infection to respectively 
hemorrhagic colitis and HUS [158,159]. In two outbreaks of hemorrhagic colitis in Michigan 
and Oregon (United States), 47 individuals suffered from sever abdominal pain and grossly 
bloody diarrhea after having ingested a hamburger from a well-known tast-food restaurant 
There was no evidence for an infection by a recognized enteric pathogen However, in the 
stools of the patients and the suspected meat an E coli strain serotype 0157 H7 was found 
[160] Soon, other studies showed that the verocytotoxin-producing E.coli 0157 H7 was a 
common isolate from patients with hemorrhagic colitis and bloody diarrhea in which no 
causal enteric pathogen could be found [158,161,162] Verocytotoxin-producing £ coll strains 
were First associated with HUS in 1981 by Karmali and co-workers [159] He isolated these 
bacteria from the stool from an infant who died alter having severe hemorrhagic colitis and 
in whom after autopsy the diagnosis HUS was made Since then several reports confirmed 
the involvement of VTEC in outbreaks and sporadic cases in HUS, and VTEC was strongly 
implicated with D+ HUS [29,11.41.163-165] Usually no recurrent HUS follows alter 
VTEC-associated HUS However, Siegler recently reported a patient who got VTEC-
associated HUS, cured and approximately 18 months later again developed HUS upon VTEC 
infection with E coll serotype OI57.H7 [167] Although in the first episode of HUS 
serological antibodies to the Ol57 lipopolysacchande as well free fecal verocytotoxin were 
positive, no VTEC 0157:H7 strain could be isolated and therefore it is not clear if this 
patient was infected with the same VTEC 0157 H7 strain for the second time 
Until now much information has been gained from the reported outbreaks and sporadic 
cases of hemorrhagic colitis and HUS in relation to VTEC infection [168]. First, not 
everybody who is infected with VTEC gets HUS Infection with VTEC can be asymptomatic, 
or lead to a mild diarrhea, bloody diarrhea, hemorrhagic colitis or HUS [162,168] The 
inoculum size to get ill is not known Secondly, variability in the frequency of complications 
may be a function of several factors including young age ( < 5 years), prolonged antimolihty 
treatment, presence or absence of antitoxic immunity and the inoculum size [29,169] 
Thirdly, the incubation-period of VTEC of 3 to 8 days, is longer than that of most other 
known enteric pathogens [29,170-172] Fourthly, most outbreaks have been associated with 
E.coli serotype 0157 H7 which is only partly due to the fact that other serotypes are less 
easy to isolate [29,160,168]. A two-year prospective study by Pai and co-workers in 1988 
in Calgary among 5414 Canadian patients with diarrhea, showed that VTEC was the most 
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commonly isolated enteric pathogen (3.1%) in comparison to Campylobacter jejuni (2.7%), 
Aeromonas spp (1.3%), Shigella spp (0.5%), Yersinae enterocolitica (0.2%) and 
enteropathogemc E.coli (0.15%)[162]. The E.coli 0157:H7 was isolated in 78% of VTEC 
strains. Bloody diarrhea was indeed a feature associated with the majority of the VTEC 
strains. Fifthly, several outbreaks of disease caused by E.coli 0157:H7 has been linked 
epidemiologically by the consumption of raw milk and most of all ground beef 
[29,40,160,173,174]. Using verocytotoxin genotyping, plasmid profiles and DNA restriction 
fragment length polymorphisms with a bacteriophage probe, Paros and co-workers found that 
6 from the 22 examined bovine isolates were generally identical to the isolates from 5 
sporadic human cases [175]. Other studies mention the possibility of contaminated, 
unpasteurized apple-cider [176], or drinking water [177,178]. VTEC infection can also be 
required via person-to-person transmission [29,172,179]. The principal reservoir of VTEC 
is the intestinal tract of dairy cattle and perhaps other animals used in the production of food. 
Doyle et al isolated 0157:H7 from 6 (3.7%) of 164 beef, 4 (1.5%) of 264 pork, 4 (1.5%) 
of 263 poultry and 4 (2.0%) of 205 lamb samples obtained from retail grocery stores [180]. 
Studies done in faeces from healthy, rather than diseased cattle report the presence of VTEC 
strains up till 20% of the examined cases. Not all isolated VTEC serotypes in cattle have yet 
been associated with human diseases. The E.coli 0157:H7 has been isolated in 0.2-3% of 
the faeces of cattle in Germany, Spain, United Kingdom and United States [180-184]. 
Excretion of VTEC by cattle is transient. Because in outbreak investigations, samples from 
suspected sources have usually been collected a substantial time after the cases have 
occurred, the source animal may no longer excrete the E.coli strain. This probably accounts 
for the difficulty in recovering the same strain of E.coli from human cases and from the 
incriminated food or animal sources [183]. 
1.2.2 Biology of VTEC 
In literature verocytotoxin-producing E.coli associated with human disease are also termed 
entero-hemorrhagic E.coli (EHEC). Although E.coli strain 0157:H7 is the most commonly 
isolated VTEC, the list of other 0:H serotypes of human VTEC isolates is still growing. 
Other relatively frequent isolated serotypes isolated from patients with HUS are 026:H11, 
0111:H8, OHl:H-, 021:H19, 0145:H-, and 0157:H- [168,185-187]. Some of the VTEC 
serotypes (026:H11, Ol l i , 0119, 0127, 0128 and 055) strains were already known as 
enteropathogemc E.coli (EPEC), causing infant diarrhea in developing countries [168], but 
are now classified as VTEC or EHEC. At least three types of verocytotoxins, involved in 
human disease have been purified and cloned' verocytotoxin-1 (VT1) or shiga-hke toxin I 
(SLTI)[188,189], verocytotoxin-2 (VT2) or shiga like toxin-II (SLTII)[190,191] and 
verocytotoxin-2 variants (VT2c)[192-195]. Another variant of VT2 (VTe) is associated with 
edema disease in pigs [196-198]. Studies have shown that most VTEC produce only VT2 or 
both VT1 and VT2, a small group produces only VT1 or VT2c [43,166,187]. Due to the fact 
that there is only one amino acid difference in the Α-unit between verocytotoxin-1 and shiga 
toxin produced by Shigella dysentena type I, verocytotoxins are often called shiga-hke toxins 
[199,200]. Verocytotoxins VT1 and VT2 are encoded by temperate lambda-like 
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bacteriophages [201,202] Like several other bacterial toxins such as pertussis toxin, cholera 
toxin, E coli heat-labile toxin and shiga toxin, verocytotoxin consist of an A subunit, which 
exhibits the "toxic" activity, and а В subunit, which consists of 5 components and which 
exhibit the "ligand" activity [203] In contrast to VT1 and Shiga toxin, which are almost 
100% homologous, VT1 and VT2 show a 60% nucleotide sequence homology [204] The 
molecular weight of VT is probably about 70,000, with an A subunit of 32,000 and each 
copy of В subunit of 7,700 Lingwood's group have shown that VT1 and VT2, like shiga 
toxin, binds specifically to the glycosphingohpid globotnaosylceramide (GbOse,cer or Gb3, 
Figure 3a) [205-207] This verocytotoxin receptor Gb3 has been shown to be present in the 
human kidney and forms pari ol the Ρ blood group system (P" antigen) [205,208] Both the 
lipid moiety and the terminal disacchande moiety (Galal-4Gal) are involved in 
verocytotoxin-glycosphingohpid binding Following receptor binding, the toxin is internalized 
by a receptor-mediated endocytoxic event (Figure 3b) The active A unit gets proteolytically 
nicked, the Al fragment is released. This Al fragment acts as a specific N-glycosidase which 
can depunnate a single adenine residue from the 28S rRNA component of the ribosome. This 
may result in the blocking the interaction of elongation factor 1 with the ribosome, leading 
to an inhibition of protein synthesis [210-212] (Figure 3c) Although VT's share the same 
subunit structure, bind to the same receptor, and inhibit protein synthesis by the same 
mechanism as Shiga toxin, they tail to cross-neutralize and ditfer in biological activities in 
various cell types and animal models [190,192,213] 
Figure 3a. The biochemical structure of the verocylotoxin-receplor globolnaosylceramide (GbOse,cer) 
1.2.3 Laboratory diagnosis of VTEC 
One of the main problems encountered in isolating VTEC from primary media has been the 
relatively low numbers of VTEC in mixed flora. Tarr et al demonstrated in his study that the 
recovery of VTEC in the faeces of HUS patients is highly dependent on obtaining stool 
cultures within 6 days ot onset of diarrhea The detection-rate decreased torm 91 7% to 
33.3% if stool was cultured for VTEC 3-6 or > 7 days, respectively, after the start of 
diarrhea [214] 
The most common method to examine VTEC in faeces-samples is the use of Sorbitol 
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Figure 3b. The action ot verocytotoxin on Ur^et cells (taken from D V Mil ford et al Arch Dis Child 65,713-
715, 1990, with permission) 
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Figure 3c. Peptide elongation on the eukaryolic nbosome The cytotoxic effect ot verocytotoxin on cells is due 
to a N glycosidase activity ot the A sub-unit, preventing at the end a further binding ot the elongation factor-1 
(EF-la) to the nbosome. This results in a inhibition ot the protein synthesis, (taken trom van de Kar et al 
Behring Inst Miti] 92,202-209,1993, with permission) 
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McConkey plates Whereas 95% of the E coli strains are sorbitol termenters, VTEC strains 
belonging to serogroup 0157, 0157 H7 and some 0157 H strains, do not ferment sorbitol 
in the first 24 hours, giving therefore colourless colonies after a 24 hour incubation-penod 
[174] These non sorbitol fermenting colonies are identified as Ol57 by using specific 0157 
antiserum [215,216] Some sorbitol negative species of f hermana can cross react with this 
0157 antiserum, so testing for presence of H antigen and presence of verocytotoxins should 
be added for diagnosing VTEC [217] It has been reported, that some 0157 H- strains 
isolated from patients with HUS in Germany do ferment sorbitol [166,218] Moreover, the 
production of verocytotoxins is closely associated with enterohemolysin in some VTEC [186] 
In another recent German study, Beutin and co-workers reported that more different VTEC 
strains could be identified by using enterohemolysin and, to a lesser extent, the absence of 
β glucuronidase activity as epidemiological markers for VTEC infection, than by using the 
non fermentation of sorbitol as a criterion [219] 
Detection in faeces of VTEC other strains than 0157 H7, is possible by using the vero-
cell culture assay In this vero-cell assay, culture filtrates made from a sweep of colonies 
taken from McConkey agar plate or blood agar plate are tested for the presence of 
verocytotoxins [168 220] The use of polymyxin В to enhance the detachment of 
verocytotoxin of the E coll and mitomycin С to enhance the production ol verocytotoxin in 
this assay have been reported [220 222] Detection of free lecal verocytotoxin (FVT) in feces 
by the vero cell assay is often more successful in detection VI EC than the culture-filtrate 
procedure [220,221] Scotland and co workers introduced specific DNA probes for detecting 
verocytotoxins in feces [224] They found that the DNA hybridization method to be at least 
as sensitive as the detection of FVT in fecal samples Other methods, such as colony blot 
assay with VT monoclonal antibodies and ELISA's to detect verocytotoxin, have been 
reported [225 227] 
Sera of patients with VTEC infection may develop the ability ot neutralizing VT This 
ability to neutralize VT activity has been used to diagnose VTEC infection in sera of patients 
without other evidence of infection [220] Patients infected with E coli 0157 and other VTEC 
appear not always to raise serum antibodies against VT This may be due to the fact that the 
first serum sample is mostly taken 1 6 days after the onset of the diarrhea Another reason 
might be the fact that VT has shown to bind rapidly to its receptor on endothelial cells 
[205,228] A more adequate serological diagnostic method is the detection of antibodies 
against the hpopolysacchande of the VTEC by ELISA and immunoblotting Extensive 
screening of sera from patients with HUS for antibodies to the hpopolysacchande of the 
E coli 0157 confirmed the value of immunological test for detecting evidence of infection 
with E coli 0157 [229] Due to serological cross-reaction, infections caused by E coll 0157 
can not be distinguished by serology alone from those caused by Brucella abortus [230] 
Antibody cross-reactions between E coli 0157 and Yersinia enterocolitica 09 is only a one 
way cross reaction Sera containing antibodies to Yersinia enterocolitica 09 were shown to 
react with the LPS of both Yersinia and E coli 0157 Antibodies to LPS of E coli 0157 did 
not react with the LPS trom Yersinia enterocolitica 09, but only with the LPS from E coll 
0157 [210] Certain strains of Citrobacter freundu spp and Escherichia hermanu share also 
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epitopes with the hpopolysacchande of E.coll 0157. Serum antibodies to VTEC antibodies 
persist for several months following onset of disease enabling both current and retrospective 
serological testing and are a valuable adjunct to bacteriological procedures for detecting 
VTEC and VT [229,230]. 
For epidemiological studies in outbreaks and in food several molecular biological 
techniques have been become available. In feces from cattle or patients and in food samples, 
different types of verocytoloxins can be detected by using a set of synthetic oligonucleotide 
primers and the polymerase chain reaction [231,232]. Several characteristics which have been 
used to differentiate strains have included verocytotoxin genotypes [232-235], plasmid 
profiles [183,236], bacteriophage typing [237,238], antibiotics susceptibilities [178], 
restriction enzyme digestion and electrophoresis of plasmid or whole cell DNA [175,239], 
and multilocus enzyme electrophoresis of bacterial proteins [240]. Plasmid profiles and toxin 
genotypes have been shown to be less discriminatory than the analysis of restriction enzyme 
fragments with bacteriophages [175]. Each of these techniques assigns E.coli 0157:H7 strains 
to a limited number of subtypes, but due to the fact that they were performed in only a few 
reference laboratories, more studies, especially in an epidemic setting, are warranted. 
1.2.4 Pathogenesis of VTEC infection in H US 
Adhesion of bacteria to the intestinal mucosa is an important factor in the pathogenesis of 
intestinal infections. In contrast to Shigellae, VTEC strains are not invasive. Verocytotoxins 
themselves play probably no role in the adhesion of VTEC to the intestines. However not 
much is known about the presence and distribution of the verocytotoxin-receptor GbOsejCer 
in the human intestines [241,242]. During the last two years much has been unravelled about 
the adherence of VTEC to the intestinal mucosa. Although most information of intestinal 
colonization and multiplication of VTEC comes from studies in animal models and in tissue-
cultures, they may be relevant to the human situation [243,244]. A well-defined pattern of 
colonization of VTEC infection has emerged from studies of natural and experimental 
infections in animals. This pattern is consistent with the attaching and effacing adherence (AE 
lesions) characteristic of human enteropathogenic E.coli (EPEC) infection [243,244]. These 
AE lesions are characterized by extremely close attachment of the bacteria to the intestinal 
cells, with effacement of the underlying microvilli and accumulation of filamentous actin in 
the subjacent cytoplasm. Recently, the E.coli attaching and effacing (eae) gene, responsible 
for part of the attaching and effacing lesions in animal models and tissue cultures, has been 
cloned for EPEC and EHEC [245,246]. Donnenberg et al proposed a three stage model of 
EPEC adhesion and attaching and effacing (AE) lesion formation [247] (Figure 4). First, an 
initial adhesion of the bacteria, probably mediated by plasmid factors including the plasmid-
encoded bundle-forming pili (bfp) and by additional chromosomal loci (x), is needed. A 
further intimate adhesion requires the eaeA gene product, a 94-kDa outer membrane protein 
termed intimin. The eae gene cluster is activated by plasmid encoded regulators (per).The 
eaeA gene itself is not sufficient for full expression of attaching and effacing (AE) lesions. 
Other proteins, chromosomally encoded by at least two additional genes, the eae В gene and 
the cfm (class four mutants) gene(s) (x,y), appear to be necessary for the recruitment of the 
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host cytoskeletal elements, including filamentous actin, forming the electrodense 
characteristics adhesion pedestals or cups [247 249,2*50] 
[Ca ] 
Figure 4 Three stage model ot EPEC pathogenesis Localized adherence (A) the initial interaction between 
the bacterium and the epithelial cell This intersection is mediated by BFP shut involves additional chromosomal 
(gene x) and plasrmd loci In the second stage of infection (B) chromosomal genes (y and z) initiate a signal 
transduction event that results in increase*! intracellular calcium levels and effacement of microvilli 
Simultaneously the eae gene cluster is activated by the product of the plasrmd (per) locus The third stage ot 
infection (C) results when intiinin (solid triangle) the product of the eaeA locus and other products of the eae 
gene cluster mediate close attachment to the epithelial cell From this proximity effects on the epithelial are 
amplified with accumulation of filamentous actin and other cytoskeletal proteins (geometric shapes) (taken trom 
Donnenberg and Kaper Infect Immun 60 3953 3961,1992 with permission) 
The adhesion of VTEC in the human intestines may occur in a similar way as observed for 
EPEC [248] VTEC strains contain large plasmids ot approximately 60 MDa which encode 
structural and/or regulatory genes tor fimbriae that are important in mediating and/or 
regulating the attachment to human epithelial cells in vitro [2*51,252] The formation of the 
AE lesions, necessary for the intimate contact of the bacteria to the intestinal cells, is 
mediated by the gene products of VTEC eaeA [248] The precise nature and site of VTEC 
colonization in humans remains yet to be established 
Verocytotoxin is thought to be, at least partly, responsible for the systemic manifestations 
of VTEC disease [228] After gaining access to the circulation, verocytotoxins bind to 
specific target cells which are thought to be vascular endothelial cells [1,168] Capillary 
endothelial damage is accepted as a central event in the pathogenesis of HUS 
Histopathologically studies of glomerular endothelial cells in HUS patients reveal 
characteristic swelling of endothelial cells accompanied by detachment of the basement 
membrane Similar histo-pathology has been described in rabbits challenged with 
verocytotoxin 1 (VT 1) In a rabbit model Richardson et al demonstrated that intravenously 
injected '"I-labelled VT 1 was rapidly removed from the systemic circulation in minutes The 
highest uptake of 12,I labelled VT-1 was seen in the spinal cord, brain, cecum, colon, and 
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small bowel, but not in the kidney of unimmunized rabbits. Immunofluorescent staining of 
tissue after intravenously administration of VT1 showed evidence of specific vascular 
endothelial cell binding of the toxin. The localization of psI-VTl was consistent with the 
thrombotic microangiopathy in these tissues. Injection of '"l-VT-1 to rabbits immunized 
against VT1 prevented disease and binding of the toxin to the target tissues, thus further 
supporting the specific role of verocytotoxin [253]. Zoja et al demonstrated that the tissue 
damage due to verocytotoxin was correlated with the presence of the functional receptor of 
verocytotoxin, the glycosphingolipid GbOse,cer [254]. No receptors for verocytotoxin were 
detected in the rabbit-kidney, corresponding with no damage seen in the kidney after 
administration of verocytotoxin. In mice given intravenously verocytotoxin or orally E.coli 
0157:H7, the development of bilateral tubular necrosis was seen, but no glomerular vascular 
lesions were observed [255], corresponding with the presence of GbOse,cer in the tubuli of 
the mouse kidney [213]. Histological examination of other tissues than the kidney in these 
mice appeared normal by light microscopy. Very interesting in this regard is the recent 
observation of Lingwood that GbOse,cer is present in the glomeruli of the kidney of children 
younger than 3 years of age and absent in the glomeruli of children older than 3 years and 
in the glomeruli of adult-kidneys [256]. 
Unfortunately, there is no experimental animal model of HUS in which the animal 
develops the classical syndrome following VTEC infection via the natural oral route. 
However in vitro studies with cultured human endothelial cells, mostly isolated from 
umbilical cord have elucidated a part of the pathogenesis of HUS. Several in vitro studies 
have shown that shiga toxin as well as verocytotoxins are able to cause endothelial damage 
by inhibiting the protein synthesis of the cells [228,257,258]. Recently, one study reported 
that cultured endothelial cells of human glomeruli are very susceptible for verocytotoxin 
[259]. First Kavi et al, but also recently Moake and coworkers have shown that endothelial 
cells isolated from umbilical cord can release a pattern of von Willebrand factor multimers, 
including ULvWF upon stimulation with verocytotoxin [71,260]. Rose et al reported that 
filtrates of verocytotoxin-producing E.coh are capable of inducing platelet aggregating 
activity in fresh normal plasma, which is independent of vWF antigen [261]. The study of 
Karch et al revealed that incubation of purified VT1 or VT2 reduces significantly the 
production of prostacyclin in rat aortic tissue [262]. 
The verocytotoxin-receptor GbOse,cer is part of the Ρ blood group system, namely Gb3 
is the Pk antigen (table 2)[263]. The P, antigen, which displays the same terminal saccharide 
structure as P* antigen, can interfere with the verocytotoxin binding to GbOse,cer [198]. The 
antigens of the Ρ system include the P, antigen (Gala 1 -4Galß 1 -4GlcNac01 -3Gal/31 -4GlcCer), 
Ρ antigen (GalNac/31-3,Galal-4Gal/31-4GlcCer, globoside) and the precursor of Ρ antigen, 
the Pk antigen (Galal-4Gal/31-4GlcCer, GbOse3cer). Approximately 75-80% of the normal 
caucasion population express blood group phenotype P, antigen on erythrocytes, but with 
varying strength. The P" antigen phenotype is very rare (table 2). P1 antigen is present on 
all red cells except those of the ρ phenotype, but can vary in expression [263]. This may be 
related to the expression of the galactosyl-transferase activities [264]. Erythrocytes, not 
capable of synthesizing proteins and therefore resistant to the toxic effect of verocytotoxins, 
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Table 2.The Ρ blood group system 
Phenotype Frequency Antigens on erythrocytes Antibodies in serum 
P, 75 5Í P,, P,Pk None 
P, 25% P,Pk Anti-P 
ρ very rare None Anli-Ρ,ΡΡ1 
Pk, very rare P,, P k Anti-P 
P k , very rare P k Anti-P 
Structure of the Ρ antigens: 
P k antigen Globotriaosylceramide (Gh3) Gal(a, l-4)Gal(/?,l-4)Glc-Cer 
Ρ antigen Globolelraosylceramide (Gb4) GalNAc(j3,l-4)Gal(a,l-4)Gal(/3, l-4)Glc-Cer 
P, antigen Gal(a,l-4)Gal((3,l-4)GlcNAc(/3,l-3)Gal(/3, l-4)Glc-Cer 
may protect other susceptible tissues for the effect of this toxin, by 'catching' verocytotoxin 
out of the circulation. In favour of this hypothesis is the study of Taylor et al, who reported 
that the erythrocytes of patients with HUS express a weak or absent P, antigen [265]. In an 
other study done by Newburg et al, erythrocytes of patients with HUS had lower Gb3-to-
lactosylceramide ratios than did erythrocytes of controls [256]. These studies indicate that 
there might be a relationship between susceptibility to HUS and the expression of 
glycosphingohpids on their erythrocytes. A possible involvement of verocytotoxin in red cell 
changes in HUS has been reported by Rose and his co-workers [267] In accordance to 
Butler's study with red cells from Shigclla-absocmtea HUS, he reported that in vitro red cell 
vacuohsation evidence may occur upon treatment with sterile culture filtrates of verocytotoxin 
[268]. 
1.3 Outline of the thesis 
The aim of this thesis is to investigate the incidence of VTEC infection in patients with HUS 
in the Netherlands, Belgium and Germany. Parallel, in order to elucidate the pathogenesis 
of HUS further studies were performed in vitro with purified verocytotoxin-1 on cultured 
human endothelial cells. 
The results of the epidemiological study are presented in chapter 2. By using several 
detection methods, sera and feces from HUS patients were tested for the presence of VTEC. 
Cytokines or inflammatory mediators, secreted from various cell-types have been implicated 
in the mediation of host responses to infection and tissue injury. They can induce a wide 
range of secondary mediators, activate the coagulation and fibrinolytic pathways, and 
influence the function of endothelial cells. The presence of cytokines in patients with HUS 
is investigated in chapter 3. Thrombi and fibrin formed in the glomeruli of patients with HUS 
are a result of endothelial damage. The fibrinolytic system plays an important role in the 
removal of the intravascular glomerular fibrin deposits. Endothelial cells are not only the 
main source of the key-enzyme of the fibrinolytic system, tissue type plasminogen activator 
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(t-PA), but they also produce its inhibitor, the plasminogen activator inhibitor type I (PAI-1). 
In chapter 4, plasma levels of proteins of the fibrinolytic system are investigated in patients 
with HUS. The effect of verocytotoxin-1 on the production of fibrinolytic proteins by human 
cultured endothelial cells is examined. It has been shown that verocytotoxin can damage 
cultured endothelial cells. Cytokines can change the susceptibility of human cultured 
endothelial cells to verocytotoxin. The mechanisms of the cytokines, tumor necrosis factor 
a and interleukin-1, to make endothelial cells more sensitive to verocytotoxin are investigated 
in chapter 5 and 6. 
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Summary 
Sera from 45 patients from The Netherlands, Germany and Belgium who had a clinical 
diagnosis of haemolytic uraemic syndrome (HUS) were screened for antibodies to the 
lipopolysacchande (LPS) oí Escherichia coll producing Verocytotoxin (VTEC). Sera from 
43 family contacts and 34 control patients were also examined. Using the techniques of EIA 
and lmmunoblotting, antibodies to the LPS of Escherichia coli 0157 were found in 28 
patients, and to the LPS of serogroups Ol 15 and 0145 in one patient and one family member 
respectively. The results of our study suggest that VTEC, and in particular Escherichia coll 
0157, might be a significant cause of HUS in Western Europe. 
Introduction 
Strains of Escherichia coll that produce Verocytotoxin (VTEC) have been identified as a 
significant cause of the haemolytic uraemic syndrome (HUS) [1,2]. Verocytotoxin-producing 
Escherichia coll belonging to serotypes 05:H-, 026:H11, 055H7, O104 H2, O105:H18, 
Ol 11:H-, Ol 15-H10, 0128.H2, 0145:H25, 0153:H25, 0163:H19and 0165:H25 have been 
isolated from patients with HUS [3]; however, strains belonging to serotype 0157:H7 are 
most frequently isolated [3]. The detection of VTEC or Verocytotoxin in patients' stools 
identifies the causative organism in cases of HUS Unfortunately, since VTEC and the toxins 
they produce are detected in patients' stools for only a short time following onset of disease 
[4], the infectious agent may go undetected 
Previous studies [5-8] have shown that infection with Escherichia coll 05, 0115, 0145, 
0157 an 0165 can result in the production of serum antibodies to the lipopolysacchande 
(LPS) of these VTEC. The value of serology was further illustrated when a serum from a 
patient with HUS, taken in 1974, was found to contain circulating antibiodies to the LPS of 
Escherichia coll 0157 [9], making this patient the earliest known case of HUS caused by this 
organism. Cases of HUS caused by VTEC have been reported in the UK [2], and also in 
Germany [10] and Italy [11]. 
In the present study we examined sera from 45 patients with HUS, and in the case of 14 
of these patients sera were also taken from family members. Sera from 34 control patients 
were also examined. 
Materials and Methods 
Materials 
Sera were obtained trom 45 patients with HUS, a group with a mean age of 4.2 years 
(δ = 4.5) comprising 21 males, 23 females and one patient of unknown sex. Patients were 
from The Netherlands (n= 29); Cologne, Germany (n= 12), and Leuven, Belgium (n= 4). 
34 
Patients were characterised by having elevated levels of blood urea and creatinine, and 
thrombocytopenia. Thirty-two patients had bloody diarrhoea, certain patients exhibited stages 
of renal failure and some required renal dialysis. Sera were also obtained from 43 family 
contacts. Thirty-four patients (δ = 2.6 years, δ = 2.4 years) with acute gastroenteritis were 
used to provide control sera for serological testing. All sera were stored at -10°C in the 
Laboratory of Enteric Pathogens, PHL, London. 
Lipopolysacchande was prepared from 13 strains of Escherichia coli belonging to 
serotypes 05:H- (E41787), 026:H11 (E36039), 055:H7 (E40230), O104:H2, (E32627), 
O105:H18 (E43549), 0111:H- (E52849), O115:H10 (E47747), 0128:H2 (E41509), 
0145:H25 (E38938), 0153:H25 (E31695), 0157:H- (E32511), 0163:H19 (E31708) and 
0165:H25 (E40235). With the exception of Escherichia coli strain E40235 (0165:H25), all 
strains had been isolated from patients with HUS. For enzyme immunoassay (EIA) in SDS-
PAGE/immunoblotting, LPS was prepared from bacterial outer membranes using the hot-
phenol procedure of Westphal and Jahn [6, 12]. 
Methods 
SDS-PAGE was carried out as described previously [5] using the method of Laemmli [13]. 
Lipopolysaccharide (lO^g) was applied onto gels comprising a 4.5% stacking gel and a 
12.5% separation gel [13], and electrophoresis performed as described elsewhere [6]. SDS-
PAGE gels were either used for immunoblotting [6] or fixed for subsequent silver staining 
[14]. 
For the EIA [5] plates were coated with 1 μg of LPS in 100 ^g coating buffer and reacted 
with sera diluted (xlOOO) in phosphate buffered saline (PBS). Antibody-antigen complexes 
were detected using an alkaline phosphatase conjugated goat-anti-human polyvalent antiserum 
(Sigma, USA) at a dilution of 1/800 in PBS. Results were expressed as the absorbance at 405 
nm. Sera giving an EIA absorbance value > 0.7 were considered positive for antibody and 
sera giving an EIA absorbance value of < 0.4 were considered negative for antibody [8]. 
Sera giving an EIA absorbance value > 0.4 but < 0.7 were examined for antibodies to LPS 
by immunoblotting. Sera from a previous study [5] known to contain antibodies to the LPS 
of Escherichia coli 0157, 05, 0115 and 0145 were used as positive controls. 
Results and Discussion 
Forty-five sera from patients with HUS, 43 sera from family contacts and 34 control sera 
were tested by EIA for antibodies to the LPS from Escherichia coli 0157. Twenty-eight 
patients were found to have serum antibodies reacting with LPS from Escherichia coli 0157. 
Six of these sera, giving EIA absorbance values ranging from 0.50-0.69, were found to be 
positive for antibody on immunoblotting (Figure 1, lane 1). A serum giving an EIA 
absorbance value of 0.43 was found to be negative for antibody on immunoblotting (Figure 
1, lane 2). Eleven of the 14 patients for whom sera from family members were available 
were found to be positive for antibodies to LPS of Escherichia colt 0157 (Table 1), giving 
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Figure l. Immunoblotting of sera from patients and contacts to detect antibody to LPS of VTEC. Lane 1: 
example of the immunoblot in a patient with antibodies reacting with long-chain LPS (bracketed) from 
Escherichia coli 0157. Lane 2: example of a negative immunoblot reaction. Lane 3: immunoblot in the one 
family contact with antibodies to LPS of VTEC Ol 15. Lane 4: immunoblot in the one patient with antibodies 
to LPS of VTEC 0145. 
mean EIA absorbance values ranging from 0.52 to 1.46. Three of these patients, with EIA 
absorbance values of 0.52, 0.57 and 0.69 were confirmed to be positive for anti-0157 LPS 
antibody on immunobotting. The three antibody negative patients had mean EIA absorbance 
values of 0.12, 0,16 and 0.26. These results indicate that more than 60% of patients were 
suffering from HUS caused by VTEC, and demonstrates the value of serological testing as 
a means of obtaining evidence of infection with VTEC. Evidence of a causative agent 
responsible for the remaining 20 cases of HUS was not found and the aetiology of these cases 
remain unknown. The possibility arises that these cases of HUS may have been caused either 
by VTEC as yet unassociated with HUS, or by other microbial agents. Alternatively, some 
of these cases of HUS might have been caused by VTEC without production of O-antigen 
specific antibodies [5]. None of the family contact had serum antibodies to the LPS of 
VTEC, giving EIA values considerably lower than the absorbance cut-off value 0.4. 
However, one contact from family no. 7 was found to have serum antibodies to the LPS 
of Escherichia coli Ol 15 giving a mean EIA absorbance value of 0.95 and a positive 
immunoblot result (Figure 1, lane 3). Unfortunately, since bacteriological examination of 
faeces of this contact was not performed, information concerning carriage of VTEC are not 
available. One control serum was found to have antibodies to Escherichia coli 0157 as 
detected by immunoblotting. Unfortunately there was insufficient information to establish 
whether this person might have had a previous infection wit this organism. 
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Table I Reaction o\ sera trom 14 patients with hemolytic uremic syndrome and their respective family contacts 
in an EIA to delect antibodies to the LPS oi Esthiìtihui ioli 0157 EIA results are expressed as absorbante 
at 4(b nm 
Mean EAI absorbante value 
Patient 
0 16 
0 57 ' 
1 12 
0 69* 
0 12 
0 95 
1 00 
1 12 
1 46 
0 90 
0 90 
0 52' 
1 18 
0 26 
Family contatti1. 
0 22 (3) 
0 24 (2) 
0 23 (2) 
0 18 (2) 
0 27 (2) 
0 26 (3) 
0 14 (9) 
0 13 (4) 
0 23 (5) 
0 21 (S) 
0 31 (3) 
0 34(3) 
0 28 (3) 
0 16 (2) 
* Confirm«! to be anlibocl) positive on immnnohlottinj; 
" Number ot contacts is shown in brackets 
Patients were also examined tor antibodies to the LPS prepared trom 12 other VTEC strains 
One patient was found to have antibodies to the LPS oí Escherichia coll 0145 (Figure 1, lane 
4) Serum antibodies to the LPS ot Escherichia coll 0157 were not delected in the thirty-four 
control sera The incidence of cases of HUS caused by VTEC in The Netherlands has been 
reported only rarely, however in one study 54% ot sera from Dutch patients with HUS were 
found to have circulating antibodies to the LPS of Escherichia coli 0157 [9] In the present 
study more that 60% of patients had evidence of infection with Escherichia coll 0157 and 
strains of Brucella abortus and Yersinia enterocohtua 09 [15], infections caused by these 
organisms are unlikely to be confused with cases of HUS caused by Escherichia coli 0157 
When the results of this study are considered together with the findings from other 
European countries [10,11], HUS caused by Escherichia coli and other VTEC appears to be 
an emerging problem in Europe 
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Summary 
From September 1989 till September 1993, stool specimens and sera from 113 children 
with diarrhea-associated hemolytic uremic syndrome (HUS) from the Netherlands, two 
university hospitals in Belgium and one university hospital in Germany were examined 
for the presence of verocytotoxin-producing Escherichia coli (VTEC) infection. Stool 
examination for VTEC and for free fecal verocytotoxin combined with serological 
evidence of verocytotoxins and antibodies to the lipopolysacchande of 0157-antigen, 
demonstrated a VTEC infection in 88 (78%) patients with HUS and in 2 (3%) of the 65 
examined control children with acute gastro-ententis The serotype 0157 was the 
causative agent in 86% of these 88 patients with VTEC-associated HUS. 
VTEC 0157 strains were isolated from the stool of 19 patients with HUS and in one 
of the controls. Cytotoxicity of the culture filtrates of all isolated strains could be 
neutralized by antibodies to verocytotoxin-2. The fecal samples tested by a procedure for 
verocytotoxin detection in polymyxin В extracts of colony sweeps (VT/PECS) and free 
fecal verocytotoxin (FVT) assays were positive in 27% and 54% respectively in the HUS 
group as compared to 2% in the control group 
Sera of 71 (65%) of 110 patients with HUS and 1 control serum contained antibodies 
to 0157-antigen. Serological testing for antibodies to 0157 O-antigen yielded the highest 
number of positive results compared to the other test methods. Stool and sera examination 
for VTEC in 95 family contacts of 28 patients with HUS, demonstrated an evidence for 
VTEC infection in 33 (35%) family contacts. Serological antibodies to 0157 O-antigen 
were found in only 3 (4%) of 85 family contacts 
We conclude from this study that in this part of Western Europe VT2-producing 
Escherichia coll, mainly those belonging to serogroup 0157, are the major cause of HUS 
in childhood. 
Introduction 
Hemolytic uremic syndrome (HUS), preceded by an acute, often bloody gastroenteritis, is 
mostly seen in children. It is a major cause of acute renal failure in childhood [13] Since 
the first report by Karmah and coworkers [14], verocytotoxin-producing Escherichia coll 
(VTEC) infections are recognized as an important cause of diarrhea-associated HUS in the 
United States, Canada, United Kingdom and other countries [3,5,16,21,26] VTEC strains 
may belong to different serogroups, but the most commonly isolated VTEC is the 
serotype 0 1 5 7 Ή 7 . A family of at least three verocytotoxins has been identified, 
verocytotoxin-1 (VT1) or Shiga-like toxin I (SLTI), verocytotoxin-2 (VT2) or Shiga-hke 
toxin II (SLTII) and verocytotoxin 2 variants (VTc)[15] Not all those infected with 
VTEC will develop HUS. Infection with VTEC can be asymptomatically, lead to a mild 
diarrhea, bloody diarrhea, hemorrhagic colitis or HUS [19] 
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In this study, we report the results of a four year prospective study in which we 
examined the presence of VTEC infection in patients with diarrhea-associated HUS in the 
Netherlands, two adjacent university hospitals in Belgium and one in Germany at a 
distance of approximately 150 km from the University of Nijmegen, The Netherlands 
Patients and Methods 
Patients 
Between September 1989 and September 1993, stool and sera specimens from 113 
patients with diarrhea-associated HUS (58 female, 55 male, mean age ± SD 46 ± 35 
months, range 9-162 months) were received by the Department of Medical Microbiology 
of the University Hospital Nijmegen for examination of the presence of VTEC infection. 
Specimens of patients with HUS were obtained from 77 Dutch patients admitted to 
pediatric nephrology departments of the academic hospitals in the Netherlands, 21 patients 
admitted to the pediatric nephrology department of the Children's Hospital, Cologne in 
Germany and 15 patients admitted to the University Hospital of Leuven and Antwerpen in 
Belgium A case of HUS was determined by a sudden onset of illness with a prodromal 
phase of acute gastro-enlentis, and by laboratory evidence of microangiopathic hemolytic 
anemia, thrombocytopenia and disturbed renal function [10] All patients with HUS 
included in this study had a prodromal phase with acute gastro-ententis, in 73% the 
gastro-ententis was reported to be bloody. Stool and serum specimens were also obtained 
from 95 family contacts (27 fathers, 28 mothers, 35 siblings and two other family 
contacts) of 28 patients with HUS referred to the pediatric department of the University 
Hospital, Nijmegen, The Netherlands The family members included all family contacts 
who lived with the HUS index case in the same house Sixteen (17%) family members 
had diarrhea at lime ot admission or one week before admission of the HUS case to the 
hospital The control group consisted of 65 children (28 females, 37 males, mean age + 
SD, 3 1 + 2 5 months) with acute gastro-ententis (18% of the cases had bloody diarrhea) 
and without any evidence of HUS, who were admitted to the pediatric department of the 
University Hospital Nijmegen and to three referral hospitals in the Netherlands between 
September 1990 and September 1993 
On admission stools were collected from patients and controls as soon as possible 
Blood samples were taken on admission and, when possible, after two to three weeks 
(convalescent phase) After centrifugaron sera samples were frozen at -20°C and 
transported on dry ice to the Medical Microbiology department, where they were kept 
frozen at -70°C until the assays were performed 
Stool samples 
All stool samples examined for VTEC were plated on sorbitol MacConkey (Oxoid 
Sorbitol MacConkey agar containing 1% sorbitol) and blood agar. After 24 hours 
incubation non-sorbitol fermenting, colourless colonies were tested for agglutination with 
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anti-0157 O antigen serum (Difco, Detroit, Michigan, USA) and tested for verocytotoxin 
activity in the Verocell-assay (see below) VTEC 0157 strains were serotyped by Dr W 
Jansen, RIVM, Bilthoven, the Netherlands Furthermore, fecal samples were tested by a 
procedure for Verocytotoxin (VT) detection in polymyxin В extracts (PE) of colony 
sweeps (CS) (VT/PECS), as described by Karmali et al [14] Briefly, a colony sweep was 
taken from a blood agar, inoculated with a fecal sample for 24 hours at 37°C, suspended 
in Antibiotica Broth No 3 and incubated overnight at 37°C After incubation and the 
following centnfugation (10,000 χ g for 10 min), the cell-pellet was suspended in 0 1 
mg/ml of polymyxin В and incubated for another 30 mm at 37°C After centnfugation 
(10,000 χ g for 10 mm), the culture filtrate was tested for cytotoxicity on confluent 
Verocell monolayers and incubated for three days at 37°C in a 5% C02 atmosphere The 
titre of the cytotoxic activity was expressed as the reciprocal of the highest dilution 
inducing 50% cytotoxic effect (CD50) after incubation tor three days at 37CC Positive 
cytotoxicity by verocytotoxin was neutralized by using a polyclonal antibodies to VT1 and 
VT2c and the monoclonal antibody BC5 BB12 to VT2 
To detect free fecal verocytotoxin (FVT), fecal filtrates were made from fecal samples 
as follows equal volumes of the fecal specimen and sodium phosphate buffer (pH 7 2) 
were thoroughly mixed by using a vortex mixer and then centntuged (10,000 χ g for 10 
min), the fecal filtrate was tested tor cytotoxicity in the Verocell assay as described above 
[14] The stools of all patients with HUS and patients with acute gastro-ententis were also 
tested for the most common enteric pathogens 
Scrum samples 
Paired serum samples, collected on admission and after 14 days were used to detect 
neutralizing ability to VT1 and VT2 or VT2c with the Verocell assay [14] Briefly, two 
CD50 of the verocytotoxin preparations, obtained from culture supernatants of reference 
strains H30 (VT1 -producing E coll) and E32511 (VT2 and VT2c producing E coli)[\Q], 
were incubated for one hour with twofold dilutions ot patient's serum After 
preincubation the mixture was added to a confluent monolayer of verocells The highest 
serum dilution that caused inhibition of cytotoxic effect after three days of incubation of 
cell-culture, was taken as the end point Paired samples were always tested in the same 
Verocell microtitre plate A fourfold or more rising titre to VT1,VT2 and/or VT2c in the 
sera was regarded as positive for recent VTEC infection Serum antibodies to the 
lipopolysacchande of E coll 0157 were analyzed by ELISA and immunoblotting, as 
described previously [6] A case was defined positive for VTEC infection when one or 
more of the above described detection methods were positive 
Statistical analysis 
The significance of differences between the groups was determined by using the Fisher's 
exact test (two tailed) 
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Results 
The results are shown in Table 1. Evidence for VTEC infection was found in 88 (78%) 
out of 113 patients with HUS. Only two patients (3%) from the control group of 65 
children with acute gastroenteritis demonstrated a VTEC infection. 
Table 1. Verocylotoxin-producing Eichenchia coli infection in patients with hemolytic uremic syndrome 
and controls with acute gastro-ententis 
Methods 
Feces 
Isolation of VTEC 0157 
0157:H7 
0157:H-
VT/PECS 
Free fecal verocyloloxin 
One or more methods 
Serology 
VT-neutralizing ability 
Antibodies to 0157-anligen 
One or both methods 
No of patients with HUS 
positive for VTEC ( n = l l ) 
19/90 
18/19 
1/19 
24/90 
49/90 
54/90 
4/76 
71/110 
72/110 
(21%) 
(95%) 
(5%) 
(27%) 
(54%) 
(60%) 
(5%) 
(65%) 
(65%) 
No of controls 
positive for VTEC (n = 65) 
1/57 
0/57 
1/57 
1/57 
1/56 
1/57 
0/19 
1/53 
1/50 
(2%) 
(0%) 
(2%)-
(2%) 
(2%) 
(2%) 
(0%) 
(2%) 
(2%) 
Total VTEC infection 88/113 (78%) 2/65 (3%) 
The other isolated E coli 0157:H- strain in the control group did not produce verocyloloxin and is not 
mentioned in this table All methods, except the assay lor VT-neutralizing ability, had ρ < 0.001 compared 
with controls. 
Examination of stool was possible in 90 patients with HUS. By using Sorbitol 
MacConkey plates (VTEC serotype 0157 isolation), the VT/PECS method and FVT-
assay evidence for VTEC infection was provided in 54 (60%) patients with HUS. VTEC 
strains could be isolated in 19 HUS patients. Strains of E.coli belonging to serotype 
0157:H7 were isolated from eighteen cases and a strain belonging to serotype 0157:H- in 
one case. All strains demonstrated cytotoxicity in the Verocell-assay which could be 
neutralized by polyclonal antibodies to VT2. Infection with Shigella dysentenae I 
occurred in one patient with HUS. No Campylobacter, Salmonella or Yersinia species 
were isolated in the stool of the HUS group. Evidence for Clostridium difficile infection 
was found in three patients with HUS. One HUS patient had both E.coli 0157:H7 and 
Clostridium difficile in the stool. The FVT assay proved to be more sensitive than the 
VT/PECS method. The observed cytotoxicity observed in the Verocell assays for both 
culture- and fecal filtrate was in all, except two, cases neutralizable with antibodies to 
VT2. Antibodies to VT1 neutralized the cytotoxic effect in the filtrates of two HUS 
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patients 
E coli 0157 H- was isolated in two control cases One strain E coll 0157 H- was 
isolated from the non-bloody stool of a patient with coeliac disease This isolated strain 
could not be classified as VTEC because culture filtrates of the strain did not demonstrate 
any cytotoxicity in the Verocell assay The other E coli Ol57 H strain was found in the 
stool of a patient with acute, bloody gastro-ententis The cytotoxin produced by this strain 
could not be neutralized by the antibodies to VT1 or VT2 used in our Verocell assay 
Nevertheless, using polymerase chain reaction in amplifying the genomic DNA of the 
strain and specific primers for VT, a positive result was obtained for VT1 and VT2 genes 
(Ir A Heuvelink, personal communication) Other enteric pathogens isolated from the 
stool of control cases were Salmonella spp (llx), rotavirus (9x), adeno-virus (3x), 
enterovirus (3x), Campylobacter jejuni (3x), Giardia lamblia (2x) and Coxsackie vims, 
Yersinia and Clostridium difficile (lx) 
The Verocell-assay tor neutralizing ability to verocytotoxins was positive in paired 
sera samples from 4 of the 76 patients with HUS and in none of the 19 control children 
with acute gastroenteritis (Table 1) All detected neutralizing ability to VT were against 
VT1 Antibodies to VT2 or VT2c were not detected in any of the examined sera 
Antibodies to 0157 O-antigen were present in 71 of the 110 tested HUS patients and in 
one of the 53 control cases By using both serological methods evidence for VTEC 
infection was present in 72 (65%) of the 110 tested HUS patients and in 1 (2%) of the 53 
controls 
To investigate which of the used detection methods was the most sensitive for 
diagnosing VTEC infections, we examined the data of 69 patients with HUS in which all 
assays could be performed (Table 2) Presence of serological antibodies to 0157 O-
antigen was found in 70% and yielded the highest number of positive results compared to 
the fecal assays (59%) The neutralizing Verocell assay for VT was positive in only 3% 
of test cases No further investigation was done to identify the VTEC strains with 
serotypes other than serogroup 0157 which were responsible for the positive results in the 
VT/PECS and FVT assays However, the results of VTEC 0157 H7 isolation by Sorbitol 
McConkey agar and the positive serological tests for antibodies to the 0157 O-antigen 
demonstrated that VTEC 0157 infection was present in 76 (86%) of the 88 patients with 
HUS having a VTEC infection 
Stool and sera examination were performed in 95 family contacts of 28 patients with 
HUS admitted to one of the hospitals In all families two or more members could be 
examined Sixteen family contacts had an acute gastro-ententis none of the ten adults had 
bloody diarrhea, in four ol the six siblings the diarrhea was bloody The results are 
shown in Table 3 In 17 families one or more members were found to have a VTEC 
infection at the time the patient was admitted to the hospital In all these seventeen 
families, VTEC infection was present in the respective patient as well Nine families with 
a VTEC positive HUS patient had at least two family members positive for VTEC 
infection Thirty three (35%) family members had evidence of VTEC infection Evidence 
for VTEC infection was found in 50% of the family members with diarrhea VTEC strain 
44 
Table 2. Combined microbiological and serological assays for VTEC detection tested in 69 patients with 
HUS. 
Methods No of patients with HUS 
positive tor VTEC ( n = 6 9 ) 
Feces 
Isolation of VTEC 0 1 5 7 
VT/PEC 
FVT 
ToUl 
Serology 
VT-neutralizing ability 
Antibodies to 0157 
Total 
13 
17 
36 
41 
2 
48 
48 
(19%) 
(25%) 
(52%) 
(59%) 
(3%) 
(70%) 
(70%) 
All methods (Sorbitol MacConkey agar, VT/PECS assay, FVT assay, VT neutralization assay and ELISA 
and immunoblotling for antibodies to 0157 O-antigen) could be used in the examination of teces and sera ot 
69 patients with HUS Serological examination for the presence ot antibodies to the E ioli 0157 O-anligen 
gave the highest number ot positive results 
0157 was isolated in 16 family members. 0157:H7 and 0157:H- could be isolated from 
the stool of 14 respectively 2 family contacts. In the stools of one family, the VTEC 
serotype 0157:H7 was isolated in all members including the patient. E.coli OI57:H7 was 
isolated on six occasions and once E.coli 0157:H- was isolated from family members of 
Table 3. Evideni-e for VTEC intection in 28 patients with HUS and their family contacts 
Methods No of patients with HUS 
positive for VTEC 
(n = 28) 
No of family members No of families 
positive tor VTEC' positive tor VTEC 
(n = 95) (n = 28) 
Feces 
Isolation of VTEC strain 
VT/PEC 
FVT 
Total VTEC infection 
5/26 (19%) 
10/26 (26%) 
18/26 (69%)" 
Serology 
VT-neutralizing ability 1/25 ( 4%) 
Antibodies to OI57-antigen 21/28 (75%)" 
26/28(93%) 
16/81 (20%) 
23/81 (28%) 
25/75 (33%) 
2/54 (4%) 
3/85 (4%) 
33/95 (35%) 
10/25 
16/25 
15/25 
2/28 
3/28 
17/28 
' Evidence for VTEC infection in family contacts was most prominent in the siblings of the patient (49%), 
Evidence for VTEC infection in mothers or fathers of the patient was present in 18% and 26% of the parent 
respectively. " ρ < 0.01 , ~ ρ < 0.001 compared with family-members 
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seven HUS patients who had evidence for VTEC infection, but in whom's stools VTEC 
strain were not isolated All isolated VTEC 0157 strains of family members gave 
cytotoxicity in the Verocell assay which could be neutralized by antibodies to VT2 alone 
Verocell-cytotoxicity of culture and fecal filtrate, positive in 28% respectively 33% of the 
samples tested, could in all cases be neutralized by antibodies to VT2 and not by 
antibodies to VT1 Only three of the 85 family members, children of 1, 4, and 6 years of 
age, had serum antibodies to the 0157 O-antigen All three children had diarrhea Two of 
the three children had an acute bloody gastro-ententis one week before the symptoms 
started in the patient 
Discussion 
Combined microbiological and serological procedures provided evidence for VTEC 
infection in 78% of the patients with HUS compared with 3% in the control group of 
children with acute gastro-ententis Infection by VT-producing E coli 0157 were the 
predominant cause of diarrhea-associated HUS in our patients These results are 
comparable with other published epidemiological studies in Europe in which combined 
microbiological and serological tests were performed [3,5,6,16] Cytotoxicity of the 
culture filtrates made from the isolated VTEC 0157 strains was neutralizable with 
antibodies to VT2 only Population studies in the United States and United Kingdom have 
reported that almost all isolated strains of E coli 0157 H7 possessed the VT2 gene 
Approximately two-thirds of these strains also contained the VT1 gene and only less then 
3% of E coli 0157 H7 strains had only VT1 [18,23,26,28] VT2-producing strains are 
associated with a higher frequency of bloody gastro-ententis and systemic complications 
in human diseases [4,18,26,28] Although the isolated E(oli 0157 strains from HUS 
patients in other European studies are shown to be mainly VT2 producers [3,5,16], a 
recently published Canadian study reported that 22 out of the 26 VTEC 0157 H7 isolated 
from HUS patients were VT1 and VT2 producers [21] 
Not much is known about the occurrence of VTEC, especially strains belonging to 
serotype 0157, in the human population in Europe Dunng an 18 month screening study 
for VTEC 0157 in Belgium, VTEC 0157 H7 was isolated in 8 (0 2%) of 3940 stool 
specimens [20] The isolation rate for all VTEC in this study was 0 3% A higher 
isolation rate of E colt 0157 H7 was found in the population studies performed in Canada 
(1 9%, 2 5%) and United States (2 9%) [4,11,19] Тагт and coworkers have shown that 
the recovery rate for E coli 0157 H7 depended on the interval of days between the onset 
of symptoms and the collection of stool [27] This rate decreased from 100% to 33% if 
the stool was cultured within two days or respectively one week after the diarrhea began 
In our study, patients were hospitalized 7 + 3 (SD) days after the onset of diarrhea In 
the samples of 69 HUS patients in which all microbiological and serological methods 
could be performed, serological testing of antibodies to the 0157 O-antigen was the most 
successful method for demonstrating VTEC infection Serological testing for antibodies to 
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0157 О antigen can provide evidence of VTEC infection for several weeks after the onset 
of diarrhea and has been proven a valuable method in VTEC detection [6] In accordance 
to other studies, no neutralizing activity against VT2 or VT2c could be detected in the 
sera samples of patients with HUS and control cases [1,7-12] Neutralizing activity to 
VT1 were found in only 4 patients with HUS This is surprising because in this study the 
cytotoxicity of filtrates could be mainly neutralized by antibodies to VT2 It has been 
suggested that the discrepancy of no serological response to VT2 and the VT2 positive 
results of the fecal tests, might be due to a different ability of VT1 and VT2 to elicit a 
specific antibody response during the disease or the contact time to the toxin in the blood 
to establish an immune response may be too short [5] The observation that the 
cytotoxicity of the culture filtrate of the 0157 H- strain isolated from one control patient 
could not be neutralized by the used antibodies to VT, although the polymerase chain 
reaction assay of chromosomal DNA demonstrated the presence of VT1 and VT2 genes, 
has also been observed by others [24] Smith et al observed that in the neutralization test 
with VT1 and VT2 producing strains cytotoxicity could not be neutralized by antibodies 
to VT1 whereas partial neutralization was observed in some cases with antibodies to VT2 
[23] This might be due lo a difference in VT-production of the VTEC or maybe some of 
these strains who have the VT1 and VT2 sequence, do not produce VT1 in contrast to 
VT2 
VTEC isolation, VT/PECS, FVT assay and serological tests demonstrated a high 
percentage (35%) of VTEC infection in the stool of mostly asymptomatic family members 
of HUS patients Caprioli et al demonstrated a VTEC infection by using combined 
microbiological and serological assays in only three of the 110 family members [5] In 
contrast to the study of Lopez et al [17], who reported that 75% of the family members 
of HUS patients had neutralizing serological antibodies to VT1 and or 2, in our study 
only 2 of the 54 family members had antibodies to VT1 and nobody had antibodies to 
VT2, the same percentage as in the HUS group (Table 3) Although fecal tests 
demonstrate that VTEC infection is often present in family members, it is remarkable that 
the presence of serum antibodies to 0157 O-antigen were significantly lower in the family 
members as compared to the patients The three family members who were positive for 
serum antibodies to 0157 LPS were children Two of them had bloody diarrhea Bloody 
diarrhea was a more prominent feature of VTEC infection in patients with HUS than in 
the family members and correlated significantly with the presence of antibodies to 0157 
antigen (p < 0 05) Assuming that a VTEC infection in a family was due to the same 
strain of E coli 0157, these family studies might indicate that other, yet unknown, host 
factors in the intestine are involved in making it more easier for VTEC 
lipopolysacchandes to cross the mucosal surface A difference in adherence of VTEC to 
the intestinal epithelium of adults and children might be an explanation for the occurrence 
of HUS in mostly children as compared to adults Cimolai et a! reported that a patient's 
age and prolonged use of an antimotility agent might be a risk factor for the progression 
of gastro enteritis and HUS [25] No antimotility agents were used in these three families 
Several outbreaks of VTEC infection by strains of E coli of serotype 0157 H7 in the 
47 
United States and Canada have revealed that the major route of acquisition of VTEC 
seems to be the consumption of contaminated meat [2,15], unpasteurized milk [9], 
exposure to contaminated water [25], and through person-to-person transmission [22]. 
Although there is some indication that in our family study VTEC transmission through 
person-to-person might be very important, this study was not designed to detect the 
source of VTEC. Further studies to characterize strains of E.coli 0157 and to establish 
the source of these strains are currently going on. 
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Dear Sir, 
Evidence for an autosomal recessive or autosomal dominant mode of inheritance is present 
in a small minority of patients with hemolytic uremic syndrome (HUS) [1]. 
In one report of a familial relapsing autosomal dominant form, the disease was associated 
with HLA-A3, B7 haplotype [2]. In the Netherlands and the Flemish part of Belgium, the 
epidemic or classical form is most frequently observed. An infection by verocytotoxin-
producing Escherichia coll was a proven frequent cause of this epidemic form during recent 
years [unpubl. study]. Not all infants and children infected by verocytotoxin-producing E.coh 
develop HUS. In one outbreak of E.coli 0157 only 3 (8.3%) of the symptomatic children 
developed HUS. In another outbreak, HUS became evident in 3 (7%) of 42 symptomatic 
children [3]. A genetic predisposition was suspected. 
Sheth et al. [4] evaluated HLA-A, B, C, DR, DQ antigens in 31 children, who had 
classical HUS previously. They reported a relative risk of 5 of developing HUS with the 
presence of HLA-B 40 alone. The severity of HUS was not related to the genetic 
predisposition. 
The distribution of HLA-A, В and DR antigen was studied in 31 patients with chronic 
renal failure due to the epidemic form of HUS. All patients were on dialysis or transplanted. 
One patient was excluded because he was of Turkish origin. All other patients were of 
Caucasian origin and were cared for in six transplantation centres. 
Compared with the control population, there was no significant difference in the 
distribution of HLA-A, B, and DR antigens with one exception. Ann odds ratio of 2.5 (X2, 
p=0.039) could be calculated in our group of patients for HLA-B40 (Table 1). In contrast 
to Sheth et al. [4], who found that all their patients had at least one of the following HLA-B 
types: 40,13,7,44, which share a distinct amino acid sequence of a, domain, this was found 
in only 23 of our 31 patients (4 patients had more than 1 of the 4 HLA-B types). 
We may conclude that in the severe form of epidemic HUS, as seen in the six 
transplantation centres there is a significant association with HLA-B 40. 
Table 1. Comparison of HLA frequencies in Sheth's study compared with our study 
B40 
B l l 
B44 
B7 
pati 
% 
45 
13 
23 
23 
Study 
lenls 
η 
14 
4 
7 
7 
of Shelh (n = 31) 
random population 
% 
14 
6 
23 
23 
pati 
% 
25 
0 
34 4 
25 
leni 
Our 
:s 
η 
8 
0 
11 
8 
study (n =  31) 
random population 
% 
12 
3 3 
22.1 
28 9 
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Summary 
The cytokines tumor necrosis factor a (TNFa) and Us soluble TNF receptors 55 and 75 
(STNFR55, STNFR75), ïnterleukin-10 (IL 1/3) and ïnterleukin 6 (IL-6) were measured in the 
plasma from 13 patients with the hemolytic uremic syndrome (HUS) on admission No 
significant changes in the plasma-levels of TNFa and IL-1/3 were detected in the HUS 
patients as compared to the plasma-levels of the control groups Levels of IL-6 were 
significantly elevated in the plasma of those HUS patients, who had extra-renal 
manifestations, consisting of seizures, loss of consciousness, coma and pancreatic necrosis 
Although the exact function of IL-6 in the plasma of HUS patients is still unknown and the 
group of HUS patients is small, plasma IL 6 is associated with the seventy and outcome of 
the disease Plasma levels of sTNR55 and sTNFR75 were significantly elevated in all HUS 
patients compared to the healthy controls, but they were also elevated in the children with 
chronic renal failure This indicates that elevated levels of circulating sTNFR should be 
carefully interpreted when kidney failure exist 
Introduction 
Hemolytic uremic syndrome (HUS) is characterized by hemolytic anemia, thrombocytopenia 
and acute renal failure The most common form of HUS seen in children is the epidemic 
form, which is preceded by an acute, often bloody, gastro-ententis [1] In the last decade it 
has become clear that infections with a verocytotoxin-producing E coll strains are the main 
cause of HUS in childhood [2,3] Although the exact pathogenesis of HUS is still unknown, 
it is generally accepted that endothelial cell activation and damage play a central role 
Cytokines such as tumor necrosis factor α (TNFa), ïnterleukin 1 ß (IL-10) and interleukin-6 
(IL 6) are known to play an important role in infectious and inflammatory diseases, and have 
been extensively studied in diseases such as sepsis, severe infectious purpura and Kawasaki 
disease [4-6] Elevated levels of cytokines are also found in plasma taken in the acute phase 
of patients with thrombotic thrombocytopenic purpura (TTP), a syndrome which is in many 
aspects familiar with HUS [7] 
The aim of this study was to determine whether circulating cytokines are detectable in 
the blood of HUS patients For this purpose, we measured TNFa and its soluble receptors 
STNFR55 and STNFR75, IL-Iß and IL-6 in the plasma of 13 patients admitted to the hospital 
with the epidemic form of HUS 
Patients and Methods 
Patients 
Thirteen children (4 females / 9 males, mean age 38 ± 28 months, range 6-112 months), 
56 
were diagnosed as having HUS, because of the presence of hemolytic anemia with burr cells 
in the peripheral blood smear, renal failure and thrombocytopenia [8]. HUS was preceded 
by mostly blood-stained diarrhea. Antibodies against the most common verocytotoxin-
producing E.colt (VTEC) serotype 0157, which indicates an infection with VTEC, were 
detected in the plasma of seven out of twelve patients [9]. 
The main laboratory indexes of the patients on admission are displayed in Table 1. On 
the day of admission to the hospital, before any treatment was given, blood from these 
thirteen children was collected into EDTA containing tubes, centnfuged and the plasma was 
stored in small aliquots at -70°C until assays were performed. Plasma of eight age-matched 
healthy control children and eight children known with chronic renal failure taken before 
dialysis, served as controls. 
Table I. Laboratory indices ot patients with HUS on the day ot admission. 
Number of 
patient 
1. 
2 
3 
4. 
5. 
6. 
7. 
8. 
9. 
10\ 
n
- e 
12". 
13". 
Aye 
(months) 
14 
21 
6 
53 
112 
36 
54 
10 
41 
22 
36 
22 
40 
Hb 
(nimol/l) 
3.9 
4 9 
4 7 
5 3 
5 5 
4 2 
3.7 
4 1 
3 7 
3 9 
9 2 
7 5 
5 7 
Platelets 
(lO'/l) 
276 
45 
25 
56 
55 
138 
203 
56 
130 
37 
304 
11 
30 
WBC 
(1071) 
22.3 
20 4 
25 5 
31 5 
10 9 
17 7 
8 8 
23.2 
12 
19 5 
24 1 
53 6 
33 6 
Urea 
(mmol/1) 
20 2 
33 
29 6 
36 
67 
40 
63.2 
61 6 
45 
26.9 
6 8 
68 2 
17 2 
Creatinine 
(μπιοΙ/Ι) 
106 
295 
350 
770 
1020 
640 
928 
514 
178 
288 
54 
335 
157 
Normal values children 6-9 140-440 4-11 3-7 30-90 
The laboratory indexes are given for each HUS patient,individually indicated by numbers " On the second day 
after admission the laboratory parameters of patient 11 were as following Hb 4.5 mmol/1, platelets 25 χ lCrVl, 
urea 10 5 mmol/1 and creatinine 130 μπιοΐ/l " Patients 10,11,12 and 13 had, in contrast with the other HUS 
patients, severe extra-renal manifestations, consisting of seizures, loss of consciousness, coma. Pancreatic 
necrosis was also diagnosed in patient 10 
Methods 
TNFa was assessed by radioimmunoassay (RIA), as previously 
described [10]. This RIA measures total TNFa (both free and complexed to its receptors), 
as demonstrated by the lack of interference of the addition of up to 5 ng/ml recombinant 
STNFR55 and sTNFR75) to sera containing known amounts of TNFa. The sensitivity of this 
assay is 100 pg/ml. IL-1/3 assay was also performed with a RIA [11]. Before application, 
both RIA's (TNFa and IL-1/3) were thoroughly validated towards linearity and determination 
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of matrix effects. When 100 μΐ of plasma was tested, recovery experiments of the respective 
cytokine resulted in recovery values exceeding 90%, both at the low and the high 
concentration range tested IL-6 was measured by an ELISA as described by Barrera et al 
[12], materials were a gift from Dr.J.Wijdenes (Innotherapy, Besancon, France). The 
sensitivity of this ELISA is 20 pg/ml 
Soluble TNF receptors (sTNFR55 and STNFR75) were measured by ELISA (Hoffmann-
La Roche, Basel, Switserland) These assays measure total circulating (both free and bound) 
receptor concentrations, since addition of up to 10 ng/ml recombinant TNFa to plasma 
containing known amounts of sTNFR does not influence these assays The sensitivity of these 
assays is 100 pg/ml 
Statistical analysis 
Results are expressed as mean + SD The significance of differences between the various 
groups of patients was determined by using the Mann-Whitney test The Spearmann's ranks 
test was used for determining the correlation between cytokine levels and the laboratory 
indexes in the HUS group 
Results 
The individual data of cytokine levels in the plasma of the HUS patients are displayed in 
Table 2 Only the patients 10,11,12 and 13 had severe extra-renal manifestations, consisting 
of seizures, loss of consciousness and coma Patient 10 also developed necrosis of the 
pancreas The latter three patients (11-13) died due to cerebral complications in the acute 
phase of the disease No significant increased levels of TNFa and IL-1/3 were found in the 
plasma of patients with HUS as compared to the control groups (Table 2) Only the four 
patients, who had extra-renal manifestations (severe form of HUS), had significantly elevated 
levels of IL-6 ( 277 pg/ml + 103), as compared to the control group of healthy children, 
whereas the IL-6 levels in the plasma of the other HUS patients ( < 30 pg/ml, mild form of 
HUS) was not significantly elevated Significant increased levels of both soluble TNF 
receptors were found in all HUS patients (sTNFR55 22 ng/ml ± 12 and sTNFR75 21 ng/ml 
± 13 ) as compared to the control group of healthy children (sTNFR55 1 4 ng/ml ± 1 and 
STNFR75 4 2 ng/ml ± 1) There was no difference in the plasma concentrations of 
STNFR55 and STNFR75 between the mild and severe forms of HUS However, both 
sTNFRs were also increased in the plasma of the children with chronic renal failure (17 
ng/ml ± 6 for STNFR55 and 27 ng/ml ± 7 for the sTNFR75), which suggest that renal 
failure per se, and associated with a decrease in clearance causes high levels of sTNFR in 
the plasma. 
Plasma levels of TNFa, IL-1/3 or sTNFR75 did not correlate with hemoglobin, platelets, 
white blood cell count, urea or creatinine. Only sTNFR55 and IL-6 showed a mild 
correlation with hemoglobin (r=0 56 respectively r=0.52) and white blood cell count (both 
r=0.60, Spearman's correlation) in the total HUS group. 
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Table 2. Plasma cytokine levels m patients with the hemolytic uremic syndrome 
Number of 
patient 
1 
2 
3. 
4 
5. 
6. 
7. 
g 
9 
io·. 
ir. 
12". 
13'. 
Patients 1-9 
Patients 10-13 
Control (n = 8) 
CRF (n = 8) 
TNFa 
ng/ml 
0.15 
0.10 
0.14 
0.15 
0.15 
0 12 
0.13 
0 15 
0.13 
0.15 
0.13 
nm 
0.14 
0.13 ± 0.02 
0 
0. 
0. 
13 ± 0.05 
12 + 0.02 
14 ± 0.04 
IL-1/3 
ng/mL 
< 0 10 
< 0.10 
< 0.10 
< 0.10 
< 0.10 
< 0.10 
< 0.10 
< 0.10 
< 0.10 
< 0 10 
< 0.10 
nm 
< 0.10 
< 0 085 
< 0.10 
0.07 ± 0 02 
0 08 ± 0.05 
IL-6 
pg/ml 
< 20 
< 20 
30 
< 20 
< 20 
< 20 
< 20 
20 
< 20 
275 
160 
262 
410 
< 30 
277 ± 103" 
< 20 
< 20 
STNFR55 
ng/ml 
3 5 
13.2 
45.1 
38.5 
17.2 
26.4 
11 1 
nm 
10.1 
22.0 
28.2 
32.1 
20.2 
20 + 16" 
26 ± 6' 
1.4 + 1 
17 ± 6 я 
STNFR75 
ng/ml 
9 3 
9.0 
6.4 
39.8 
10.9 
35.7 
4.3 
nm 
20 6 
24 7 
34.0 
33.2 
22.4 
17 ± 14' 
29 ± 6' 
4.2 + 1 
27 ± 7' 
Plasma cytokine levels were determined on admission in patients with HUS. ' Patients 10,11,12 and 13 had, 
in contrast with the other HUS patients, severe extra-renal manifestations, consisting ol seizures, loss of 
consciousness, coma. Pancreatic necrosis was also diagnosed in patient 10 The data are expressed individually 
and as the mean ± SD of the various groups To compare the data of the difieren! groups of patients and 
healthy controls the Mann-Whitney test was used. ' p<0.05, " p< 0 001 as compared to the control group, 
"= ρ<0.01 as compared to HUS patients (and the control group), nm means not enough material for the test 
available. 
Discussion 
The role of circulating cytokines and soluble TNF receptors in the pathogenesis of HUS was 
investigated in this study. No elevated levels of TNFa, IL-1/3 and IL-6 were found in the 
plasma of HUS patients, who had no extra-renal manifestations during the disease. In the 
study done by Filzpatnck et al, in which IL-8 and TNFa were measured in the plasma of 16 
HUS patients, only one patient had an elevated concentration of TNFa in the plasma [13]. 
However, the occurrence of these cytokines in the plasma during the initial phase of the 
disease can not be excluded, because these cytokines have a short half-life (less than 1 hour) 
and may therefore no longer be detectable in the plasma taken on admission in the hospital. 
On the other hand, Siegler et al [14] reported that, although TNFa is not detectable in 
plasma, it is elevated in the urine of HUS patients, suggesting that TNFa may be locally 
produced in the kidney and have a local effect in the kidney of HUS. Elevated levels of 
urinary cytokines have also been found in other kidney diseases and are believed to play a 
role in local inflammatory and infectious processes in the kidney [15]. Evidence for locally 
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produced cytokines in the kidney has also been obtained by miimino-staining and in situ 
hybridization [16] and from in vitro experiments with renal cells [17,18] Evidence for a 
local role of TNFa in HUS was recently given by Harel et al [19], who gave shiga like toxin 
I to transgenic mice bearing a chloramphenicol acelyltransferase (CAT) reporter gene with 
the TNFa promoter When given shiga like toxin I to these mice, CAT activity, which 
reflects the degree ot the activation of TNFa synthesis, was induced within the kidney, but 
not in other tissues Increased production of the cytokines TNFa, IL-1/3 and IL-6 can also 
be found in the media of cultured human monocytes after stimulation with verocytotoxin 1 
[20] A possible role for the locally produced TNFa in the kidney could be to increase the 
susceptibility of the endothelial cells locally for verocytotoxin by inducing more 
verocytotoxin receptors on the cell surface [21] 
Elevated levels of IL-6 were only found in the plasma of those HUS patients, who had 
extra-renal manifestations, consisting of seizures, loss of consciousness, coma and pancreatic 
necrosis In inflammatory conditions IL 6 is synthesized by a wide variety of cell-types 
(macrophages, endothelial cells and fibroblasts) upon stimulation with TNFa, IL-1 and other 
agents The major effects of IL-6 in an infection, are the induction ot acute phase proteins 
in hepatocytes and the final differentiation of B-cells into antibody producing cells We have 
shown before, that IL-6 did not induce the receptor of verocytotoxin on cultured human 
endothelial cells and therefore did not increase the susceptibility of the endothelial cells tor 
verocytotoxin, in contrast to TNFa and IL 1 [21]. Although the exact function of IL-6 in the 
plasma of HUS patients is still unknown and the group of HUS patients is small, plasma IL-6 
is associated in our study with the severity and/of outcome ol the disease Closely related to 
HUS is thrombotic thrombocytopenic purpura (TTP), a syndrome which in many aspects is 
familiar to HUS (micro-angiopathic hemolytic anemia, thrombocytopenia and renal 
impairment), but in which always generalized symptoms (lever and neurological 
complications) are present In the plasma ot all the thirteen patients of TTP, examined by 
Wada et al [7], elevated circulating levels of TNFa, IL 1/3 and IL 6 were found These data 
suggest that in patients with TTP and in severe cases of HUS, who develop also extra-renal 
manifestations, circulating cytokines may play a role in the pathogenesis of the disease 
Recently, two immunologically distinct soluble receptors sTNFR^ and sTNR75 have 
been identified [22] These soluble receptors represent forms of the extracellular domain of 
the cell surface receptors for TNba and studies done in healthy volunteers indicate that 
TNFa itself is involved in the induction of sTNFR release [22,21] Recent studies have 
shown that in sepsis and in malaria elevated levels of sTNFR are present [22,24,25] 
Although both sTNFR were elevated in the plasma of HUS patients, they were also elevated 
in the group of children with chronic renal failure This implies that these elevated sTNFR 
levels can not only be explained by increased activity of TNFa or by other substances with 
proteolytic activity, like elastase, but may be caused by insufficient kidney function In favor 
of this hypothesis is the recently report by Bemelmans et al [26], who demonstrated in a 
murine model that kidney malfunction induces an increase in the amount of sTNFRs in the 
plasma 
In conclusion, no elevated levels of circulating TNFa,IL iß and IL-6 were detected in 
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the mild form of HUS. On the other hand, elevated levels of IL-6 in the plasma were 
delected in HUS patients who displayed severe extra-renal manifestations. Probably locally 
produced cytokines may be more important in the pathogenesis of HUS than the circulating 
concentration. However, when in HUS extra-renal manifestations occur, circulating cytokines 
may have played or play a role in the pathogenesis. Results of elevated circulating sTNFR 
as shown in this study, should be carefully interpreted when kidney failure exist. 
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Summary 
Fibrinolytic parameters and von Willebrand factor (vWF) antigen were measured in the 
plasma of 10 patients with hemolytic uremic syndrome (HUS) Samples were taken at 
presentation and again two weeks later, before and after infusion of l-desamino-8-arginine 
vasopressin (DDAVP) Compared with the plasma values of healthy control children, levels 
of tissue-plasminogen activator (t-PA) antigen, plasminogen activator inhibitor type I (PAI 1) 
activity, vWF as well as fibnn(ogen) degradation products were significantly elevated in the 
plasma of HUS patients on admission No response ot the fibrinolytic parameters and vWF 
were seen when DDAVP-infusion was given on admission After two weeks, t-PA antigen 
and vWF had partially returned to basal values, and t-PA antigen increased rapidly again 
after DDAVP-infusion 
In order to investigate whether verocytotoxin contributes to the alteration of the 
fibrinolytic system found in HUS patients, purified verocytotoxin-1 (VT-1) was added to the 
media ot cultured human endothelial cells Addition ot VT 1 alone did not change the 
production of t-PA, PAI 1 and vWF antigen in these cells However, when the endothelial 
cells were pre-incubated with tumor necrosis factor a (TNF-a) to increase the number of 
VT-1 receptors, VT 1 induced a marked decrease ot the synthesis of t-PA, PAI-1 and vWF 
This was due to a decrease in overall protein synthesis in the TNF α and Т-1-treated 
endothelial cells 
We conclude from this study that the systemic fibrinolytic parameters measured in the 
plasma of HUS patients, are probably not a direct effect of VT-1 on the endothelium, but are 
sequelae of the disease in which the intestine and the kidney are predominantly affected 
Introduction 
Hemolytic uremic syndrome (HUS) is characterized by the triad microangiopathic hemolytic 
anemia, thrombocytopenia and acute renal failure The most common form ot HUS seen in 
children is the epidemic torm, which is preceded by an acute, often bloody, gastro-ententis 
Although the exact pathogenesis is not known, it is evident that the endothelium plays a 
central role. Histopathological studies of the kidney show swollen endothelial cells, detached 
from the glomerular basement membrane and bulging into the lumen of the capillaries, 
thrombi and fibnn depositions These thrombotic obstructions contribute to the acute renal 
failure in HUS patients [1] Since the beginning ot the eighties several studies have 
demonstrated that verocytotoxin-producing E coll are the main cause of the epidemic form 
of HUS [2] In vitro studies on human endothelial cells have shown that verocytotoxins are 
able to damage endothelial cells and may lead to inhibition ot the protein synthesis in the cell 
[3,4] 
The endothelial cells play an important role in the maintenance of the hemostatic balance 
in the blood [5] Besides having anticoagulant properties, the endothelial cells also prevent 
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the aggregation of platelets and stimulate fibrinolysis Endothelial cells are the principal 
source of tissue plasminogen activator (t-PA) in the blood In addition, they synthesize and 
secrete plasminogen activator inhibitor type 1 (PAI-1) [6] PAI-1 can also be liberated from 
platelets, but the platelet PAI activity is rather low and only contributes to a minor degree 
to a prolonged elevation of PAI activity in the circulating blood [7] Endothelial cells not 
only provide circulating t-PA under resting conditions, but they can also rapidly release t-PA 
upon stimulation by various agents including l-desamino-8-D-arginine vasopressin (DDAVP) 
This results in a marked increase in the fibrinolytic capacity of the blood [8] and is also 
accompanied by a marked, transient, release of von Willebrand factor (vWF) antigen from 
endothelial storage sites [9] In addition to the increase in circulating t-PA and vWF, the 
urokinase (u-ΡΑ) concentrations also rapidly increase in plasma after DDAVP-infusion [10] 
The mechanisms by which DDAVP causes increases in t-PA, u-ΡΑ and vWF are not 
completely understood, but it is likely that extrarenal V2-hke receptors are involved in the 
effects of DDAVP [11] 
The role of the fibrinolytic system in HUS has recently been highlighted by the report 
of Bergstein et al [12], who suggest that a decrease in PAI-1 antigen during peritoneal 
dialysis in HUS patients contributes to the recovery of the patients In order to get a better 
insight into the fibrinolytic system in HUS patients and to see it the regulation of the 
production of the fibrinolytic proteins by the endothelial cell is disturbed, we have measured 
fibrinolytic parameters in plasma samples taken on admission and after two to three weeks 
(convalescent phase), before and after stimulation with DDAVP In addition we have 
investigated whether verocytotoxin contributes to the change in the circulating fibrinolytic 
proteins and vWF To that end, we have examined whether human endothelial cells in culture 
change their synthesis of fibrinolytic proteins when they are incubated with purified 
verocytotoxin-1 (VT-1) 
Materials and Methods 
Patients 
Ten children (5 females/5 males, mean age 27 2 + 16 months, range 6 5 - 52 5 months), 
were diagnosed as having HUS, based on the presence of hemolytic anemia with burr cells 
in the peripheral blood smear, renal failure and thrombocytopenia [13] HUS was preceded 
by diarrhea, usually blood-stained Seven patients needed peritoneal dialysis, which ranged 
from one to 10 days (mean 5 3 + 3.3 days) In the blood of eight of these 10 patients, 
antibodies were detected against the most common verocytotoxin-producing E coli (VTEC) 
serotype 0157, indicating an infection with VTEC [14] In the faeces of one of the other two 
patients a VTEC serotype 0157:H7 was isolated. The main laboratory indexes of the patients 
are displayed in Tabie 1. In the first morning after admission to the hospital, before dialysis 
was undertaken, 0 3 μg/kg body weight DDAVP, diluted in 100 ml saline, was administered 
intravenously over a period of 30 minutes The same DDAVP-infusion was given to nine of 
the 10 HUS patients in the convalescent phase, ranging from 10 to 21 days after admission 
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Table 1. Laboratory indexes of patients known with HUS. 
Convalescent phase 
mean ± SD 
5.4 ± 0 7 
398 ± 159 
8 4 ± 2 5 
6.3 + 1.7 
60 ± 14 
not determined 
: (n = 9) 
(range) 
(4 5-6 4) 
(171-652) 
(5 5-12.5) 
(3.9-9 6) 
(44-84) 
Hemoglobin (mmol/1) 
Platelets (x lO'/mJ) 
Leucocytes (x lOVl) 
Urea (mmol/l) 
Creatinine (¿imol/l) 
Fibrinogen (g/1) 
Presence of VTEC 
infection 
On ac 
mean 
4 5 
63 
17 2 
38 
386 
3.1 
Imission (n = 
± SD 
± 1.0 
± 59 
± 8 2 
± Π 
± 265 
± 1 
9 patients 
H O ) 
(range) 
(3 4-6 5) 
(23-203) 
(7 6-33.8) 
(12-63.9) 
(139-928) 
(1 5-4 6) 
(14 + 4 days, mean ± SD). A 4.5 ml blood sample was collected immediately before and 
after the DDAVP-infusion. Blood samples were transferred to plastic tubes, containing 0.5 
ml 3.8% sodium citrate, and immediately cooled on melting ice. Platelet-poor plasma, 
obtained by centrifugation at 4°C for 10 minutes at 3000 g, was quickly frozen and stored 
at -70°C until assays were performed. In the same way, control blood samples were taken 
from ten children with chronic renal failure (CRF); from six children immediately before the 
hemodialysis session and 4 children during peritoneal dialysis. Blood samples from thirteen 
age-matched children in good clinical condition and with no underlying hematological or 
renal disease were used as controls. This study was approved by the local Institutional 
Committee of the Department of Pediatrics and carried out according to the guidelines of the 
Institutional Review Board of the Sint Radboud Hospital in Nijmegen, the Netherlands. 
Material 
l-desamino-8-D-arginine vasopressin (DDAVP), MinrinR was obtained from Ferring 
Pharmaceuticals AB (Malino, Sweden). Purified verocytotoxin-1 (VT-1) was prepared in the 
laboratory of Dr. Karmali (1.2 mg protein/ml; CDW vero-cells: titer 108-109M) [15]. 
Endotoxin content of the VT-1 preparation was < 0.05 EU/ml by Limulus amoebocyte lysate 
assay (Ε-Toxic, Sigma Chemicals Co (St. Louis, MO); at detection level of 0.05-0.1 EU/ml). 
Monoclonal antibodies PHI against VT-1 was a generous gift from Dr. C. Lingwood, Dept. 
of Microbiology, Hospital for Sick Children, Toronto, Canada. M199 medium supplemented 
with 20 mmol/1 HEPES was obtained from Flow Laboratories (Irvine, Scotland); tissue 
culture plastics were from Costar (Cambridge, MA). A crude preparation of endothelial cell 
growth factor was prepared from bovine brain as described by Maciag et al. [16]. Human 
serum was obtained from the local blood bank and was prepared from fresh blood of healthy 
donors, pooled, and stored at 4°C; it was not heat-inactivated before use. Newborn calf 
serum (NBCS) and fetal calf serum (FCS) were from GIBCO (Grand Island, NY) and 
Boehnnger Mannheim (Mannheim, Germany), respectively; they were heat-inactivated before 
use (at 56°C for 30 min). Heparin was purchased from Leo Pharmaceuticals fWeesp, the 
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Netherlands) Penicillin/streptomycin was from Boehnnger Mannheim (Mannheim, 
Germany) Human fibronectin was a gift of J A van Mounk, Central Laboratory of the Red 
Cross Blood Transfusion Service (Amsterdam, the Netherlands) Human recombinant tumor 
necrosis factor α (TNF-α) was a gitt from Jan Tavernier (Biogent, Ghent, Belgium) The 
TNF-α preparation contained 2 45 χ IO7 U/mg protein and less than 40 ng LPS per mg 
protein 35S- methionine was purchased from Amersham (Amersham, UK) 
Isolation and culture of cells 
Endothelial cells from human umbilical vein were isolated by collagenase treatment [17], 
cultured and characterized as previously described [18], endothelial cells from human 
foreskin were isolated and characterized as described [19] The tissues for isolation of 
endothelial cells were obtained according the guidelines of the Institutional Ethical Committee 
of the Academic Hospital and St Elisabeth Hospital in Leiden, the Netherlands The 
endothelial cells were seeded in fibronectin-coated 10 cm2 wells and cultured in M199 
medium supplemented with 20 mmol/1 HEPES (pH 7 4), 10% human serum (HS), 10% 
newborn calf serum (NBCS), 2 mmol/1 L-glutamine, 5 U/ml heparin and 150 μg/ml crude 
preparation of endothelial cell growth factor under 5%C02 and 95% air at 37°C When the 
cells reached confluency, they were detached by trypsin/EDTA and seeded in 2 cm2 
fibronectin-coated dishes with a split ratio of 1 3 The medium was renewed every two or 
three days The cells in the experiments were used after 2-4 passages Experiments of 
endothelial cells from umbilical cord and foreskin used in this study, were isolated from three 
different donors 
In vitro experiments 
For the experiments cells were released with trypsin/EDTA and seeded in a split-ratio 1 3 
in 2 cm2 fibronectin-coated plates and cultured in complete culture medium (400 μΐ/well) In 
the culture medium, 20% FCS was used instead of 10% human serum and 10% NBCS, 
because neutralising activity of NBCS was found against VT-1 and because of potential 
neutralising activity against VT-1 in human pooled serum When confluency was reached, 
medium was renewed and the cells were pre-incubated for 24 hours with or without TNF-a 
After this pre-incubation period media were renewed and media with or without VT 1 (17 
pmol/1 - 17 nmol/1) were added 24 hours later the media above the cells were collected, 
centnfuged and the supernatant was stored at 20°C until fibrinolytic assays were performed 
The cells were washed with M199 medium and released with trypsin/EDTA The cells were 
diluted with 1 1 trypan blue dye solution and counted in a hemocytometer Those cells, that 
did not absorb trypan blue dye, were recognized as viable cells The experiments were done 
in duplicate wells 
Protein synthesis was determined by assay of the incorporation of 3SS labelled methionine 
(0 25 μθ/ml added to complete culture medium) in 15S-proteins during an 24 hour 
incubation period After incubation the cells were washed and the cellular 3SS-labelled 
proteins were precipitated by adding 10% trichloroacetic acid Precipitated radioactivity was 
dissolved in 0 3 ml 0 3 mol/1 NaOH and counted in a liquid scintillation counter Protein was 
67 
determined according to the method of Lowry using bovine serum albumin as a standard 
[20]. 
Fibrinolytic assays 
Assay of t-PA antigen was performed with the ELISA Thrombonostika t-PA from Organon 
Teknika (Turnhout, Belgium) as described by Bos et al. [21]. PAI-1-antigen in the patients' 
sera was determined using the commercially available TintElize PAI-1 kit from Biopool 
(Umeâ, Sweden). For the in vitro assays the Immulyse ELISA from Biopool was used. For 
the u-ΡΑ antigen determination a sandwich ELISA was used as described by Binnema et al 
[22]. The assay measures the u-ΡΑ antigen present in plasma, irrespective of molecular form 
i.e. pro-u-PA, active u-ΡΑ and u-ΡΑ in complex with inhibitors. The plasmin-activable 
single-chain u-ΡΑ (scu-PA) was measured with a biological immuno-assay [23]. PAI activity 
was determined by a titration method with purified t-PA. Residual activity of t-PA was 
measured with a spectrophotometnc assay and the inhibitor activity was calculated from the 
amount of t-PA inhibited as described by Verheijen et al. [24]. vWF antigen was measured 
with a modified ELISA adapted from Ingerslev, using pooled plasma from healthy donors 
as a reference ( = 100%) [25]. Fibrinogen was measured with the Chronometrie assay as 
described by Clauss [26]. Total fibnn(ogen) degradation products (TDP), fibrin degradation 
products (FbDP) and fibrinogen degradation products (FgDP) were measured with the 
sandwich-type enzyme immunoassays Fibrinostika TDP, Fibnnostika FbDP and Fibnnostika 
FgDP respectively, from Organon Teknika (Boxtel, the Netherlands). The data of TDP, 
FbDP and FgDP are expressed as mg fibrinogen equivalent unit/1 [27] All measurements 
were done in duplicate. 
Statistical analysis 
Results are expressed as mean + SD. The significance of differences between the different 
groups of patients was determined by using the Mann-Whitney test. The Wilcoxon-test was 
performed for paired data when the fibrinolytic parameters before and after DDAVP-infusion 
in HUS-patients were compared. The Pearson's coefficient correlation-test was used to 
determine the correlations between fibrinolytic parameters,- clinical severity and laboratory 
indexes. 
Results 
Patients 
Table 2 summarizes fibrinolysis parameters and vWF antigen values in the blood of children 
with HUS, children with chronic renal failure and of children with no underlying 
hematological or renal disease (control children). Basal values of t-PA antigen were lower 
in control children (2.8 ± 1.5 μg/l) than in healthy adults (6.4 ± 2.3 ^g/1) [21]. These 
observations resemble the recently published fibrinolytic parameters measured in plasma of 
children by Andrew et al. [28]. Basal values of u-ΡΑ antigen were higher in control children 
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Table 2. Fibrinolytic parameters and vwf measured in plasma of patients, with HUS. 
t-PA antigen (pg/l) 
PAH antigen (fig/1) 
PAI activity (IUxltf/1) 
u-ΡΑ antigen (/ig/l) 
scu-PA (Mg/l) 
vWF 
(% ot pooled plasma) 
TDP (mg/1) 
FbDP (mg/1) 
FgDP (mg/1) 
HUS (n = 10) 
Admission 
9.2 
68 
14.8 
5 2 
2 5 
311 
11 
6.7 
3 9 
± 
± 
+ 
+ 
+ 
+ 
± 
± 
+ 
3.9 
75 
11 4 
1 8 
0 7 
92 
8 
6.7 
1.9 
HUS (n = 9) 
Convalescent 
4 5 
21 
5.2 
5.8 
3.2 
166 
2 7 
0 9 
1.5 
+ 
+ 
+ 
+ 
± 
+ 
± 
± 
+ 
1 3' 
6 
1.8' 
1 2 
0 5' 
87' 
4.7' 
1 3 " 
2 9 
CRF (n=IO) 
2.5 
27 
5.9 
5.6 
3 1 
180 
0 9 
0.9 
0.5 
± 2 3" 
± 21 
± 2 6" 
± 1 7 
± 1.3 
+ 69' 
+ 1.3" 
± 1.9" 
± 1.0" 
Control 
2.8 
29 
3.4 
4.9 
3.2 
105 
0 26 
0.07 
0.07 
± 
± 
± 
+ 
± 
+ 
+ 
± 
± 
(n=13) 
1.5" 
13 
ο δ ­
ι.2 
0.6 
62" 
0 20" 
0 05" 
0 09" 
The data of HUS patients on admission (mean ± SD) are compared with dala from the same patients two or 
three weeks after admission (convalescent phase), with those ot patients with chronic renal failure (CRF) and 
those of the control group with no hematological and nephrological problems (control) To determine significant 
changes in the HUS patients, paired dala obtained on admission and in the convalescence phase were compared 
with the Wilcoxon lest. " = ρ < 0 05, " ρ < 0 01 as compared to data on admission. To compare the data 
of different groups of patients, the Mann-Whitney test was used = ρ < 0.01, " = ρ < 0.001 as compared 
to the HUS group on admission 
(4.9 ± 1.2 ¿tg/1) than in adults (3.5 ± 1.2 fig/1) [23]; basal values of vWF antigen and PAI-
1 antigen are comparable to adults [29]. In accordance with other studies [30] elevated vWF 
concentrations were found in children with acute and chronic renal failure. 
The plasmas of HUS patients on admission had significantly elevated levels of t-PA 
antigen, vWF antigen and PAI activity compared with control children. PAI activity 
correlated very well with PA1-1 antigen (r=0.71, Pearson's coefficient correlation). t-PA 
antigen levels measured from plasma taken on admission, showed moderate correlation with 
PAI activity and resp vWF (r=0.67 resp r=0.59, Pearson's coefficient correlation). No 
correlation was found for the fibrinolytic parameters and the clinical severity, white blood 
cell count, platelets or leucocytes. Only vWf antigen correlated with the amount of white 
blood cells on admission. 
After two to three weeks hospitalization, the increases in t-PA antigen and vWF antigen 
were reduced by about 75% and the PAI activity levels had been normalized (Fig. I). In 
contrast to children with HUS, children with chronic renal failure showed similar plasma t-
PA antigen and PAI-1 antigen levels as control children; PAI activity and vWF antigen were 
higher in these patients than in the control group. Elevated levels of TDP, FbDP and FgDP 
were detected in the plasma of HUS patients on admission. A decline in these degradation 
products was seen in the convalescent phase, but the values were not yet entirely normalized 
(Fig. 1). 
The concentration of circulating t-PA, u-ΡΑ and vWF can rapidly be increased by 
infusion of DDAVP. When DDAVP infusion was given upon admission to the HUS patients, 
we observed no significant increase in t-PA antigen or vWF antigen in the plasma (Table 3). 
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Figure 1. T-PA antigen, PAI activity, vWF antigen and fibrin degradation products (FbDP) measured in the 
plasma of nine Η US patients, individually indicated by numbers Measurements were done in plasma (aken on 
admission (A) and in the convalescent phase of HUS (C). 
Neither did the plasma concentration of u-ΡΑ antigen change in HUS patients during DDAVP 
infusion. When DDAVP was given to the same patients two to three weeks later during the 
convalescent phase, an increase in t-PA antigen was found in all patients, whereas no 
increase was seen for vWF antigen or u-ΡΑ antigen (Table 3). 
In vitro experiments 
It is generally assumed that endothelial damage by verocytotoxins plays a key role in the 
pathogenesis of the epidemiological form of HUS As the prolonged elevations of the plasma 
t-PA, PAI-1 and vWF levels suggest that the synthesis of these proteins in endothelial cells 
is enhanced, we examined whether verocytotoxin-1 (VT-1) changes the production of t-PA 
and PAI-1 by human endothelial cells in vitro. Fig. 2A shows that VT-1 did not significantly 
affect the production of t-PA and PAI-1 in non-stimulated confluent umbilical vein 
endothelial cells. To enhance the sensitivity of human umbilical vein endothelial cells for VT-
1, we also studied these parameters in endothelial cells that had been preincubated for 24 h 
with TNFa. This preincubation causes a marked increase in the expression of VT-1 receptors 
[4]. Under these conditions VT-1 markedly reduced the synthesis of t-PA and PAI-1 (Fig. 
2B). In agreement of the known inhibitory effect of VT-1 on the cellular protein synthesis, 
a marked decrease in the synthesis of cellular proteins and in the number of cells was 
70 
Table 3 Effect of DDAVP on fibrinolytic parameters and vwf measured in plasma ot patients with HUS 
HUS on admission (n= 10) HUS convalescent phase (n~9) 
t-PA antigen (μκ/1) 
PAI-1 antigen (/ig/1) 
PAI activity (IUxlC/l) 
u-ΡΑ antigen (μξ/\) 
scu-PA antigen (μξ/\) 
vWF (% of pooled plasma) 
before DDAVP 
9 2 ± 3 9 
68 + 75 
15 ± 11 
5 2 ± 1 8 
2 5 ± 0 7 
311 ± 9 2 
after DDAVP 
109 ± 5 0 
44 ± 51 
20 ± 27 
5 6 + 14 
2 5 ± 0 6 
373 ± 172 
before DDAVP 
4 5 ± 1 3 
21 ± 6 
5 2 + 18 
5 8 ± 1 2 
3 2 ± 0 5 
166 ± 87 
after DDAVP 
8 0 ± 3 3" 
17 ± 7 
4 0 + 1 4 
5 0 + 0 9 
2 9 ± 1 1 
211 ± 100 
The effect of DDAVP on fibrinolytic parameters and vWF was measured before and after treatment with 
DDAVP in the acute and in the convalescent phase The data are expressed as mean ± SD Statistical analysis 
of the paired data obtained on admission and in the convalescent phase was performed with the Wilcoxon test 
" = ρ < 0 05 
observed after incubation with VT-1 Similarly, the production of vWF antigen decreased 
after exposure of the cells to TNFcv and VT-1 (not shown) These effects were not found 
when VT-1 was inactivated by heat-treatment before being added to the cells or when VT-1 
was preincubated with monoclonal antibody to VT-1. Similarly, in TNFa-treated human 
microvascular endothelial cells VT-1 induced a concentration-dependent decrease in cell 
number, PAI-1 production and accumulation of t-PA (Fig 3) These experiments indicate 
that VT-1 does not induce t-PA, PAI-1 or vWF production, but rather decreases their 
synthesis in endothelial cells by its inhibitory effect on protein synthesis 
Discussion 
In this study we report on the fibrinolytic parameters and vWF antigen in plasma of HUS 
patients, patients with chronic renal failure and healthy children 
Elevated levels of t-PA antigen and PAI activity were found in the plasma of HUS patients 
on admission These findings correspond with the recent observations in thrombotic 
thrombocytopenic purpura and HUS patients by Monteagudo et al [31] Simultaneously the 
plasma vWF concentration was enhanced Elevated fibnn(ogen) degradation products found 
in the plasma on admission, indicate that there is a systemic fibrinogenolysis and fibrinolysis 
secondary to an activated state of coagulation 
Nowadays it has become clear that verocytotoxin-producing E coli infection is the major 
cause of the epidemic form of HUS In nine HUS patients we found evidence for a 
verocytotoxin-producing E coli infection [14] Verocylotoxin can cause endothelial cell-
damage, which is the predominant feature of the glomeruli in the kidney of patients with 
HUS. We demonstrated that addition of VT-1 to human endothelial cells that contained 
sufficient VT-1 receptors (as induced here by TNFa-pretreatment [4]) causes a decrease in 
the production of t-PA and PAI-1 antigens likely due to an inhibitory effect of VT-1 on 
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Cell-vlablllty "S-сеІІиІаг proteins t-PA antigen PAl-1 antigen 
Figure 2. Confluent human umhilical vein endothelial cells in 2 cm: wells, were pre-incuhated for 24 hours 
without (A) or with (B) 500 U/ml TNF-a and subsequently incubated in 0.4 ml M199-HEPES medium 
supplemented with 20% telai calf serum and the same amount of TNF-a, together with 17 pmol/l VT-I (hatched 
bars) and 17 nmol/1 VT-I (black hars) and without VT-1 (double hatched bars). The number of cells at the start 
of the preincubation was 9x10" cells/cnv tor all wells. After preincubation the number ot cells was 9.3 χ 10a 
cells/cnv for control cells (A) and 6 3x10* cells/cnv for TNFa-trealed cells (B) Because VT-I caused cell 
death during the incubation with VT-1 and TNFor, by which the number of viable cells changed during the 
incubation period, the production of l-PA and PAI-1 antigens are expressed per cur'. Viability of the cells was 
determined by trypan hlue exclusion test. Other expenmental details are given in the Material and Methods 
section. Data are expressed as mean ± SD ot three experiments with endothelial cells from different donors. 
Cell-viability t-PA antigen PAI-1 antigen 
Figure 3. Confluent human toreskin microvascular endothelial cells in 2 cm : wells were pre-incubated for 24 
hours with 500 U/ml TNF-a and subsequently in 0.4 ml M 199-HEPES medium supplemented with 20% fetal 
call serum and the same amount of TNFa, together with 17 pmol/l VT-1 (hatched bars) and 17 nmol/l VT-1 
(black bars) or without VT-1 (double hatched bars). The number of cells after 24 hours preincubation with 
TNFa was 8 χ 10* cells/cm: for all variables. Because VT-1 caused cell death during the incubation with VT-1 
and TNF, by which the number of viable cells changed, the production of t-PA and PAI-1 antigens are 
expressed per cnv Data given are expressed as mean ± SD ot three independent experiments. 
JL 
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overall protein-synthesis. Such inhibition of protein-synthesis has also recently been observed 
in renal endothelial cells [32]. 
The t-PA, PAI-1 and vWF levels were elevated in the plasma of HUS patients on 
admission. This suggests that - in addition to the hemorrhagic colitis and the kidney failure-
HUS patients display a general activation of the vascular endothelium. A similar pattern of 
elevated levels of t-PA, PAI-1 and vWF has been observed in the plasma of patients with 
sepsis, during which endotoxins and endogenous mediators, in particular the inflammatory 
mediators TNFa and interleukin-1 (IL-1) contribute to these alterations [33,34]. TNFa, IL-1 
and IL-6 were not elevated in the plasma of patients with a mild form of HUS [35,36] and 
own unpublished observations), but we observed that they were elevated in patients with a 
severe form of HUS, i.e. in patients who also developed neurological complications and 
pancreas involvement (N.van de Kar, manuscript in preparation). These data suggest that 
circulating cytokines may play a role in HUS, but are unlikely to be significant in mild forms 
of HUS. On the other hand, locally produced inflammatory mediators in the kidney of HUS 
patients may escape detection in plasma, because of their short biological short half-life [37]. 
In favour of a local effect of inflammatory mediators, Siegler et al. reported that TNFa was 
elevated in the urine of HUS patients [36]. Even, if inflammatory mediators may contribute 
locally to the increase of the t-PA, PAI-1 and vWF levels in plasma, it is likely that other 
factors which are generated in the injured intestines and/or kidney, are an important cause 
of the sustained elevation of the t-PA, PAI-1 and vWF concentration in the blood of HUS 
patients [38-40]. Activated leucocytes, which can be found in the peripheral blood in HUS 
[41], contribute to endothelial activation, and also other factors such as activated complement 
and coagulation factors may be involved [42-45]. 
In our patients no release of t-PA, u-ΡΑ and vWF could be evoked by DDAVP-infusion 
on admission. Unresponsiveness to DDAVP cannot entirely be explained by the renal 
problems seen in HUS, because patients with terminal renal insufficiency and anephnc 
patients can still react to DDAVP-infusion [46,47]. However, it is well-known that patients 
with kidney diseases respond less pronouncedly to DDAVP than healthy volunteers, and 
some are non-responders [46,47]. Unresponsiveness to DDAVP-infusion of t-PA and vWF 
antigen release has also been observed in patients with inflammatory bowel disease (M. 
Crohn, ulcerative colitis), who have a normal level of t-PA and vWF before DDAVP-
infusion [48]. It is therefore possible that the lack of response to DDAVP in HUS patients 
is caused by a simultaneous disturbance of the kidney and the intestine. On the other hand, 
it is unlikely that the lack of response of t-PA and vWF to DDAVP-infusion is due to the 
depletion of endothelial 'storage pools', because the biological half-life of t-PA is very short 
and depletion of the t-PA should result in a drop in circulating t-PA. After two weeks of 
hospitalization not only the plasma levels of t-PA, PAI-1 and vWF antigen were normalizing, 
but also t-PA antigen increased upon DDAVP-infusion. This indicates that the activation of 
the endothelium had decreased and that the response to DDAVP was recovering. It is of 
interest to note that a DDAVP-induced increase in t-PA antigen was also found in patients 
recovering from M.Crohn or ulcerative colitis. Recently, Bergstein et al. reported that 
elevated levels of PAI-1 during the clinical course was related to a poor outcome [12]. In our 
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study, all patients, including those with a high PAI-1 level on admission, completely 
recovered. 
While VT-1 causes a decrease of the production of fibrinolytic proteins by endothelial 
cells in vitro, the plasma levels of these proteins in HUS patients changed in the opposite 
direction. Although these data appear to be paradoxical, they do not really conflict. We 
hypothesize that the following events may occur in HUS. After a period of hemorrhagic 
colitis, the main organ affected in HUS is the kidney. The human kidney contains receptors 
for verocytotoxin [49], the toxin is generally assumed to contribute to the damage of the 
endothelium in the glomeruli in the kidney. This damage can lead to a local procoagulant 
situation. In this condition thrombin and inflammatory mediators are generated and 
polymorphonuclear leucocytes are activated, which probably cause a general activation of the 
endothelium at sites distal of the affected areas. This is reflected in the elevated levels of t-
PA, PAI-1 and vWF found in the plasma of the HUS patients in the acute phase of the 
disease. Further studies will be necessary to prove this hypothesis. 
We conclude from this study, that the systemic fibrinolytic parameters measured in 
plasma of HUS patients are probably not a direct effect of VT-1 on the endothelium, but are 
sequelae of the disease in which the kidney and the intestine are predominantly affected. 
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Summary 
The epidemic form of the hemolytic uremic syndrome (HUS), beginning with an acute 
gastro-ententis has been associated with a verocytotoxin producing E toh infection The 
endothelial cell is believed to play an important role in the pathogenesis of HUS Endothelial 
cell damage by verocytotoxin-1 (VT-1) in vitro is potentiated by the additional exposure of 
inflammatory mediators, such as tumor necrosis factor a (TNFa) Preincubation of human 
umbilical vein endothelial cells with TNFa resulted in a ten to hundred fold increase of 
specific binding sites for 12,I-VT-1 Furthermore, interleukin 1 (IL-1), lymphotoxin (TNF/3) 
and lipopolysacchande (LPS) also markedly increase VT 1 binding An exposure of several 
hours to TNFa was enough to enhance the number of VT 1 receptors on the endothelial cells 
for 2 days The TNFa induced increase in VT-1 binding could be inhibited by simultaneous 
addition of the protein synthesis inhibitor cycloheximide Glycolipid-extractsofTNFa-treated 
cells tested on thin layer chromatography demonstrated an increase of globotnaosylceramide 
(GbOse^er), a functional receptor for VT-1, suggesting that preincubation of human 
endothelial cells with TNFa leads to an increase in GbOse^er synthesis in these cells 
We conclude from this study that TNFa and IL 1 induce one (or more) enzyme(s) that 
is (are) rate-limiting in the synthesis of the glycohpid VT 1 receptor, GbOse,cer These in 
vitro studies suggest that in addition to verocytotoxin 1 inflammatory mediators play an 
important role in the pathogenesis of the hemolytic uremic syndrome 
Introduction 
The hemolytic uremic syndrome (HUS) is a clinical syndrome consisting of the tnad 
hemolytic anemia, thrombocytopenia and acute renal failure Although the exact pathogenesis 
is still unknown, it is believed that endothelial cell damage plays a central role in this 
syndrome and that one of the requirements for an agent to cause HUS is its ability to injure 
endothelial cells The epidemic form of HUS starting with an acute, often bloody, gastro-
enteritis is mostly seen in children [1] In 1985 Karmali associated this form of HUS with 
an infection of verocytotoxin or shiga-hke toxin producing E coli infection [2] Since then 
several other investigators across the world have been able to confirm this association A 
family of three verocytotoxins or shiga-like toxins has been described verocytotoxin-1, 
verocytoloxin-2 (shiga-like toxin II) and verocytotoxin 2 variant [4,4] Recently, the 
functional receptor for these toxins has been identified as the glycosphingohpid, 
globotnaosylceramide [5,6] This receptor has also been found in the human kidney [7] and 
on cultured human endothelial cells [8] 
In most HUS patients, the endothelial damage is primarily concentrated in the kidney 
endothelium, whereas in severe HUS patients the endothelial damage extends to other organs, 
such as pancreas and brain [9] When we investigated whether local factors generated dunng 
coagulation or inflammation can make the endothelium more vulnerable to verocytotoxins, 
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we observed that endothelial damage by verocytotoxin-1 (VT-1) depends on the additional 
presence of the inflammatory mediator TNFa [10] Similarly, two other groups have recently 
found that endothelial cells become more sensitive to other related toxins, shiga-hke toxin 
Hand shiga toxin when they are simultaneously exposed to TNFa [11,12] The inflammatory 
mediators TNFa and IL-1 are produced and released by monocytes [13] and by mesangial 
cells [14,15] and hence may play a local role in the kidney 
In this report we extend our observations and demonstrate that the inflammatory 
mediators TNFa and IL-1 make the endothelial cells sensitive to VT 1 by the induction of 
VT-1 receptors on their surface 
Mai e rial s and Methods 
Materials 
Purified verocytotoxin-1 (VT 1) was prepared in the laboratory of Dr Karmali (1 2 mg 
protein/ml, CDS0 vero-cells titer 10" 10
9) [16] Endotoxin content of the VT-1 preparation 
was < 0 05 EU/ml by Lnnulus amoebocyte lysate assay (Ε-Toxic, Sigma Chemicals Co (St 
Louis, MO), at detection level of 0 05-0 1 EU/ml) Monoclonal antibodies РЬ^ against VT-1 
was a generous gift from Dr С Lingwood, Dept of Microbiology, Hospital for Sick 
Children, Toronto, Canada M199 medium supplemented with 20 mM HEPES was obtained 
from Flow Laboratories (Irvine, Scotland), tissue culture plastics were from Costar 
(Cambridge, MA) A crude preparation of endothelial cell growth factor was prepared from 
bovine brain as described by Maciag et al [17] Human serum was obtained from the local 
blood bank and was prepared from fresh, healthy donors, pooled, and stored at 4°C, it was 
not heat-inactivated before use Newborn calf serum (NBCS) and fetal calf serum (FCS) was 
from GIBCO (Grand Island, NY) and Boehnnger Mannheim (Mannheim, Germany), 
respectively, they were heat-inactivated before use (at 56°C lor 30 min) Heparin was 
purchased from Leo Pharmaceuticals (Weesp, The Netherlands) Penicillin/streptomycin was 
from Boehnnger Mannheim (Mannheim, Germany) Human fibronectin was a gift of J A 
van Mounk, Central Laboratory of the Red Cross Blood Transfusion Service (Amsterdam, 
the Netherlands) Pyrogen-free human serum albumin was purchased from the Central 
Laboratory of the Red Cross Blood Transfusion Service (Amsterdam, the Netherlands) a-
Thrombin was obtained from Sigma Chemical Co (St Louis, MO) Human recombinant 
tumor necrosis factor α (TNFa) and lymphotoxin (TNF/3) were gifts from Jan Tavemier 
(Biogent, Gent, Belgium) The TNFa preparation contained 2 45 χ 107 U/mg protein and 
less than 40 ng LPS per mg protein, the specific activity of lymphotoxin (TNF/3) was 1 6 χ 
IO6 U/mg protein Human recombinant IL-6 (expressed in yeast cells) was prepared in the 
Laboratory of Molecular Biology, State University, Gent, Belgium it was biologically active 
and had a specific activity of 1 4 χ 10* U/mg protein as tested on 7TD1 cells Human 
recombinant interleukin-ΐα (IL-la) and interleukin-1/3 (IL-1/3) were a gift from S Gillis 
(Immunex Corporation, Seattle, WA) they had a specific activity of 108 U/mg 
Lipopolysacchande (LPS) of E coli serotype 0128 B12 was obtained from Sigma Chemical 
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Co (St Louis, MO) "S-methionine and Na'2SI-iodine were purchased from Amersham 
(Amersham, UK) Iodo-gen, ïodination reagent was obtained from Pierce (Rockford, II) 
Anti-Tj" serum [18], serum which contains antibodies against P"(Globotnaosylceramide 
GbOse,cer), Ρ (Globotetraosylceramide GbOsejCer) and P, blood group antigens, was 
obtained from DiaMed (Morat Murten, Switzerland) Chlorolorm, methanol, and hexane was 
obtained from Merck (Darmstadt, German)) Plastic coated silica gel F1500 TLC-plates 
came from Schleicher and Schuell (Dassel, Germany) Polyisobutylmethacrylate was obtained 
trom Polysciences Ine (Washington, MD) A standard mixture of pure neutral glycolipids 
containing Gal/31 lCeramide(Cer)(CMH) Ga]j81-4GlciSl-lCer(CDH), Galal-4Ga]01-4Glq31-
lCer(GbOse3cer) GalNac/3MGalal 4Gal/31-4Glc/31-lCer(GbOse4cer), GalNacal 
1GalNac/31-3Galal-4Gal01-4Glc01 ICer (Forssman pentasaccharide) was from BioCarb AB 
(Lund, Sweden) X-OMAT X-ray film came from Eastman Kodak Co (Rochester NY) 
Cell culture 
Endothelial cells from human umbilical vein and from human temoral vein were isolated by 
collagenase treatment [19], cultured and characterized as previously described [20,21] The 
endothelial cells were seeded in fibronectin coated 10 cm' wells and cultured in M199 
medium supplemented with 20mM HEPES (pH 7 4), 10% human serum (HS), 10% newborn 
calf serum (NBCS), L-glutamine, 5 U/ml heparin and ПО Mg/ml crude preparation of 
endothelial cell growth factor under 5%CO, and 95% air at M°C When the cells reached 
confluency, they were detached by trypsin/EDTA and seeded in 2 cm2 fibronecnn coated 
dishes with a split ratio of 1 "\ Umbilical vein endothelial cells in the experiments were used 
after 2-4 passages, femoral vein endothelial cells after 6 or 7 passages The medium was 
renewed every two or three days 
Cytotoxicity Assay 
For these experiments cells were released with trypsin/EDTA and seeded in confluent density 
in 2 cm2 fibroneclin-coated plates and cultured in complete culture medium (400 μΙ/well) 
20% FCS was used instead of 10% human serum and 10% NBCS, because neutralising 
activity of NBCS was found against V I 1 and because of potential neutralising activity 
against VT 1 in human pooled serum When confluency was reached, medium was renewed 
and the cells were preincubated for 24 hours with TNFa (500 U/ml) The next day the 
medium was renewed, and punned VT 1 (17pM-17nM) with or without TNFa or a-
thrombin, was added to the wells After 24 hours incubation the cells were washed with 
M199 medium, the viable cells released with trypsin/EDTA and counted in a hemocytometer 
The experiments were done in duplicale 
Other assays 
Protein synthesis was determined by assay of the incorporation of "S-labelled methionine 
(0 25 μθ/ml added to complete medium) in "S-proteins during an 8 or 24 hour incubation 
period After incubation, the cells were washed and cellular "S-labeled proteins were 
precipitated by adding 10% trichloroacetic acid Precipitated radioactivity was dissolved in 
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0.3 ml 0.3 M NaOH and counted in a liquid scintillane counter Protein was determined 
according to the method of Lowry et al [22] using bovine serum albumin as a standard. Cell 
counts were performed in triplicate with a hemocytometer. 
Binding ofl2SI-VT-l to human endothelial ceils 
VT-1 was radiolabeled with Na'2SI according to the Iodogen-procedure [23] Four 
preparations of purified VT-1 were ìodinated to specific activities of 2 7 μΟ, 4.1 μΟ, 21 
¿¿Ci and 37 μ£\Ιμ% of protein. All preparations gave similar results 
The binding-assay was carried out as follows: after the incubation period at 37°C with or 
without inflammatory mediators, the endothelial cell cultures in 24-well plates were washed 
with M199 medium + 0 1% human serum albumin (HSA) Subsequently the cells were 
incubated for 3 hours with 0.3 or 1 nM ,2,I-VT-1 in M199 medium + 0.1% HSA at 0°C. 
After this incubation, the supernatant fluid was aspirated, the cells were washed five times 
with M199 medium + 0 1 % HSA, and total cell protein was solubihzed in 400 μΐ IM 
sodium hydroxide at room temperature. Radioactivity of the endothelial cells was measured 
in a gamma-counter Non-specific binding was determined by assay of '2Т- Т-1 binding in 
the presence of a 100-told excess of unlabelled VT-1. Cellular specific binding was 
determined by subtracting the non-specific binding from the cellular binding of l24-VT-l 
determined in the absence of unlabelled VT-1. To study the effect of anti-Tja serum ( 
blocking of the binding of VT-1 to GbOse,cer), anti-Tj3 serum in M199 medium + 0.1% 
HSA was added 2 hours prior to and during the binding assay with '2<I-VT-1. 
Extraction of Glycolipids 
Confluent human umbilical vein endothelial cells (HUVEC) in 162 cm2 flasks were incubated 
for 24 h with or without TNFa (500 U/ml). Subsequently the glycolipids were extracted as 
described by Lingwood et al [6] in short, the cells were trypsimzed, harvested with ice-cold 
PBS and spinned down by 3 min centnfugation (3000 rpm) at 4CC. The pellet was washed 
3 times with PBS. The pellet was finally resuspended in PBS, and 20 volumes of 
chloroform/methanol (2:1, v/v) were added. Cell debris was removed by filtration through 
glass-wool. One volume of water was added and partitioned. The lower phase was dried and 
incubated at 37°C for 2 hours in 0.4 M КОН in ethanol; two volumes (v/v) of chloroform 
were added and the mixture was partitioned against two volumes of water The lower phase 
was separated and frozen at -20°C until TLC-studies were performed. 
Thin Layer Chromatography 
The lower phase from the extraction above was dried and resuspended in 
chloroform/methanol (2:1). Samples were separated on a silica gel TLC plate using 
chloroform: methanol water (65:254). After separation the plate was soaked 3 times for 1 
minute in 0.01% polyisobutylmethacrylate in hexane and air dried, followed by overnight 
incubation in PBS supplemented with 1 % BSA and 0 05% Tween 20. Subsequently, the plate 
was incubated with 50 ml VT-1 solution (15 nM unlabelled and 1.5 nM 12,I-VT-1 in 1 % BSA 
and 0.05% Tween in PBS) during 4 hours at 4°C The plate was extensively washed with 
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0.05% Tween 20 and 1% BSA in PBS, air dried and exposed overnight to X-OMAT X-ray 
film. 
Results 
Cytotoxicity of VT-1 towards human endothelial cells 
Verocytotoxin-1 (VT-1) caused a decrease in cell viability of endothelial cells when they had 
been preincubated with the inflammatory mediator TNFa (Figure la). VT-1 had no 
significant effect on the cell viability of untreated cells. Only in two out of seven independent 
cell cultures of umbilical vein endothelial cells, 24 h incubation with 17 nM VT-1 alone 
caused a small degree of cell detachment (21 and 24%). Even upon prolonged incubation 
with 17 nM VT-1 alone (72 h) we found in only four out of six independent cell-cultures a 
moderate cell detachment (32% + 17%; mean + SD). In all conditions, no cytotoxicity was 
found when VT-1 was inactivated by heat-treatment prior to addition or when the VT-1 was 
preincubated with monoclonal antibodies to VT-1. Preincubation of the cells with thrombin 
(0.1 to 1 U/ml) did not change the sensitivity of endothelial cells for VT-1 (3 independent 
experiments; not shown). Similar results were obtained when endothelial cells from adult 
human vein (v.femoralis) were used (Figure 2a) 
Verocytotoxin may inhibit eukaryotic protein synthesis by depunnation of a single adenine 
residue from the 28S RNA component of the ribosome [24], which may result in the 
inhibition of the interaction of elongation factor-1 with the ribosome. Cellular protein 
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Figure J. Toxicity of verocytotoxin-1 (VT-1) tor confluent human umbilical vein endothelial celK (HUVEC) 
preincubated for 24 h without or with T N F a 500 U/ml A Number of viable cells after an 8 and 24-hour 
incubation period with VT-1. After a preincubation period of 24 hours without (open symbols) or with (closed 
symbols) T N F a , cells were incubated without VT-1 (circles), with 17pM VT-1 (triangles) or with 17nM VT-1 
(squares) for 8 and 24 h, and the number ot viable cells was counted in a hemocytometer В Incorporation of 
, sS-methionine in 13S-proteins was determined by trichloroacetic acid precipitation after an 8- or 24-h incubation 
period with the various concentrations of VT-1 given above. 
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time (h) ντ-1 
Figure 2. Toxicity ot VT-1 for confluent human femoral vein endothelial cells preincubated with TNFa 500 
U/ml for 24 hours 
A: After a preincubation period of 24 hours without (open symbols) or with (closed symbols) TNFa, cells were 
incubated without VT-1 (circles), with 17pM VT-1 (triangles) or with 17nM VT-1 (squares) for 8 and 24 h, 
and the number of viable cells was counted. 
B: Incorporation of ,5S-methionine in 3,S-proleins. Cells were preincubated for 24 h without TNFa (double 
hatched bars), with 50 U/ml TNFa (hatched bars) or with 500 U/ml TNFa (black bars) After preincubation, 
cells were incubated for 24 hours with 17pM, 170pM or 17nM VT-1 or without VT-1 (control) 
synthesis was measured by assaying the incorporation of "S-methionine into total cellular 
protein. Incubation of the cells with VT-1 alone did not affect the protein synthesis over a 
24 h period (Figure lb,). However, when the cells were preincubated for 24 h with TNFa, 
the protein synthesis rate was decreased dramatically by VT-1, whereas the protein synthesis 
was not decreased by TNFa alone As is shown in Figure 2b, the observed decrease 
depended on the concentrations of both VT-1 and TNFa. 
Binding of VT-1 to human endothelial cells 
To evaluate whether the enhanced VT-1 sensitivity of endothelial cells caused by TNFa was 
due to an increase in VT-1 receptors on the cell surface, binding experiments with 12T-VT-1 
were performed. TNFa induced an increase in VT-1 binding after a 6 to 8 hour lag period; 
this increase continued for up to 48 hours (Fig. 3). The increase was due to an increase in 
specific binding of 12T-VT-1, as nearly all 12,I-VT-1 binding could be displaced by excess of 
unlabelled VT-1. No change in VT-1 binding was observed in non-treated cells (Fig. 3). In 
six independent experiments with confluent HUVEC of different donors, 24-hour incubation 
with 500 U/ml TNFa resulted in a 38-fold increase in specific VT-1 binding (range 13- to 
90-fold). 
Subconfluent HUVEC displayed a higher basal VT-1 binding than highly confluent cells, 
as is shown in Fig. 4 for a representative experiment. When the same cells were incubated 
for 18 hours with TNFa, the binding of VT-1 increased for all cells, but the relative increase 
was larger in highly confluent HUVEC. In further experiments highly confluent cells have 
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Figure 3 (left) Effect of T N F a pretrealment on the binding of VT l to confluent HUVEC 
Atter preincubation of the cells wilh 500 U/ml T N F a (triangles) at 37°C for the indicated period of time the 
cells were washed and binding of 0 3 nM ' 'I VT 1 was assayed at 0°C in the presence (open symbols) or 
absence (closed symbols) of 40 nM unlabeled VT 1 Binding of VT 1 to control cells that were prcincubatcil 
without T N F a are indicated in squares 
hlgure 4 (right) Effect of cell density on the specific binding of VT 1 to HUVEC 
During the assay of VT 1 binding subconfluent cells had a 70% to 80% cell density of that of confluent cells 
Highly confluent cells were maintained tor three days al confluent density before the start ol the experiment 
Before assay of the binding of 0 3 nM 'I VT 1 the cells were preincubatcd with 500 U/ml T N F a (black bars) 
or without it (open bars) Non specific binding (determined in the presence ol 30 nM unlabeled VT 1) was 5% 
or less in all conditions 
been used 
The etfect oí TNFa on PT-VT-1 binding was concentration dependent (Fig Sa) The 
binding saturated at about 10 nM VT-1 (Fig 5b) From analysis of Scatchard plots of the 
binding curves (Fig 5c, Table 1) it was concluded that the number of specific VT 1 binding 
sites increased by one or two orders of magnitude after 24 hours of incubation with TNFa, 
whereas the apparent affinity of VT-1 binding to HUVEC did not significantly change (Table 
1) Similarly in human femoral vein endothelial cells the number of VT 1 binding sites 
increase 14 fold after a 24 h incubation period with 100 U/ml TNFa from 2 χ 10s VT 1 
binding sites/cell in control cells to 29 χ 10s VT 1 binding sites in TNFa treated cells 
In addition to TNFa, înterleukin la (IL la) , interleukin-1/3 (IL-10), lympholoxin (TNF/3) 
and bacterial lipopolysacchande (LPS) induced a more than ten-fold increase in specific VT 1 
binding to HUVEC (Fig 6) Thrombin induced only a three fold increase, whereas IL 6 (5 
or 50 U/ml) did not significantly alter VT 1 binding The increase induced by 10 μg/ml I PS 
was two told less than that induced by 500 U/ml TNFa LPS increased VT 1 binding in a 
concentration dependent way (Fig 7) As can be seen in Fig 7 24 h incubation with small 
amounts of TNI α and LPS resulted in an additional rise in the binding of VT 1 to HUVEC 
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Figure 5 Effect of T N F a on the 
binding of VT-1 to HUVEC 
A Atter preincubation of confluent 
HUVEC tor 24 hours with varying 
concentrations ot T N F a , binding of 0 3 
nM _ ,I VT 1 was assayed in the 
absence (hatched bars) or presence ot 30 
nM unlabeled VT 1 (open bars) В 
Binding ot 0 15 50nM , = 5I VT-1 to 
human endothelial cells treated for 24 
hours without (open squares) or with 
T N F a (dark squares) С Scatchard plot 
of '-'I VT 1 binding to human 
endothelial cells preincubated with 500 
U/ml T N F a for 24 h (circles) Control 
cells are indicated by the square 
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As the half-life time of TNFa in plasma is relatively short (several minutes) [25], we have 
evaluated how long after exposure of HUVEC to TNFa an effect on the VT 1 binding can 
be established To that end, HUVEC were incubated for various time periods with 20 U/ml 
TNFa, vigorously washed and subsequently incubated tor another penod without TNFa, 
after which the VT-1 binding was assayed The results of two independent experiments are 
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Table I Binding of verocytotoxin-1 (VT-1) to human umbilical vein endothelial cells (HUVEC) 
Cells 
HUVEC 1 
HUVEC 2 
Addition 
None 
T N F a (500 U/ml) 
None 
T N F a (500 U/ml) 
Binding ь 
0 ОЗхІО5 
9 4ХІ01 
0 8x10' 
11 ЗхІО5 
tes/cell Apparent Kd (M) 
0 6 x 1 0 ' 
1 7 x 1 0 ' 
1 2 x 1 0 ' 
1 9 x 1 0 ' 
Binding or l:iI-VT-l was performed at various concentrations (0 15 to 50 nM) and with excess of unlabeled VT-
1, in two independent HUVEC cultures The number of binding sites lor the hololoxin VT-1 and the apparent 
Kd were calculated by analysis of Scatchard plots 
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Figure 6. Binding of VT-1 to HUVEC after preincubation with various inflammatory mediators and thrombin 
A Binding of 0 3 nM °I-VT-1 to confluent HUVEC was determined in the absence (hatched bars) or presence 
of 30 nM unlabeled VT-1 (open bars) after a 24-hour preincubation period wilh 500 U/ml TNFa, 500 U/ml 
TNF/?, 50 U/ml IL-la, 50 U/ml IL-10, 50 U/ml IL-6, 10
 Mg/ml LPS or 1 U/ml α-thrombin (Па) 
В Specific binding of '-T-VT-1 to subcontluent HUVEC after 24-hour preincubation with 500 U/ml TNFa, 
varying concentrations of IL-la and IL-1/3 (0 5, 5 and 50 U/ml), 10 ßglmi LPS or 50 U/ml IL-6 
given in Table 2. Six hours of incubation with TNFa was enough to detect an increase in 
VT-1 binding after a 24- or 48-hours incubation. This suggests that the increased sensitivity 
of endothelial cells for VT-1 can last for at least one day after the disappearance of 
inflammatory mediators. 
The nature of the TNFa-mduced VT-1 binding to endothelial cells 
Globotnaosylceramide (GbOse,cer) has been identified as a receptor for VT-1 in various cells 
[26]. To evaluate whether the increase in specific VT-1 binding was due to an increase in the 
exposure of GbOse,cer to the cell surface, we have incubated HUVEC with anti-Tj" serum 
(which contains antibodies against the Pk(GbOse,cer), Ρ (GbOse4cer) and P, blood group 
antigens). The addition of anti-Tj" serum inhibited the binding ot VT-1 in a concentration 
86 
E 
υ 
о 
E 
•о 
с 
э 
о 
л 
г-
> 
Figure 7. Specific binding ot 
I nM ' - Ί - ν Τ - l io HUVEC 
after preincubation for 24 hours 
with varying concentrations of 
LPS, and in combination with 
20 or 500 U/ml T N F a . 
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dependent way (Fig. 8). This finding was confirmed in three other experiments of HUVEC, 
as well as in femoral vein endothelial cells. Seven different human serum preparations from 
healthy donors did not decrease the binding of VT-1 to the endothelial cells. To ascertain 
whether the increase in VT-1 binding resulted from an increase in cellular GbOse^cer 
synthesis or from a change in the availability of GbOse,cer at the cell surface, HUVEC were 
Table 2. Duration of the effect of' T N F a on the binding of VT-1 to human endothelial cells. 
TN Fa preincubation 
(hours) 
Subsequent incubation 
without TNFor (hours) 
Binding of' , :14-VT-1 
(ГтоІ/105 cells) 
Experiment 1 
0 (control) 
1 
6 
12 
24 
24 
23 
18 
12 
0 
0.68 
1.36 
3.31 
7.10 
8.75 
Experiment 2 
0 (control) 
1 
6 
12 
24 
48 
48 
47 
42 
36 
24 
0 
1.87 
1.79 
3.39 
5.38 
10.76 
10.76 
To evaluate how long confluent umbhlical vein endothelial cells have to be exposed to T N F a to express an 
increase in VT-1 binding after 1 or 2 days, the cells were incubated lor various times with 20 U/ml T N F a , 
washed vigorously three times, and subsequented incubated without T N F a for a residual time period until 24 
h (experiment I) or 48 h (experiment 2) after addition of T N F a . Binding of InM '-'I-VT-l was determined with 
two different endothelial cell cultures, which had a threefold difference in basal VT-1 binding. Binding assay 
was performed as described in Materials and Methods. 
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Figure ti Inhibition of lnM '-Ί-VT-I 
binding by anti-Τι' serum (concentration 
range 0 2-4% ) Cells were incubated for 
24 hours without or with TNFa 500 
U/ml Anli-T|'serum was. added 2 hours, 
belore and during incubation with '-1-
VT-I Similar inhibition by 4% anti-Tj" 
serum was obtained in three other 
endothelial cell cultures (45 _+ 99c; 
mean _+ SD). 
% anti-Tja serum 
incubated with and without TNFa, and glycolipid-extracls of cells were subsequently 
prepared. After thin layer chromatography of these glycohpids, an increase in VT-1 binding 
at the spot of GbOse,cer was clearly demonstrated in the TNFa-treated cells (Fig. 9). 
Occasionally, a second VT-1 binding band was observed, as demonstrated in Fig. 9. Because 
the GbOse,cer in our standard sample sometimes appeared as two bands after mixture with 
the cellular extract, it is likely that the second band here is also (derived from) GbOse,cer. 
But the involvement of aOH-GbOse,cer, which has a similar Rf-value as the second band and 
also can bind VT-1 [5], can not be excluded. When standard glycohpids were run together 
with glycolipid extracts of the TNFa-treated cells, VT-1 binding to the GbOse,cer of the 
standard mixture coincided precisely with the induced VT-1 binding glycolipids in the TNFa-
treated cells (not shown). These experiments indicate that the number of GbOse,cer 
molecules in/on the cells has been markedly increased after preincubation with TNFa. 
Requirement oj protein .synthesis for TNFa-induced VT-1 binding. 
The protein synthesis inhibitor cycloheximide was used to evaluate whether protein synthesis 
was required for the appearance of VT-1 receptors on the cell surface induced by TNFa. The 
simultaneous addition of high concentrations of TNFa and cycloheximide was toxic for the 
cells. However, it has been reported that partial protection for TNFa cytotoxicity can be 
mediated by plasminogen activator inhibitor-2 [27], the mRNA of which is rapidly induced 
in endothelial cells by TNFa itself (own unpublished data). Therefore, we have added 
various concentrations of cycloheximide 3 hours after addition of 20 U/ml TNFa, and 
incubated the cells for another 21 hours. Subsequently, the cells were counted and specific 
VT-1 binding was determined in parallel wells and calculated on a per cell basis. Whereas 
cycloheximide did not change the number of VT-1 binding sites per cell in control cells, it 
prevented the TNFa-induced increase in VT-1 binding in a concentration-dependent way 
(Fig. 10). Similarly, in human umbilical vein endothelial cells 0.5 and 2 /¿g/ml 
cycloheximide reduced the TNFa-induced increase in VT-1 binding sites per cell by 58% and 
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Figure 9. Verocytotoxin-1 binding to HUVEC glycolipids. Glycolipids from endothelial cells were extracted, 
separated by TLC and assayed for l25I-verocytotoxin-l binding. Lane a-f: Autoradiographs of l25I-VT-l binding 
to separated standard or endothelial glycolipids. Lane a: standard neutral glycosphingolipids 0.2 /ig of each 
glycolipid, lane b: idem, 2 /ig of each glycolipid. Lane с and d: glycolipid extracts of 1.6 χ IO5 HUVEC, lane 
c: 500 U/ml TNFa-treated cells, lane d: control cells. Lane e and f: glycolipid extracts of 1.44 χ IO6 cells, lane 
e: TNFa-treated cells, lane f: control cells. Lane g: standard neutral glycosphingolipids 2μg of each glycolipid, 
stained by orcinol spray. 1: galactosylceramide, 2: lactosylceramide, 3: globotriaosylceramide, 
4: globotetraosylceramide, 5: Forssman pentasaccharide, 6: Origin of the lane. 
1 2 3 9 10 11 
Cycloheximide (pg/ml) 
Figure 10. Effect of cycloheximide on 
the TNFa-induced increase in VT-1 
binding to human femoral vein 
endothelial cells. Various concentrations 
of cycloheximide were added 3 h after 
addition of 20 U/ml TNFa and the cells 
were incubated for another 21 h. 
Subsequently, the cells were counted 
and specific VT-1 binding was 
determined in parallel wells and 
calculated on a per cell basis. The 
number of TNFa-treated cells decreased 
by 13%, 19% and 46% after 
simultaneous incubation with 0.5, 2 and 
10 /tg/ml cycloheximide as compared to 
cells incubated with TNFa but without 
cycloheximide. 
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73%, respectively (not shown). These data suggest that the TNFa-induced increase in VT-1 
receptors involves the induction of de novo synthesis of protein(s), that is (are) involved in 
the synthesis pathway of the glycolipid VT-1 receptor. 
Discussion 
Infections with verocytotoxin-producing E.coli are associated wiih the hemolytic uremic 
syndrome and verocytotoxins are believed to play a role in the etiology of HUS [28,29]. A 
functional receptor (GbOsejCer) for VT-1 has been demonstrated on human umbilical vein 
endothelial cells (HUVEC), but it is present in a very low amount [8]. We have demonstrated 
here that incubation of human endothelial cells with TNFa, IL-1 or LPS markedly enhances 
the binding of VT-1 to these cells. Furthermore, we have demonstrated that the TNFa-
induced increase in VT-1 binding is accompanied by an increase in the cellular content of 
GbOsejCer, a molecule that has been recognized as a functional receptor for VT-1 [5,6]. 
Two recent papers [11,12] have demonstrated that human endothelial cells also become 
more sensitive to other related toxins, shiga-like toxin II and shiga toxin, when they are 
simultaneously exposed to TNFa. Tesh et al. [11] has suggested that this may be due to a 
higher TNFa-susceptibility of endothelial cells whose protein synthesis was inhibited by VT-
1. However, in our study, VT-1 was ineffective in untreated confluent endothelial cells, and 
only reduced protein synthesis in these cells when they were pre- or co-incubated with 
TNFa. As the incubation with TNFa resulted in a ten- to hundred-fold increase in VT-1 
receptors, it is likely that the reduction of protein synthesis and the increased cytotoxicity 
caused by VT-1 is primarily the consequence of enhanced VT-1 binding to endothelial cells. 
Once the VT-1 binding sites are increased on the cell surface, the toxicity of TNFa itself 
may act synergistically to the effect of VT-1. 
Obrig et al [30] have observed that shiga toxin has a higher cytotoxicity for subconfluent 
cells than for confluent cells. Our observation that subconfluent cells bind more VT-1 may 
correspond with this finding. However, it should be noted that the subconfluent cells were 
studied 24 hour after exposure to a strong proteolytic agent (trypsin, during passage of the 
cells), by which the cells certainly have been activated. Furthermore the half-life lime of 
endothelial cells in the normal adult human body is in the order of magnitude of hundred to 
thousand of days [31], the patho-physiological relevance of VT-1 cytotoxicity towards 
subconfluent cells will be limited to areas of neovascularisalion. Although our confluent cells 
displayed a low basal VT-1 binding, the amount of VT-1 binding was apparently not 
sufficient to interfere with the viability and protein synthesis of the endothelial cells. 
An exposure of several hours of endothelial cells to TNFa was enough to induce a 
detectable increase in VT-1 binding to these cells for two days. Therefore, an increase in 
endothelial VT-1 receptors may persist, even though inflammatory mediators are no longer 
detectable. No increase in concentrations of TNFa and IL-1 could be established in the 
plasmas of HUS patients upon arrival in the hospital [32] (and our own unpublished results). 
However, Siegler [32] recently reported that TNFa was elevated in the urine of HUS 
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patients. This suggests that TNFa may indeed have an effect in the kidney of HUS patients. 
Possible local sources of TNFa in the kidney are glomerular macrophages [33] and mesangial 
cells [14,15]. It is of interest to note that a study in mice on the toxicity of a related toxin, 
verocytotoxin-2 (shiga-like toxin II), has suggested a role of TNFa in the toxicity of this 
toxin [34]. Mice defective in macrophage response to LPS, including a defective production 
of TNFa, showed a consistently longer mean time to death than mice who were normal 
responsive. In addition, Barrett found that verocytotoxin-2 induced normal peritoneal 
macrophages to produce TNFa [34]. This may indicate that verocytotoxins act at various 
levels, i.e. in activating macrophages to produce TNFa and in damaging endothelial cells 
after the induction of their toxin receptors by TNFa. It would be of great interest to know 
whether mesangial cells can also be induced to release TNFa upon exposure to 
verocytotoxins. 
In addition to TNFa, other inflammatory mediators, in particular IL-1, lymphotoxin 
(TNF/3) and LPS also enhance VT-1 binding sites on endothelial cells. The parallel effects 
of these mediators on the synthesis of many endothelial proteins is well known [13]. Co-
incubation of LPS with Shiga toxin resulted in one recent study [35] in more sensitive 
endothelial cells than with Shiga toxin alone, whereas in another study [11] no additional 
effect was observed. Louise and Obng [12] reported that co-incubation of IL-1 in 
combination with Shiga toxin did not result in an enhanced cell death. In contrast, 
unpublished experiments in our laboratory demonstrate that after 24 h preincubation of 
HUVEC with IL-la or IL-1/3 (5 or 50 U/ml) the endothelial viability becomes more sensitive 
towards VT-1, albeit less dramatical than towards 500 U/ml TNFa The variation in these 
data suggests that, IL-1 and LPS, similar to TNFa, can induce VT-1 receptors on endothelial 
cells, necessary to make these cells vulnerable to verocylotoxin, and that they act in concert 
with VT-1 on endothelial cell viability, but less profound than high concentrations of TNFa. 
The combination of low concentrations of both LPS and TNFa, which, in our study, caused 
a larger increase in the binding of VT-1 on the endothelial cells than did incubation with 
these mediators separately, may be of interest in HUS, because the patient may become 
exposed to very low concentrations of LPS during the prodromal phase of acute gastro-
enteritis. 
Because of the fibrin seen in the histopathology of the kidney in HUS and the presence 
of thrombin-antithrombin complex (TAT), elevated levels of prothrombin fragment F1+2 
(marker of thrombin formation) [36], and increased concentrations of fibnnopeptide A [37] 
which are seer in the plasma of HUS patients on admission, we wondered whether thrombin 
might make HUVEC more sensitive to VT-1. This was not the case. The small increase in 
VT-1 binding caused by thrombin might be explained by the fact that thrombin can induce 
HUVEC to produce IL-la, which in turn will induce more VT-1 binding sites on the cell 
surface [38]. 
The endothelial binding of VT-1, induced by TNFa, was inhibited by the presence of 
anti-Tj" serum, which indicates that at least a major part of the specific VT-1 binding is a 
glycosphingolipid (GbOsejCer). From VT-1 binding to cellular glycolipid extracts, which 
were separated by thin layer chromatography, a large increase in the GbOse,cer content of 
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TNFa-treated endothelial cells was established. The increase must be due to an increase in 
GbOse3cer synthesis rather than to a change in the availability of existing GbOsejCer on the 
cell surface, because the amount of GbOse^er increased in the cellular extracts and the 
increase in binding could be prevented by simultaneous condition of cycloheximide. 
Therefore, we conclude that TNFa induces one (or more) enzyme(s) that is (are) rate-limiting 
in the synthesis of GbOsejCer. 
It is believed that the presence of verocytotoxins is necessary but not sufficient for getting 
HUS [1]. Our study suggests that one of the additional stimuli needed to develop the 
syndrome is the exposure of kidney.endothelial cells to one or more of the inflammatory 
mediators TNFa, IL-1 and LPS. We cannot yet discriminate whether the local availability 
of inflammatory mediators causes the preferential kidney damage in HUS in children, or 
whether the sensitivity of the endothelium in human glomeruli is larger than that of other 
endothelia. Only recently, endothelial cells of glomeruli have been isolated from animal 
kidneys [39] and isolation of these cells from human glomeruli is still in its infancy. 
However, in severe cases of HUS, not only kidney endothelial cells are affected, but also the 
endothelium in many other organs, including brain and pancreas [8]. We therefore believe 
that our observations on the induction of verocytotoxin receptors on human vein endothelial 
cells bear impact for understanding the etiology of HUS, as well as for a better understanding 
of the biological actions of inflammatory mediators. 
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Summary 
Infections with verocytotoxin (VT) producing E.coli have been strongly implicated in the 
epidemic form of hemolytic uremic syndrome (HUS). Endothelial damage plays a central role 
in the pathogenesis of HUS. In vitro studies have shown that VT can damage endothelial 
cells after interaction with its cellular receptor globotnaosylceramide (GbOse,cer). Cytokines, 
such as TNFa and IL-1 can potentiate the toxic effect of VT by inducing a protein-synthesis 
dependent increase in VT receptors on endothelial cells. In this study the mechanisms 
underlying the increase in endothelial VT receptors induced by TNFa were studied in more 
detail. 
To investigate which proteins were involved in this induction, endothelial cells were 
incubated with and without TNFa in the presence of 14C-galactose or '4C-glucose. TLC 
analysis of the glycolipid extracts of these cells demonstrated a markedly enhanced 
incorporation of 14C-galactose in GbOse3cer and other galactose-containing glycolipids, 
suggesting that TNFa enhanced galactosyl-transferase activity(ies). 
To examine the role of the two recently cloned TNF-receptors (TNFR-p75 and TNFR-
p55) in the TNFa-induced increase in GbOse,cer in human endothelial cells, cells were 
incubated with TNFa, the TNFR-p55 selective R32W-S86T-TNFa-mutantor the TNFR-p75 
selective D143N-A145R-TNFa-mutant. The effect of TNFa activation, determined by 
binding-experiments with 12<,I-VT-1, could be largely, but not completely mimicked by 
R32W-S86T-TNFa. Although incubation of cells with D143N-A145R-TNFa did not show 
an increase in VT-1 binding, the monoclonal antibody utr-1, which prevents binding to 
TNFR-p75 decreased the TNFa-induced VT-1 binding. 
Activation of protein kinase С by phorbol ester increases the expression of VT-1 receptors; 
this effect was prevented by the protein kinase С inhibitor Ro31-8220 and by homologous 
desensitization by pretreatment with phorbol ester. In contrast, the presence of the protein 
kinase inhibitor Ro31-8220 or desensitization of protein kinase С activity reduced the TNFa-
induced increase in VT-1 receptors maximally by 50% and 24%, respectively. Comparable 
reductions in overall protrein synthesis and the synthesis of E-selectin and PAI-1 were 
observed. This suggests an effect on general protein synthesis rather than a specific effect 
of protein kinase С in the signal transduction pathway, by which TNFa induces VT-1 
receptors. 
Our results indicate that TNFa can increase the VT-1 receptors on endothelial cells by 
inducing galactosyl-transferase activity(ies); that this action of TNFa mainly occurs via the 
TNFR-p55; and that protein kinase С activation increases expression of VT-1 receptors by 
a separate mechanism that acts additively to the TNFa-induced increase in VT-1 receptors. 
Introduction 
The epidemic form of the hemolytic uremic syndrome (HUS) is characterized by hemolytic 
anemia, thrombocytopenia and acute renal failure. It is mostly seen in young children and 
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has a prodromal phase of acute, often bloody, gastro enteritis [1] Since the beginning of the 
eighties, it has become clear that verocytotoxin or Shiga-like toxin producing E coli 
infections are the main cause of this form of HUS [2] A family of three verocytotoxins has 
been described verocytotoxin 1 (VT-1) or shiga like toxin I (SLTI), verocytotoxin-2 (VT-2) 
or shiga like toxin II (SLTII) and verocytotoxin-2 variant (VT-2c) [3] Although the exact 
pathogenesis is still unknown, endothelial cell damage, predominantly seen in the glomeruli 
in the kidney, is believed to play a central role [1] 
Several in vitro studies have shown that punfied verocytotoxins can damage the 
endothelium [4-7] The functional verocytotoxin receptor, the glycosphingolipid 
globotnaosylceramide (GbOse,cer), plays a crucial role in the endothelial cell damage [8] 
This receptor has been found in the human kidney [9] and on cultured endothelial cells [10] 
Recently, we have reported that inflammatory mediators, such as tumor necrosis factor α 
(TNFa) and interleukin-1 (IL-1), can potentiate the toxic effect of verocytotoxin-1 to human 
endothelial cells by inducing an increase in the GbOse,cer synthesis in these cells [7] 
Inflammatory mediators are produced and released by monocytes [11] and mesangial cells 
in vitro [12,11], and may play a local role in the kidney A recent report from Harel et al 
[14] demonstrated that shiga-like toxin I can specifically induce TNFa activity in mouse 
kidney Increased production ot the cytokines TNFa, IL-10 and IL-6 can also be found in 
the media of cultured human monocytes after stimulation with verocytotoxin 1 [15] In this 
report, we extend our observations and demonstrate that TNFa and IL-1 induce specific 
galactosyl transferase(s), which is (are) necessary for the synthesis of GbOsejCer in the 
endothelial cells 
Recently, two TNF receptors (TNFRs) have been identified and cloned, a 55 kDa receptor 
TNFR-p55 and a 75 kDa receptor TNFR-p75 [16] Both receptors are present on human 
endothelial cells [17,18] The TNFR p55 has been demonstrated to be involved in the signal 
transduction of TNFa during the induction of several products ol endothelial cells, such as 
E-selectin and VCAM-1 [17] The involvement of both TNF receptors in the TNFa induced 
increase in GbOse3cer synthesis and the role of protein kinase С (PKC) in the induction of 
verocytotoxin receptors in human endothelial cells were studied 
Materials and methods 
Materials 
Punfied VT 1 was prepared in the laboratory of Dr Karmali ( 1 2 mg protein/mL, CD50 vero-
cells titer 10s to 109) [19] Endotoxin content of the VT-1 preparation was less than 0 05 
EU/mL by Limulus amoebocyte lysate assay (E Toxic, Sigma Chemicals, Si Louis, MO) at 
detection level 0 05 to 0 10 EU/mL M199 medium supplemented with 20 mmol/L HEPES 
was obtained from Flow Laboratories (Irvine, Scotland), tissue culture plastics were from 
Costar (Cambridge, MA) A crude preparation of endothelial cell growth factor was prepared 
from bovine brain as described by Maciag et al [20] Human serum was obtained from a 
local blood bank and was prepared from fresh blood of healthy donors, pooled and stored 
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at 4°C: it was not heat-inactivated before use Newborn calt serum (NBCS) was from 
GIBCO (Grand Island, NY), it was heat-inactivated before use (at 5 6 T for 30 minutes). 
Heparin was purchased from Leo Pharmaceuticals (Weesp, the Netherlands). 
Penicillin/streptomycin was from Boehnnger Mannheim (Mannheim, Germany). Human 
fibroneclin was a gift from J.A. van Mounk, Central Laboratory of the Red Cross Blood 
Transfusion Service (Amsterdam, the Netherlands). Pyrogen-free human serum albumin 
(HSA) was purchased from the Central Laboratory of the Red Cross Blood Transfusion 
Service (Amsterdam, the Netherlands). Human recombinant TNFa was a gift from Jan 
Tavernier (Biogent, Ghent, Belgium). The TNFa preparation contained 2.45 χ 10' U/mg 
protein and less than 40 ng hpopol y saccharide (LPS) per mg protein. Human recombinant 
IL-1 /3 was a gift from S. Gillis (Immunex, Seattle, WA), it had a specific activity of 108 
U/mg. The mutant R32W-S86T-TNFa, which selectively binds and activates the human 
TNFR-p55, and does not react with the human TNFR-p75; and the mutant D143N-A145R-
TNFa, which specifically recognizes the TNFR-p75, were previously reported [21]. The 
antagonistic monoclonal antibody utr-1, specific for the TNFR-p75, and the agonistic 
monoclonal antibody htr-9, specific for the TNFR-p55 were previously reported [22]. 
The specific PKC-inhibitor C3 (Ro-31-8220) [23] was a gift from Dr G Lawton 
(Hoffmann La Roche, Welwyn Garden City, UK). The inhibitors H-7 and HA-1004 were 
purchased from Seikagaku, Tokyo, Japan). Phorbol 12-mynstate 13-acetate (PMA), bovine 
serum albumin (BSA) and Tween 20 were obtained from Sigma Chemical Co (St Louis, Mo) 
Nap4-iodine, 14C-glucose (50-60 mCi/mmol) and 14C-galactose (50.3 mCi/mmol) were 
purchased from Amersham (Amersham, UK). Iodo-gen îodination reagent was obtained from 
Pierce (Rockford, IL). 
Chloroform, methanol, and hexane were obtained from Merck (Darmstadt, Germany). 
Plastic coated silica gel F1500 thin-layer chromatography (TLC) plates were from Schleicher 
and Schuil (Dassel, Germany). Polyisobutylmethacrylatc was obtained from PolySciences 
(Washington, MD). A standard mixture of pure neutral glycosphingolipids containing Gal/31-
lCeramide(Cer) (CMH), Gal/31-4Glc/31-lCer (CDH), Galal-4Gal/31-4Glc/31-lCer 
(GbOse,cer), GalNac/31-3Galal-4Gal/31-4Glc/31-lCer (GbOse4cer) and GalNacal-
3GalNac/31-3Galal-4Gal/31-4Glc01-lCer (Forssmann pentasaccharide) was from Biocarb 
(Lund, Sweden). X-OMAT x-ray film was from Eastman Kodak (Rochester, NY) 
Cell culture 
Endothelial cells from human umbilical vein (HUVEC) and from human foreskin were 
isolated by collagenase treatment, cultured, and characterized as previously described [24-
27]. The endothelial cells were seeded in fibronectin-coated 10-cm2 wells and cultured in 
M199 medium supplemented with 20 mmol/L HEPES (pH 7 4), 10% (v/v) human serum 
(HS), 10% (v/v) heat-inactivated newborn calf serum, 2 mmol/L L-glutamine, 5 U/mL 
heparin, and 150 Mg/mL cnide preparation of endothelial growth factor under 5% C02 and 
95% air at 37°C. When the cells reached confluency, they were detached with trypsin/EDTA 
and seeded in 2-cnr fibronectin coated dishes with a split ratio of 1:3. HUVEC in the 
experiments were used after one to three passages Human foreskin microvascular endothelial 
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cells were used after four to six passages. The medium was renewed every 2 or 3 days. 
Binding of'25I-VT-l to human endothelial celli 
VT-1 was radiolabeled with Na1"! according tot the Iodogen procedure [28]. Five 
preparations of purified VT-1 were ìodinated to specific activities ranging from 16.2 ^Ci/^g 
till 26.8 μθ/zig of protein. All preparations gave similar results For the experiment, 
confluent HUVEC, cultured in 2-cm2 wells, were incubated for indicated times with medium 
M199 to which the appropriate concentration of the test-compound(s) was (were) added. The 
inhibitory antibody utr-1 and the PKC-inhibitor Ro31-8220 were added one hour before the 
start of the experiment. 
The binding assay was performed as follows: after the incubation period at 37CC with the 
indicated compounds, the endothelial cell cultures in 24-well plates were washed with M199 
medium plus 0.1% HSA (w/v). Subsequently, the cells were incubated for 3 hours with 1 0 
nmol/L '2T-VT1 in M199 plus 0.1 % HSA (w/v) at 0°C. After the incubation, the supernatant 
fluid was aspirated, the cells were washed five times with M199 plus 0.1% HSA, and total 
cell protein was solubihzed in 400 μΐ. 0.5 mol/L sodium hydroxide at room temperature. 
Radioactivity of the endothelial cells was measured in a gamma-counter. Non-specific binding 
was determined by assay of '"I-VTl binding in the presence of 50-fold excess of unlabeled 
VT-1. Cellular specific binding was determined by subtracting the non-specific binding from 
the cellular binding of '"I-VT-1 determined in the absence of unlabeled VT-1. 
Extraction of glycolipids 
Confluent endothelial cell cultures were incubated for 24 hours with or without 20 ng/mL 
TNFa or 0.5 ng/mL IL-1/3. Six hours after the start of the incubation, 0.5 μCl/mL ЫС-
glucose or MC-galactose was added to the media. Subsequently, after the 24 hours incubation 
period, the glycolipids were extracted as described by Lingwood et al [8]. In short, the cells 
were trypsinized, harvested with ice-cold phosphate-buffered saline (PBS), and spun down 
by 3-minute centrifugation (3,000 rpm) at 4°C. The pellet was washed three times with PBS. 
The pellet was finally suspended in PBS, and 20 vol of chloroform/methanol (2:1, vol/vol) 
was added. Cell debris was removed by filtration through glass-wool. One volume of water 
was added to obtain phase separation. The lower phase was dried and incubated at 37CC for 
2 hours in 1 mL 0.4 mol/L K.OH in ethanol; 2 vol of chloroform was added and the mixture 
was pardoned against 2 vol of water. The lower phase was separated and frozen until TLC 
studies were performed. 
Thin layer chromatography (TLC) 
The lower phase from the extraction above was dried and resuspended in 
chloroform/methanol (2:1, v/v). Samples were separated on a silica gel TLC plate using 
chloroform:methanol:water (65:25:4, v/v/v) Standard neutral glycosphingolipids, 2 μg of 
each glycolipid, together with an equal volume of unlabeled glycohpid cell-extract, were run 
on the same TLC and afterwards stained by orcinol-spray. After separation, the plate was 
air-dried, and exposed to X-OMAT x-ray film. 
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After developing the film, the plate was soaked three times tor 1 minute in 0 01% 
polyisobutylmethacrylate in hexane and air-dried, followed by overnight incubation in PBS 
supplemented with 1% BSA and 0 05% Tween 20 Subsequently, the plate was incubated 
with 50 mL VT 1 solution (15 nmol/L unlabeled, 1 5 nmol/L '2T VT 1 in PBS supplemented 
with 1 % BSA and 0 05% Tween 20) for 4 hours at 4°C The plate was extensively washed 
with 0 05% Tween 20 and 1 % BSA in PBS, air-dned, and exposed to X OMAT χ ray film 
Assays 
Levels of PAI-1 antigen in endothelial cell conditioned medium were assayed by ELISA 
(IMULYSE1M PAI-1) obtained trom Biopool (Umea, Sweden), according to the 
manufacturer's description 
The presence of E-selectin was determined by cell-ELlSA in triplicate wells with HUVEC 
cultured in fibronectin-coated 96 multiwell dishes After 5 h incubation with 20 ng/mL TNFa 
(inhibitors added 1 h before addition of TNFa), the amount of E selectin was determined on 
fixed cells by using an anti E selectin monoclonal antibody Ena 2 [29] (gift of Jet 
Leeuwenberg, Maastricht, The Netherlands) and a rat peroxidase labeled anti-mouse IgG 
After development of the assay, the optical density was recorded 
Statistics 
Experiments were done with at least three different cultures of HUVFC, unless otherwise 
mentioned Data are given as mean ± SEM Statistical analysis was performed with the 
Wilcoxon test Statistical significance was accepted tor ρ < 0 05 
Results 
TNFa increases the activities of glycohpid galactosyl transferases 
Our earlier report showed that the incubation of human endothelial cells with the cytokines 
TNFa or IL 1/3 causes a protein synthesis-dependent increase in the number of VT-1 receptor 
molecules, the glycosphingohpid globotnaosylceramide (GbOse,cer, Galal-4Gal/31-4Glc/31 
ICer)7 The biosynthesis of glycosphingolipids occurs via sequential transfer of sugar 
moieties from nucleotide sugar donors to ceramide Specific glucosyl- and 
galactosyltransferases are involved in this process 
To investigate whether the increase in GbOse3cer molecules by the cytokines TNFa or 
IL-1/3 is due to the induction of glucosyl- or galactosyltransferases, HUVEC were incubated 
with or without the cytokines TNFa or IL-1/3 together with 14C glucose or '4C-galactose for 
a period of 24 hours After the incubation-period, the NC-labeled neutral glycosphingolipids 
were extracted and separated on thin layer chromatography In Figure 1, it is demonstrated 
that the incorporation of HC-galactose in GbOse^er and other neutral glycosphingolipids is 
markedly enhanced after incubation of the cells with TNFa and, to a less extent, with IL 1/3 
(lanes b d) The presence of GbOse3cer was confirmed by the standard sample of neutral 
glycosphingolipids (lane a) and by incubation of the thin layer chromatography with l24-VT-
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Figure 1. Increase of galactose-containing glycolipids extracted from 1.6 χ IO6 HUVEC. Confluent HUVEC 
were incubated for 24 hours with or without 20 ng/mL TNFa or 50 U/mL IL-1/3. Six hours after addition of 
TNFa, 0.5 μα/mL '4C-galactose was added to the medium. After the incubation-period, glycolipids of 1.6 χ 
10' cells were extracted, separated by TLC. Lane a: standard neutral glycosphingolipids, 2 /xg of each 
glycolipid, visualized by orcinol-spray. Lane b-d: Autoradiograms of uC-galactose containing endothelial 
glycosphingolipids. Separated glycolipid-extracts of 1.6 χ lO'cells treated with no inflammatory mediator (lane 
b), with 20 ng/mL TNFa (lane c) and with 50 U/mL IL-1/3 (lane d). Lanes e-g: The same TLC was assayed 
for l25I-VT-l binding. Autoradiographs of l23I-VT-l binding to glycolipid-extracts of control cells (lane e), 
treated with 20 ng/mL TNFa (lane f), or with 50 U/mL IL-1/3 (lane g). 1, galactosylceramide; 2, 
lactosylceramide; 3, globotriaosylceramide (GbOse3cer); 4, globotetraosylceramide; 5, Forssman 
pentasaccharide; 6, origin of the lane. 
1, which specifically binds to GbOs^cer (lane e-g). The increase in the incorporation of '4C-
galactose in GbOse3cer is parallelled by an increase in
 125I-VT-1 binding to the GbOsCjCer 
position on the thin layer chromatography. A similar TNFa-induced increase in 14C-galactose 
incorporation in GbOsejcer and other neutral glycosphingolipids was also observed in human 
foreskin microvascular endothelial cells (not shown). Subsequent experiments, in which the 
incorporation of 14C-glucose and '4C-galactose were compared, demonstrated that 
incorporation 14C-glucose in glycosphingolipids in the TNFa-treated HUVEC were 
comparable to that in control cells (Figure 2). 
Involvement of the two TNF receptors in the TNFa-mediated increase in verocytotoxin 
receptors 
To investigate which of the recently cloned TNF receptors, TNFR-p55 and TNFR-p75, is 
involved in the induction of GbOse,cer in human endothelial cells by TNFa, the binding of 
l25I-VT-l was determined after incubation of HUVEC with wild-type TNFa, the mutant 
R32W-S86T-TNFa which recognizes and stimulates TNFR-p55 only, or the mutant D143N-
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Figure 2. Autoradiogram of l4C-glucose- or l4C-galactose-containing glycolipid-extracts separated on TLC. 
Confluent HUVEC treated for 24 hours without or with 20 ng/mL TNFa together with ,4C-glucose or 14C-
galactose. Glycolipids of 1.6 χ IO6 cells were extracted and separated on TLC. Lane a: Standard mixture of 2 
/ig of each neutral glycosphingolipids visualized by orcinol-spray. Lane b: Standard mixture of neutral 
glycosphingolipids mixed with unlabeled glycosphingolipid cell-extract, visualized with orcinol spray. 14C-
galactose containing glycolipid-extract of control cells (lane c) and of TNFa-treated cells (lane d).l4C-glucose 
containing glycolipid-extract of control cells (lane e), l4C-glucose containing glycolipid-extract of TNFa-treated 
cells (lane f). 1, galactosylceramide; 2, lactosylcerarrude; 3, globotriaosylceramide (GbOs^cer); 4, 
globotetraosylceramide; 5, Forssman pentasaccharide; 6, origin of the lane. 
A145R-TNFa, which specifically interacts with the TNFR-p75. With concentrations up to 
20 ng/mL, R32W-S86T-TNFa induced a concentration-dependent increase in VT-1 binding, 
whereas D143N-A145R-TNF« had no effect (Table 1, Figure 3a-c). Thus, the sole 
stimulation of the TNFR-p55 is sufficient to induce VT-1 receptor synthesis in endothelial 
cells. This was confirmed with the agonistic monoclonal antibody htr-9, that specifically 
activates the TNFR-p55 (Table 1). However, when the effects of wild-type TNFa and 
R32W-S86T-TNFa were compared, the mutant reached 77 ± 5% of the effect of the wild-
type TNFa (mean ± SEM, Ρ < 0.05; paired data of 7 cultures, incubated for 24 h with 20 
ng/ml of both TNFa forms). Furthermore, it was observed in several time course 
experiments that, at low concentrations of TNFa and its mutant (0.2 ng/ml), the initial 
increase of VT-1 receptors induced by the R32W-S86T-TNFa was detectable one or two 
hours later than that by wild-type TNFa. 
These observations suggest that wild-type TNFa provides a signal additional to 
stimulation of the TNFR-p55, probably via the TNFR-p75. This may occur by activation of 
the TNFR-p55 via TNFR-p75-mediated signal transduction, or by concentration of TNFa 
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Figure J. Ellect of various concentrations of wild-type TNFor (A), the TNFR-p55-specitic mutant 
R32W S86T-TNFa (B) and the TNFR p7S specific mutant DI43N-AI4SR T N F o (C) on the specihc '- ' l-VT-
hinding lo HUVEC Cells were incubated with a low concentration range wild type TN Fa or T N F « mutant lor 
respectively 6, 12 or 24 hours ( • control cells, D 0 2 ng/mL A 0 4 ng/mL О 0 8 ng/mL · 2 ng/mL) 
Concentrations ot 20 or 200 ng/mL D143N Al 45R-TN Fa showed the same binding as 2 ng/mL D143N Al 45R 
TNFor D '-'I-VT binding to endothelial cells incubated for 6, 12 or 24 hours with 2 ng/mL R32W-
S 8 6 T - T N F a ( · ) together with D143N-AI45R T N F a a t 0 4 ng/mL ( Δ ) , 4 ng/mL ( O ) or 20 ng/mL ( ' ) , ( • 
control cells) 
molecules on the cell surface by the TNFR-p75, so that the binding to the TNFR-p55 is 
facilitated by ligand passing [10] When we added the TNFR-pTS-stimulating mutant together 
with the TNFR-p55-stimulating mutant to the cells, no further increase in VT-1 binding was 
observed as compared to the TNFR-p'î'î mutant alone (Figure 4d) Therefore, TNFR-p75-
mediated enhancement of the TNFR p55 activity is unlikely Similarly, when the TNFR-p?1)-
binding mutant D143N-A145R-TNFa was added simultaneously with wild-type TNFa, no 
reduction of the VT-1 binding was observed (not shown) However, when the cells were 
preincubated with the monoclonal antibody utr-1, that blocks the TNFR-p75, a reduction in 
the effect of TNFa on VT-1 binding was observed after 9 h of incubation (Table 2) After 
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Table 1. Effect of TNF-receptor agonist on VT-1 binding to human endothelial cells 
Addition '-Ί-νΤ-Ι binding (lmol/10scells) 
9 h incubation 24 h incubation 
Control 2 3 ± 0 8 (9) 1 7 ± 0.6 (10) 
Wild-type TNFa (20 ng/mL) 7 7 ± 2 6(9)" 23 2 ± 5.8(10)" 
R32W-S86T-TNFa (20 ng/mL) 5.8 ± 3 8(5)" 19.7 ± 7 2(7)" 
D143N-A145R-TNFa (20 ng/mL) 2.4 ± 0.2 (3)* 2 2 ± 0 . 1 ( 4 ) ' 
D143N-A145R-TNFa (200 ng/mL) 2 2 ± 0 1(2)* 2 0 + 0 1(3)' 
MoAb htr-9 (10 Mg/mL) η d 8 5 ± 1 б (3) 
Specific binding of 1 nmol/L i:5l-VT to confluent human umbilical vein endothelial cells was determined after 
9 or 24 h incubation with wild-type TNFa, the mutant R32W-S86T-TNFa, which only activates TNFR-p55, 
or the mutant D143N-A145R-TNFa, which only activates TNFR-p75, or with the monoclonal antibody htr-9 
(moAb htr-9), which activates the TNFR-p55 Data are expressed as the mean ± SEM of the number of 
independent experiments indicated between parentheses. Statistically significant difference was evaluated by the 
Wilcoxon-test for paired data " ρ < 0.05, *" ρ < 0 01 as compared to control cells ' The control data of these 
experiments were normalized to the mean control value to aid comparability. N.D.. not determined. 
Table 2. Effect of the TNFr-p75 blocking antibody UTR-I on the TNFa-induced increase ot VT-1 receptors. 
Addition 
None 
utr-1 (10^g/mL) 
TNFa (2 ng/mL) 
TNFa (2 ng/mL) + utr-1 (10 μglmL) 
TNFa (20 ng/mL) 
TNFa (20 ng/mL) + utr-1 (10 Mg/mL) 
R32W-S86T-TNFa (20 ng/mL) 
R32W-S86T-TNFa (20 ng/mL) + 
ulr-1 (10μg/mL) 
culture 1 
0.6 
0.6 
3 2 
1 6 
4 9 
2 7 
2 6 
2 3 
'-Ί-νΤ-l bi 
culture 
0 4 
0 5 
3.1 
2.2 
4 7 
3.6 
2 9 
2 6 
nding (tmol/lO5 cells) 
;2 culture 3 
6 5 
6.7 
19 4 
15.4 
26 1 
22 6 
20 9 
21 5 
% effect utr-I 
100 
108 ± 6 
100 
66 ± 9 
100 
73 ± 9 
100 
93 ± 5 
Effect of the antagonistic monoclonal antibody utr-1, specific lor TNFR-p75 on the |:L,1-VT-1 binding to three 
different cultures of confluent HUVEC Cells were treated for 9 hours with TNFa or R32W-S86T-TNFa in 
the absence or presence of the antibody utr-1. The antibody ulr-1 was added to the cells 1 hour before addition 
ot TNFa or its mutant. After the 9 h incubation period, the media above the cells were removed and 1 nmol/L 
llsI-VT-l was added to the cells as described in material and methods Data are also expressed as the percentage 
toxin binding as compared to their counterparts, which were not incubated with utr-1 (mean ± SEM for the 
three experiments) 
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24 h of incubation, this effect was still observed at moderate concentrations of TNFa (2 
ng/mL), but not at high concentrations (20 ng/mL TNFa) (not shown). This is compatible 
with a "ligand passing' effect, which vanishes at saturating TNF concentrations. The utr-1 
monoclonal antibody had no effect on the ability of the TNFR-p55-stimulating R32W-S86T-
TNFa to induce VT-1 receptors (Table 2). This makes an aspecific effect of the utr-1 
antibody unlikely. 
Involvement of protein kinase С in the induction of VT-1 receptors 
The protein kinase С activator phorbol myristate acetate (PMA) and the protein kinase С 
inhibitors Ro31-8220 and H-7 were used to study the role of protein kinase С in the 
induction of the VT-1 receptor GbOse3cer. Stimulation of protein kinase С by PMA enhanced 
the specific binding of VT-1 to a moderate extent in comparison with TNFa (Figure 4a). In 
six different HUVEC cultures 10 nmol/L PMA stimulated specific 12VVT-1 binding 4 ± 1 -
fold, while 20 ng/mL TNFa induced а 16 + 3 -fold increase in the same cells (mean + 
SEM, 24 h incubation). When HUVEC were incubated with PMA and TNFa or 
R32W-S86T-TNFa simultaneously, the increase of VT-1 receptors was considerably larger 
than that obtained by TNFa or R32W-S86T-TNFa alone, and the induction occurred faster 
than after stimulation by TNFa, R32W-S86T-TNFa or PMA alone (Figure 4a). No 
additional increase in specific VT-1 binding was seen when PMA was given together with 
D143N-A145R-TNFa, as compared with PMA alone (not shown). For comparison, the 
production of PAI-1 was assayed in the conditioned medium of the same cells. As expected, 
PMA did not alter PAI-1 production; addition of 10 nM PMA had a slight stimulatory effect 
on the TNFa-induced increase in PAI-1 production (Figure 4b). 
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Figure 4. Specific binding ot '^I-VT-l (A) and productionot PAI-1 antigen (В) by confluent human endothelial 
cells incubated with 10 nmol/L phorbol ester PMA (closed symbols) or in its absence (open symbols). HUVEC 
were simultaneously incubated with 20 ng/mL TNFa ( B , D ) or 20 ng/ml R32W-S86T-TNFa ( * , Δ ) for the 
indicated time intervals. The control cells are indicated with circles. No difference in ,:5I-VT-1 binding and PAI-
1 production was observed when D143W-A145R-TNFa was incubated together with 10 nmol/L PMA as 
compared to PMA alone (data not shown) 
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To evaluate the role of protein kinase С activity in the PMA- and TNFa-induced 
increases in VT-1 receptors, HUVEC were preincubated for 20 h with 10"6 mol/L PMA, 
washed three times and subsequently incubated for another 24 h with 10 nmol/L PMA or 2 
ng/mL TNFa Whereas PMA enhanced the induction ot VT-1 receptors under control 
conditions, its effect disappeared after homologous desensitisation (Figure 5) Desensitization 
of protein kinase С activity by PMA preteatment reduced TNFa-induced increase in VT-1 
receptors only by 24 + 9% A similar decrease (22 ±11%) was seen in TNFa-increased 
PAI-1 synthesis of these cells (302 ± 19 vs 392 ± 18 ng PAI-1/24 h/10' cells in TNFa-
stimulated cells pretreated with 10ft mol/L PMA or control medium, respectively, 3 
independent cultures) 
Comparable results were obtained with protein kinase С inhibitors While the inhibitor 
Ro31-8220 at 3 μιτιοΙ/L completely suppressed the effect of PMA on VT-1 binding (Figure 
6, inset), it reduced the induction of VT-1 receptors by the single addition of TNFŒ or 
о 
ε 
σ> 
с 
•о 
с 
Control PMA TNFa 
Figure 5 Effect ol protein kinase С 
desensitiution on the induction ol VT 1 receptors 
by T N F a and phorbol ester PMA HUVEC were 
preincubated for 20 h in culture medium 
supplemented with 10* M PMA (black bars) or 
in the same medium without PMA (open bars) 
Subsequently the cells were washed three times 
and incubated tor 24 h in culture medium 
supplemented with 20 ng/mL T N F a , 10 nM 
PMA or without addition (control), after which 
specillc binding of '-'I VT-1 to the cells was 
determined The data are the mean ± SEM of 3 
difieren! HUVEC cultures 
Time (h) 
Figure 6 Specific binding ol '-I-VT 1 to 
HUVEC incubated lor 8 16 or 24 hours with 20 
ng/mL T N F a (•) 20 ng/mL R32W 
S86T-TNF« ( Δ ) or without addition ( O ) The 
protein kinase С inhibitor Ro31 -8220 (3 /imol/L) 
was added one hour before the start of the 
experiment to the cells and remained present 
during the incubation period (closed symbols) 
Results are the mean ± SEM of three 
independent experiments Inset Specific binding 
of '-'I-VT-1 to confluent HUVEC treated with 10 
nmol/L PMA in the presence ot 3 μΓτιοΙ/L 
R O 3 1 - 8 2 2 0 ( T ) or without inhibitor (v) 
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R32W-S86T-TNFa by 48 ± 9 % (Figures 6, 7a) Incubation of the cells with another protein 
kinase С inhibitor, H-7 (30 μιηοΙ/L), gave the same results as obtained with Ro31-8220, 
whereas a structural homologue of H-7, HA-1004 (30 μΓΤΐοΙ/L), which has a similar protein 
kinase Α-inhibiting capacity as H-7, but much less protein kinase C-inhibiting activity, was 
inactive in this respect (Figure 7a) However, Ro-31-8220 (3 μΜοΙ/L) and H-7 (30 μΓΤΐοΙ/L), 
but not HA-1004 (30 μιηοΙ/L), inhibited TNFa-induced expression of PAI-1 and E-selectin, 
a protein of which the TNFa induction is not dependent on protein kinase С activity 
[31,32], to a comparable extent (Figure 7b,c). Furthermore, the reduction in TNFa-induced 
1 1 1 10 100 
Inhibitor (pmol/L) 
Inhibitor (μΓΠοΙ/L) 
Figure 7. A Concentration dependency of the inhibition ot TNFa-induced '-'I-VT-1 binding to HUVEC by 
protein kinase С inhibitors HUVEC were preincubated tor 1 h with various concentrations ot Ro3 1-8220 ( • ) , 
H-7 ( · ) or HA-1004 ( i ) and incubated tor 24 h in the presence of these inhibitors and 20 ng/mL T N F a 
Subsequently, the binding ot 1 nmol/mL l l sI-VT-l was determined В Production of PAI-1 antigen by the same 
cells during the 24 h incubation with inhibitors С Expression ot E-seleclin by HUVEC alter 5 h exposure to 
20 ng/mL T N F a and the indicated inhibitors E-selectin was assayed by cell-ELISA as described in Materials 
and methods D Incorporation ot 3 5S-methiomne in 10%-TCA-precipitable proteins7 during a 24 h incubation 
with T N F a and the various inhibitors, indicated in A The values represent the mean ± SEM of 3 to 5 
independent HUVEC cultures 
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VT-1 receptors by these inhibitors was paralleled by a comparable reduction in overall 
protein synthesis, as estimated from the incorporation of ,sS-methiomne in proteins (Figure 
7d). In the absence of TNFa, these inhibitors affected protein synthesis by less than 10% 
(not shown). 
These findings indicale that activation of protein kinase С underlies the stimulation of 
VT-1 receptors by PMA. They suggest that protein kinase С is not directly involved in the 
TN Fa-dependent signalling pathway causing induction of VT-1 receptors, but can contribute 
via another pathway additionally to the effect of TNFa on the expression of VT-1 receptors. 
Discussion 
The inflammatory mediators TNFa and IL-1 increase the toxicity of verocytotoxin and the 
closely related shiga toxin for human endothelial cells [5-7]. Previously, we have 
demonstrated that TNFa and IL-1 increase the number of VT-1 receptors known to be 
globotnaosyl-ceramide (GbOse,cer) on endothelial cells, and that protein synthesis was 
necessary for this induction [7]. Here, we have demonstrated that the TNFa-induced increase 
in VT-1 receptors is due to an increase in galactosyl-transferase activity(ies) in the endothelial 
cell. This induction occurs predominantly via the TNFR-p55 by a mechanism distinct from 
the induction of VT-1 receptors by protein kinase С activation. 
The kidney contains a relatively high amount of glycosphmgolipids [8,33]. GbOse,cer is 
in particular found in the tubular epithelial cells [33,34]. It is also encountered in the 
glomeruli of children younger than two years old [35], but the cellular distribution in the 
glomeruli has not been resolved yet. In the glomeruli of kidneys of adults and children older 
than two years no significant expression of GbOse,cer was found [35]. This suggests a 
developmental shift in the synthesis of glycosphingolipids in glomerular cells. In cultured 
cells glycosphingolipids play a role in cell growth and cell differentiation [33], but little is 
known about the physiological role of these glycosphingolipids in various cell types of the 
intact kidney. Bacterial exotoxins use specific glycohpids as receptors to enter eukaryotic 
cells where they interfere with the metabolism of the cell [36,37]. In the case of 
verocytotoxin the toxicity is primarily caused by inhibition of the interaction of elongation 
factor-1 with the nbosome, which results in a complete inhibition of protein synthesis [38]. 
Previous studies have demonstrated that the sensitivity of endothelial cells for the toxin is 
determined by the number of toxin receptors, i.e. GbOse,cer [5-7], and that the number of 
the VT-1 receptors is markedly increased after exposure of endothelial cells to inflammatory 
mediators [7]. We have suggested that (local) generation of inflammatory mediators may 
increase the sensitivity of the kidney and, in severe cases of HUS, also that of the 
endothelium of other organs to verocytotoxin. 
Our present data demonstrate that TNFa, and also IL-Iß, induce an enhanced production 
of neutral galactose-containing glycohpids by an increase in galactosyl-transferase activity. 
This explains the increase in GbOse,cer molecules found on TNFa-stimulated endothelial 
cells [5-7]. To our knowledge, this is the first report indicating an inductive effect of 
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inflammatory mediators TNFa and IL-1 on the synthesis ot neutral cellular glycolipids A 
confirmation of the induction of galactosyl-transterase(s) at the mRNA level is not yet 
possible, because ceramide glycosyl-transferases have not been cloned, with the exception 
of a brain-specific ceramide UDP-galactosyl transferase, which was reported very recently 
[39] The physiological meaning ot the induction of galactosyl-tranferase(s) in inflammation 
is not known. On the basis of sequence homologies of verotoxins and the α-interferon 
receptor, Lingwood et al [40] has suggested that GbC^cer may act as an accessory molecule 
for the α-interferon receptor. Hence, the altered synthesis of glycosphingohpids may play a 
role in the modulation of the inflammatory process In this respect it is of interest to note that 
another inflammatory mediator, 7-interferon shifts the cellular distribution of 
glycosphingohpids towards the surface of endothelial cells [41] 
TNFa acts on cells via two receptors, TNFR-p55 and TNFR-p75, to which it binds with 
similar affinity [16]. Both receptors are expressed on unstimulated HUVEC [17,18], but this 
study shows that activation of TNFR-p55 by TNFa is sulfiaent for the induction of 
GbOse,cer in human endothelial cells. This finding corresponds well with the TNFa-induced 
expression in endothelial cells of E-selectin, ГАМ-l, ICAM-1, interleiikm-8, interleukin-6 
and GM-CSF, which are under TNFR-p55 control [17,18,42] However, the TNFR-p55 
selective mutant was always slightly less potent than the wild type TNFa While activation 
of TNFR-p75 by D143N-A145R-TNFa mutant had no effect on GbOse,cer synthesis, 
blocking of TNFR-p75 by the monoclonal antibody utr-1 reduced the TNFa-induced increase 
in VT-1 receptors, in particular at low TNFa concentrations and at early time points. 
Because simultaneous stimulation of both TNF receptor types by two TNFa mutants did not 
enhance VT-1 receptor expression more than obtained by stimulation ot the TNFR-p55, it 
is unlikely that an intracellular signal generated via the TNFR-p75 enhanced TNFR-p55 
activity or TNFR-p55-mediated signal(s). Our findings are consistent with the hypothesis of 
Tartaglia et al [30], who proposed that TNFR-p75 can concentrate the TNFa molecules at 
the cell-surface, thereby facilitating the TNFa molecule to be passed on to the TNFR-p55. 
Similar observations have been made regarding the TNFa induced expression of a2-integnns 
[17] and the TNFa-induced synthesis of E-selectin [18] 
A complex cascade of signal transducing events, including activation of the nuclear 
transcription factor NF-κΒ IS probably involved in the induction of various proteins by TNFa 
in endothelial cells [43] Protein kinase С activity has been reported to be needed for the 
induction of some TNFa-induced proteins The TNFa-induced synthesis of' urokinase [44] 
and the adhesion molecule VCAM-1 [31] can be reduced by inhibitors of protein kinase C, 
whereas these inhibitors do not affect the TNFa-induced synthesis of E-selectin [31,32], 
ICAM-1 [32] and PAI-1 [44,45]. Our data indicate that the TNFa-induced increase of the 
synthesis of VT-1 receptors does not require protein kinase С activity. This conclusion is 
based on the observations that heterologous desensitisation by PMA did not specifically 
reduce the TNFa-dependent increase in VT-1 binding, while homologous desensitization 
entirely prevented an increase of VT-1 receptors by PMA In the presence of TNFa, the 
protein kinase С inhibitors Ro31-8220 and H-7, but not the structural analogue HA-1004, 
reduced VT-1 receptor expression to a similar extent as that of E-selectin and PAI-1, 
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probably as the result of a generally reduced protein synthesis This suggests that under our 
experimental conditions protein kinase С activity can become a limiting lactor in protein 
synthesis in endothelial cells exposed to TNFc* 
Activation of protein kinase С by itself causes a moderate increase in VT-1 receptors, and 
as such adds to the TNFor-induced increase in VT 1 receptors It is not known yet whether 
the effect of PMA on VT-1 binding is caused by an increased insertion of GbOse,cer-
containing caveolae in the plasma membrane after activation of protein kinase C,[46] or by 
an increased synthesis of VT-1 receptors, similar as happens after activation of endothelial 
cells by TNFa In the latter case, the induction of galactosyl transferase activity, which 
underlies the increase in VT-1 receptors, behaves similarly as the induction ol E-selectin, 
which can also be induced by protein kinase С activation by a pathway that is different from 
the TNFa induced expression Π 1,12] 
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Chapter 7 
SUMMARY AND PERSPECTIVES FOR THE FUTURE 
Summary 
The hemolytic uremic syndrome (HUS) preceded by an acute gastro enteritis (D+ HUS) is 
predominantly seen in childhood Since the first report by Karmalfs group in 1983 [1], 
several studies from other parts of the world have shown that verocytotoxin producing 
Escherichia coll (VTEC) infection are the main cause of D+ HUS [2] In this thesis we have 
studied the epidemiology and pathophysiology of VTEC infection in D+ HUS 
In chapter 2 the results are presented of a four year retrospective and prospective study 
of the epidemiology of VTEC infection in patients with HUS and children with acute gastro-
enteritis In the first retrospective study, sera of HUS patients, family members and children 
with acute gastro enteritis were examined for the presence of antibodies to the 
lipopolysacchande (LPS) of the most common O-serotypes of VTEC Antibodies to the LPS 
of 0157 antigen were found in sera trom 28 of the 45 patients examined Antibodies to the 
LPS of serotypes 0115 and 0145 were detected in the sera from one patient respectively one 
lamily member In the prospective study evidence for VTEC infection was obtained by 
performing combined microbiological and serological procedures In total 77% of the 113 
HUS patients, 35% of the 95 family members and 3% of the 65 children with acute gastro-
enteritis had a VTEC infection Serum antibodies to 0157 antigen yielded the highest amount 
of positive results compared to the other test methods Although fecal tests demonstrated that 
VTEC infection was often present in family members, it is remarkable that the presence of 
serum antibodies to 0157-antigen was significantly lower in the family members as compared 
to the patients with HUS Assuming that a VTEC infection in a family was due to the same 
genotypic 0157 strains, a hypothesis confirmed by the recent findings of A Heuvehnk et al 
[3], these family studies might indicate that in cases of diarrhea, yet unknown, host factors 
in the intestine are involved in determining the pathogenicity of VTEC The hypothesis that 
there is a difference in adherence of VTEC between the intestinal epithelium of the young 
children and adults has to be investigated These epidemiology studies show that VTEC 
infection, mainly serotype 0157, is the main cause of HUS in childhood in the Netherlands 
and parts of Germany and Belgium The fact that not all infants and children, who are 
infected by VTEC develop HUS, suggested that there might be a genetic predisposition for 
getting D+ HUS Therefore, the frequency of HLA antigens of 31 children with chronic 
renal failure due to D+ HUS from the Netherlands and Flanders were compared to the HLA 
113 
frequencies of a control population A significant association with HLA B40 was observed 
in this severe form of D+ HUS as compared with the control population 
The cytokines tumor necrosis factor a (TNFa) interleukin 1 (IL 1) and interleukin 6 (IL-
6) are known to play an important role in several infectious diseases and in acute 
inflammation The role of inflammatory mediators in the pathogenesis of HUS was 
investigated in chapter } TNFa and its soluble receptors, IL-10 and IL 6 were measured in 
the plasma of patients with HUS, children with chronic renal failure and healthy children 
No elevated levels of TNFa, IL 1/3 and IL 6 were found in the plasma ot HUS patients, who 
had no extra-renal manifestations during the disease Only in plasma of patients with HUS 
who had extra-renal manifestations, consisting of seizures, loss ot consciousness, coma and 
pancreatic necrosis, IL-6 was significantly elevated The fact that inflammatory mediators 
have a short half-life (less than one hour) may be a reason why they are no longer detectable 
in the plasma taken on admission in the hospital On the other hand, several studies have 
suggested that TNFa may play a local role in the kidney Siegler et al reported that although 
TNFa was not elevated in the plasma of HUS patients, it was significantly elevated in the 
urine of these patients [4] In an animal model with transgenic mice Harel and coworkers [^ ] 
demonstrated that injected shiga toxin induced TNFa synthesis within the kidney, but not in 
other tissues Although the exact function of IL-6 in plasma of HUS patients is still unknown 
and the number of patients in our study is small, IL 6 in plasma was associated with the 
seventy and outcome ot the disease Studies perlormed in volunteers ha\e shown that TNFa 
is involved in the induction ot soluble TNFa receptors release [6] Soluble TNFa receptors 
were elevated in the plasma of patients with HUS However, they were also elevated in the 
plasma of children with chronic renal failure This implies that elevated soluble TNF receptor 
levels may be the consequence of the decreased clearance by the disturbed kidney function 
in HUS patients 
Normal vascular endothelium has the capacity to prevent thrombosis by producing 
proteins that retard or inhibit the coagulation pathway proteins that interfere with platelet 
aggregation and vasoconstriction, and the release of tissue type plasminogen activator (t PA), 
which triggers fibrinolysis Endothelial damage causes to a disturbance in the balance 
between the coagulation and fibrinolytic system resulting in thrombi and fibrin depositions 
Endothelial damage in HUS is mainly seen in the kidney Histopathological studies show 
swollen endothelial cells detached from the glomerular basement membrane, and in the lumen 
of the glomerular capillaries, thrombi and fibrin depositions are seen The results of plasma 
levels of fibrinolytic parameters and von Willebrand factor (vWF) antigen in patients with 
HUS and the effect of purified verocytotoxin-1 (VT 1) on cultured human endothelial cells 
are reported in chapter 4 Elevated levels of t-PA plasminogen activator inhibitor type I 
(PAI-1) activity, vWF as well a fibnn(ogen) degradation products were observed in the 
plasma of HUS patients on admission as compared to the control groups of children with 
chronic renal failure and healthy control children After two to three weeks, t PA antigen and 
vWF had partially returned to basal values and PAI 1 activity had been normalized On 
admission no response ot the t-PA, vWF and urokinase (u-ΡΑ) were seen upon DDAVP 
infusion, but after two weeks t-PA increased again after DDAVP infusion These data 
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suggest that on admission- in addition to the hemorrhagic colitis and the kidney failure- HUS 
patients display a general activation of the vascular endothelium. In order to investigate the 
role of verocytotoxin in the alteration of the fibrinolytic system found in HUS, purified 
verocytotoxin-1 (VT-1) was added to the media of cultured endothelial cells. No change in 
the production of t-PA, PAI-1 and vWF was observed when VT-1 alone was added to 
endothelial cells. However, when VT-1 was added to endothelial cells that contained 
sufficient VT-1 receptors, a decrease in production of t-PA, PAI-1 and vWF was seen likely 
due to an inhibitory effect of VT-1 on overall protein-synthesis. While VT-1 causes a 
decrease of the production of fibrinolytic proteins by endothelial cells in vitro, the plasma 
levels of these proteins in HUS patients changed in the opposite direction. Although these 
data appear to be paradoxical, they do not really conflict. We hypothesized that after a period 
of hemorrhagic colitis, the main affected organ in HUS is the kidney. It is known that the 
human kidney contains the receptor for verocytotoxin and the toxin is assumed to contribute 
to the damage the endothelial damage in the glomeruli. This damage can lead to a local 
prothrombotic condition. Then, thrombin and inflammatory mediators are generated and 
leucocytes become activated, which cause to a general activation of the endothelium at sites 
distal of the affected areas. 
The effect of purified VT-1 on cultured human umbilical vein endothelial cells (HUVEC) 
was examined in chapter 5 By investigating whether local factors generated during 
coagulation or inflammation can make the endothelium more vulnerable to verocytotoxins, 
we observed that endothelial cell damage by VT-1 depends on the additional presence of the 
inflammatory mediator TNFa or IL-1. Studies with '"l-VTl demonstrated that the 
preincubation of the endothelial cells with TNFa led to an increase in VT-1 binding. 
Although confluent non-stimulated HUVEC demonstrated a low basal '"I-VT-1 binding, the 
amount of VT-1 binding was apparently not sufficient to interfere with the viability and 
protein synthesis of the endothelial cells. The effect of TNFa on U,I-VT-1 binding was 
concentration-dependent and saturated at approximately 1Ü nmol/1. From Scatchard-plot 
analysis it was concluded that the apparent affinity of VT-1 binding to HUVEC did not 
change, but the number of specific binding-sites increased after incubation with TNFa. In 
addition to TNFa, other inflammatory mediators, in particular interleukin-1 and TNF/3, and 
LPS, also enhance the binding-sites on endothelial cells. The TNFa-induced VT-1 binding 
sites on endothelial cells were identified as the glycolipid GbOsejCer. This TNFa-induced 
increase in VT-1 receptors involved de novo synthesis of protein(s). This study suggests that 
the presence of verocytotoxins is necessary but not sufficient for getting HUS. Inflammatory 
mediators, such as TNFa and IL-1 might be one of the additional stimuli needed to develop 
the syndrome. 
The mechanisms underlying the TNFa-induced increase in VT-1 receptors in human 
endothelial cells were studied more in detail in Chapter 6. The biosynthesis of 
glycosphingohpids occurs via sequential transfer of sugar moieties from an activated sugar 
donor, usually nucleotide sugars, to ceramide which involves glycosyltransferases. The 
specificity of the enzymes for their donor and acceptor substrates constitutes the primary 
basis for determining the structures of the sugar chains produced by a cell. The level of 
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glycosyltransferase transcription may change during tissue morphogenesis and embryonic 
development, cellular ditlerentialion, disease or tumor metastasis [7,8]. The data presented 
in chapter 6 demonstrate that the inflammatory mediators TNFa and IL-1, induce an 
enhanced production of the neutral galactose-containing glycosphingolipids as the 
verocytotoxin receptor Gb3 by an increase in galactosyl-transferase activity(ies) The 
physiological meaning of the induction of galactosyl-transferase(s) in inflammation is yet not 
known. TNFa acts on endothelial cells via two receptors, a 55KDa receptor (TNFR-p55) and 
a 75KDa receptor (TNFR-p75), to which it binds with similar affinity. Both receptors are 
expressed in unstimulated HUVEC By using specific TNFa mutants and monoclonal 
antibodies we have shown in this study that activation ot the TNFR-p55 by TNFa is 
sufficient for the induction of the VT-1 receptor GbOse,cer in human endothelial cells A 
role for TNFR-p75 was demonstrated at low TNFa concentrations and during the first eight 
to ten hours of TNFa incubation, probably by facilitating the TNFa molecule to be passed 
on to the TNFR-p55 Protein kinase С activity, as signalling pathway, was reported not to 
be required for the induction of the TNFa-induced increase in VT-1 receptors in HUVEC 
Perspectives for the future 
Although the recognition ot verocytotoxin-producing E coli infections as the main cause of 
the diarrhea-associated (D + ) HUS has given an impulse to a better understanding of the 
pathophysiology of HUS, the treatment has yet not changed Patients with HUS are still only 
treated supportively. In Canada a new therapeutical agent, SYNSORB-Pk, has recently been 
developed. SYNSORB-Pk is a porous particle to which synthetic oligosaccharide receptors 
for verocytotoxin are attached [9]. These particles appear to bind verocytotoxins effectively 
and make them inactive A three year Canadian multicentre-study has just starteil to evaluate 
the efficacy of this agent in preventing HUS in children with bloody diarrhea Until now 
prevention of VTEC infection is still the best method to reduce the incidence of HUS The 
most commonly isolated E coli strain 0157:H7 is generally associated with dairy cattle and 
their products, milk and beef; but it has also caused outbreaks associated with water and 
apple-cider. Handling guidelines for meal processors, retailers and food-service 
establishments should be given and controlled by National Food Services Research to 
elucidate the ecology ot E coli 0157.H7 should include identification and control ot sources 
of the pathogen in the farm environment and the development of rapid diagnostic assays for 
identifying the animals and products that harbour these pathogens 
After ingestion of food products of animal origin contaminated with VTEC or the 
acquirance of a VTEC intection via person-to-person transmission, the bacteria adhere to and 
colonize in the human intestine. By using cultured epithelial cells and animal models a lot 
of progress has been made in the understanding the mechanisms of the adherence of VTEC 
in the last four years This pattern demonstrates similar characteristics as the adhesion pattern 
of enteropathogenic E cali (EPEC). Important in the initial adhesion of VTEC strains to the 
intestinal epithelium are the plasmid encoded structural and/or regulatory genes for fimbriae 
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[10]. In a study by Windsor et al [11], it was reported that mannose can partially inhibit the 
adherence of VTEC strains belonging to serotype 0157:H7 to cultured human colon 
carcinoma cells and rabbit colonocytes. The adherence to these cells appeared to be related 
to the amount of pili present and not to the serotype [11]. In several animal studies it has 
been demonstrated that after the initially localized adherence VTEC strains colonize the 
terminal ileum, cecum and colon by the attaching-and effacing (ΛΕ) lesions, which are 
similar to that produced by certain strains of enteropathogenic E.coli (EPEC) [12-14]. These 
AE lesions are characterized by extremely close attachment of the bacteria to the intestinal 
cells, with effacement of the underlying microvilli and accumulation of filamentous actin in 
the subjacent cytoplasm. Jerse et al reported the identification of a locus in EPEC necessary 
for the intimate attachment to epithelial cells in vitro [15]. This locus, now referred to as 
eaeA (for E.coli attaching and effacing), is part of a gene cluster on the EPEC chromosome 
necessary for intimate attachment. The product of the eaeA locus is intimin, a 94 KDa outer 
membrane protein. The eae locus of VTEC strains has recently been cloned and sequenced 
[16,17]. A role of the eae gene in the characteristics of the AE lesions was for the first time 
demonstrated in vivo by Donnenberg et al [18] He constructed an eae mutant of EHEC, 
which was unable of attaching intimately to colonic epithelial cells in a newborn piglet 
model. The intimate attachment was restored in vivo when the VTEC eae gene or the EPEC 
eae gene was introduced into the mutant on a plasmid. The complementation achieved by the 
EPEC locus indicates that the eae gene of VTEC and the EHA eae gene are functionally 
homologous. The intestinal ligands of the protein products produced by VTEC and necessary 
for adherence on the intestinal epithelium are yet unknown. Diarrhea-associated HUS is 
rarely seen in adults and occurs mostly in children younger than 5 years of age. Although 
fecal tests demonstrate that VTEC infection is often present in family-members of the HUS 
index case, the presence of serum antibodies to the 0157 O-antigen is significantly lower in 
the family-members as compared patients with HUS. This may indicate that other, yet 
unknown host factors in the intestines are involved in facilitating VTEC lipopolysaccharides 
to cross the mucosal surface. 
Mobassaleh and co-workers [19] demonstrated in a rabbit model that quantitative 
differences in the Shiga toxin receptor globotnaosylceramide (GbOse^er), in the small 
intestine are the underlying basis for the age-specific differences in functional responsiveness 
of rabbit intestinal tissue to Shiga-toxin. Intestinal microvillus membranes were prepared 
from the small intestines of rabbits at various ages and glycolipids were quantilated by high-
performance liquid chromatography. In these rabbit studies a marked increase in GbOse3cer 
with age, ranging from 0.02 to 16.2 pmol^g microvillus protein in neonates and adults, 
correlated with the secretory (enterotoxic) effects of the toxin [20]. Whether the age-related 
increase in rabbit intestinal GbOsejCer content is mediated through the induction of the 
specific galactosyltransferase responsible for the a 1-4 addition of a terminal galactose residue 
to lactosylceramide, the precursor of GbOse,cer, remains to be investigated. If similar 
developmentally regulated changes in GbOse,cer occur in the human intestine as well, this 
could explain the relative resistance of human neonates to clinical shigellosis and D+ HUS. 
Developmently regulated changes in the amount of receptors have also been reported for the 
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toxins from Clostridium difficile. Vibrio cholerae and enterotoxigenic E colt [21,22] Not 
much is known about the presence and distribution of the verocytotoxin receptor GbOse3cer 
in human intestines and therefore no data are available for an assessment of the possible 
developmental regulation of intestinal GbOsejCer content in the microvillus membranes Bjork 
et al [23] observed no GbOse3cer in the epithelial cells isolated from resections of the ileum 
ot four human adults, but Keusch et al could detect GbOse,cer in proximal small bowel 
samples with normal histology which were surgically removed from adult patients [20] 
Verocytotoxin is thought to be, at least partly, responsible for the systemic manifestations 
seen in HUS After gaining excess to the circulation, verocytotoxin binds to its specific 
functional receptor GbOse,cer, which is present on endothelial cells The use of cultured 
human endothelial cells has made it possible to study in vitro the direct effect of 
verocytotoxin Although endothelial cell damage in HUS is mainly located in the capillaries 
in the glomeruli, most of the data provided about the etfect of verocytotoxin on endothelial 
cells are based on the findings in cultures using human vein endothelial cells derived from 
the umbilical cord [24-26] Recently, Obng and coworkers reported that human renal 
endothelium is more sensitive to verocytoloxin lhan the endothelium derived from the 
umbilical cord [27] This increase in sensitivity was due to an increase in the verocytotoxin-
receptor, GbOse,cer in human renal endothelial cells The observed differences in GbOse,cer 
in various cultured endothelial cells may be due to specific mechanisms for controlling the 
receptor expression by regulation ot individual glycosyllransferases responsible for addition 
of receptor sugar sequences to the glycohpids For example, administration of the hormone 
testosteron alters the glycosphingolipid synthesis, including GbOse,cer, in the kidney of 
mices, resulting in marked increases in the synthesis of glucosylceramide by inducing the 
ceramide UDP glucose glucosyl transferase [28] Not only the absolute amount of GbOse,cer 
determines the sensitivity of the various endothelial cells towards verocytotoxin, also the 
heterogenous fatty acid composition ot the GbOse,cer molecule can influence the binding and 
the toxicity of verocytotoxin to the endothelial cells [29] Recently, Jacewicz et al [30] 
demonstrated that GbOse,cer, expressed at the cell surface, is necessary but not sufficient to 
confer sensitivity of mammalian cells to Shiga toxin When liposomal GbOse,cer was 
introduced in natural resistant GbOse^er deficient CHO (Chinese hamster ovary) cells, no 
change was observed in the sensitivity ot CHO cells, even though there was an increase in 
Shiga toxin binding This raises the possibility thai CHO cells may lack a necessary 
postbinding translocation mechanism for GbOse,cer bound toxin [30] Not enough is known 
about the role and regulation ot neutral glycosphingolipids, including GbOse,cer in human 
endothelial cells [31] The tact that endothelial cells from human glomeruli can be cultured 
nowadays [retm] and the fact that the sensitivity ot various types of human endothelial cells 
to verocytotoxin can be compared, will be helpful in studying the pathogenesis of HUS 
Although the culture of endothelial cells has the advantage to study endothehal-specific 
processes without the interference of other cells, it is obvious that the culture process per se 
may also introduce artifacts Cultured endothelial cells may loose specific functions and may 
acquire new metabolic characteristics, which are not present in vivo In the in vivo situation 
blood cells and plasma are flowing over the endothelial cells Platelets, leucocytes and other 
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renal cells (niesangial cells) may contribute to the pathology seen in HUS An animal model 
would be ideal to study HUS Several animal studies have been performed with purified 
verocytotoxin, but no typical HUS pathology was observed Diarrhea and neurological 
symptoms were present in gnotobiotic piglets after oral inoculation ot E ioli strain 0157 H7 
[32] Verocytotoxin injected ι ν or ι ρ in mice leads to bilateral renal cortical tubular 
necrosis [33,34] Intravenously given verocytotoxin has been demonstrated to cause 
abnormalities in the central nervous system and the gastrointestinal tract in the rabbit without 
producing signs of renal dysfunction [35,36] The lesions seen in mice and rabbits correlated 
with the amount of expression of the verocytotoxin receptor, GbOse,cer in the damaged 
organs Glomerular thrombotic microangiopathy seen in patients with HUS, was not observed 
in any of the verocytotoxin treated animal model (mice, rabbits) In an attempt to induce 
glomerular thrombotic microangiopathy with verocytotoxin, we have recently perlormed a 
pilot-study in three rhesus monkeys Briefly the protocol was as following To upregulate the 
expression of GbOse,cer on vascular endothelial cells lipopolysacchande (LPS) ι ν was 
given 24 hours before the addition of verocytotoxin Verocytotoxin 1 (VT-1) was infused into 
the left arteria renalis and saline was infused into the right arteria renalis Histopathology and 
immunohislopathology of the both kidneys were performed 48-72 hours after VT 1 
administration The glomerular thrombotic microangiopathy as observed in patients with HUS 
was not seen in the verocytotoxin treated kidney ot the rhesus monkeys Until now an 
appropriate animal model ol human thrombotic microangiopathy occurring in HUS might be 
the modified Shwartzman reaction induced by a 5h endotoxin infusion in rabbits [37] During 
endotoxin infusion (4(Vg/kg/h) the animals developed signs ot endotoxemia, transient 
leucopenia and thrombocytopenia as well as acute renal failure By light microscopy a 
marked polymorphonuclear cell infiltration was a prominent finding within 1 hour from the 
start of the infusion At 5 h fibrin deposits and thrombi were present in the kidney of all 
animals Endothelial damage was detected few minutes after the beginning ol endotoxin 
infusion followed by leucocyte and platelet infiltration in glomerular capillaries Occasionally, 
occlusive fibrin thrombi were seen The abnormalities were reversible Lateron.ie at hour 
48 after endotoxin infusion, no more fibrin was detectable in glomerular capillaries Recently 
another rabbit model to study glomerular thrombotic microangiopathy was described by 
Faraco et al [38] Rabbits receiving cyclosporin Α ι m tor 10 days and on the 11th day an 
endotoxin infusion for 5 h developed more fibrin depositions and thrombi in the glomeruli 
than rabbits treated with one of the vehicles alone (Гагасо 1991) Although these animal 
studies can be considered as an example for human thrombotic microangiopathy, it does not 
fully represent HUS First, the reaction of rabbit endothelium towards endotoxin might be 
different than that of human vascular endothelium Secondly, the fixed amount of endotoxin 
given is different from that of patients developing HUS, who are presumably exposed to a 
lower amount of endotoxin and/or verocytotoxin but for considerably longer periods Loirat 
et al treated 33 children with HUS in a multicentre, controlled study either with urokinase 
and heparin (n = 15) or symptomatically (n= 18) [39] No differences were observed in terms 
of renal histological changes and in long-term renal function between the two groups In four 
patients, hemorrhage resulted in interruption of the antithrombotic therapy after 14-31 hours, 
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and therefore, only 11 patients had no modification of the trealment protocol. No conclusions 
can be drawn about the effect of fibrinolytic treatment in this study. First, urokinase was not 
given as a sole treatment, but it was given together with heparin. Secondly, whether the 
administered doses of urokinase was correct, can not be concluded from this study, because 
no control-values of fibrinolytic activity, such as fibrin(ogen) degradation products, 
fibrinogen and thrombin time, were measured during treatment with urokinase-heparin 
infusions. One can wonder whether the duration of urokinase administered was adequate. Still 
no good controlled study in patients with HUS has been performed to examine the effect of 
fibrinolytic agents in the treatment of HUS, but the above mentioned rabbit model receiving 
cyclosporin and LPS might be a good candidate to study the effectivity and kinetics of 
fibrinolytic treatment of the glomerular thrombotic microangiopathy. Λ better understanding 
of the pathogenesis of HUS might lead to a improvement of the treatment and outcome of 
the patients with HUS, especially for those with the D- form of HUS, who still have a worse 
prognosis compared to the D+ HUS [40]. It might be interesting to know whether plasma 
of children with D- HUS contain the 37 kDa platelet agglutinating protein which was 
reported to be present in the plasma of patients with TTP [41]. Lian el al observed that IgG 
present in human adult plasma could inhibited the TTP plasma induced agglutinating ability 
in vitro [42]. It has yet to be examined whether therapy with IgG infusions might contribute 
to a better treatment of D- HUS. 
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SAMENVATTING 
In dit proefschrift worden de resultaten beschreven van epidemiologisch en 
pathophysiologist onderzoek van het hemolytisch uremisch syndroom (HUS) HUS, 
voorafgegaan door een periode van acute, vaak bloederige, diarree, wordt met name gezien 
bij kinderen onder de vijf jaar en wordt gekenmerkt door een hemolytische anemie, 
thrombocytopenic en een acute niennsufficientie. Sinds het begin van de tachtiger jaren wordt 
een infectie met verocytotoxine producerende E coli gezien als de voornaamste oorzaak van 
deze vorm van HUS. 
Hoofdstuk 1 vormt een introductie tot de verschillende aspecten van HUS en de 
verocytotoxine-producerende E < oli De verschillende vormen van HUS worden hier 
genoemd en uitgebreider wordt ingegaan op HUS voorafgegaan door een acute gastro 
enteritis (D+ HUS) en op de belangrijkste veroorzaker van D+ HUS, de verocytotoxine-
producerende E coli 
Gedurende vier jaren werd retrospectief en prospectief onderzoek verricht naar de 
aanwezigheid van een infectie met verocytotoxine-producerende E.colt (VTEC) in feces en 
sera van patientjes met D+ HUS afkomstig uit Nederland en de academische ziekenhuizen 
te Leuven, Antwerpen en Keulen De resultaten van dit onderzoek worden beschreven in 
hoofdstuk 2 In het eerste retrospectieve deel van dit hoofdstuk werden sera afgenomen bij 
opname van patientjes met HUS, familieleden van patientjes met HUS en patientjes met acute 
gastro-ententis onderzocht op de aanwezigheid van antihchamen tegen de lipopolysacchande 
O-antigenen van de 13 meest voorkomende serotypen van de met HUS geassocieerde VTEC 
stammen Anlilichamen tegen het lipopolysacchande 0157-antigeen werd aangetroffen in het 
serum van 28 van de 45 (62%) patientjes met HUS Antihchamen tegen het 0115-antigeen 
waren aanwezig in het serum van een patientje met HUS In het serum van één van de 43 
onderzochte familieleden werden antihchamen tegen het 0145 antigeen aangetroffen Geen 
van de 34 sera van de controle groep van patientjes met acute gastro-ententis was positief 
De resultaten van het prospectieve deel staan beschreven in het tweede deel van dit 
hoofdstuk Feces-onderzoek naar de aanwezigheid van VTEC en/of vnj verocytotoxine 
gecombineerd met serologisch onderzoek naar antihchamen tegen verocytotoxine en tegen 
het 0157-antigeen toonden aan dat er in 88 (78%) van de 113 patientjes met HUS en 2 (3%) 
van de 65 patientjes met acute gastro-ententis sprake was van een VTEC infectie 
Aanwijzingen voor een infectie met VTEC serotype 0157 werden in 76% van de 88 HUS 
patientjes gevonden Het testen op de aanwezigheid van antihchamen tegen het 0157-antigeen 
was de meest sensitieve methode Tevens werd feces- en serologisch onderzoek verncht bij 
95 familieleden van de 28 HUS patientjes VTEC infectie werd aangetoond in 33 (35%) van 
de familieleden Hoewel VTEC en/of vrij verocytotoxine vaak werd aangetroffen in de feces 
van familieleden, werden antihchamen tegen het 0157-antigeen maar in de sera van 3 
familieleden aangetroffen Daar het genotype van de geïsoleerde VTEC stammen niet 
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verschilde per familie, zou dit kunnen betekenen dat andere, nog onbekende factoren in het 
maag-darm kanaal van de gastheer een rol spelen in de invasiviteit van VTEC. Een mogelijk 
verschil in adhesie van VTEC aan hel darm-epitheel van kinderen ten opzichte van 
volwassenen dient te worden onderzocht. Deze epidemiologische studies laten zien dat VTEC 
infectie, met name het serotype 0157, de belangrijkst oorzaak is van HIJS bij kinderen in 
Nederland en delen in België en Duitsland. Niet alle kinderen die geïnfecteerd worden met 
VTEC krijgen HUS. In het derde deel van dit hoofdstuk werd onderzocht of er een 
genetische predispositie is voor het verkrijgen van HUS. HLA types van 31 patientjes met 
een chronische nier-insufficièntie ten gevolge van HUS werden vergeleken met de HLA types 
van de Nederlandse populatie. Er werd een significante associatie gezien tussen HLA-B40 
en de ernstige vorm van D+ HUS. 
Cytokines spelen een belangrijke rol in de Pathogenese van infectie ziekten en 
inflammatoire processen. Verhoogde spiegels van cytokines zijn o.a. beschreven bij sepsis, 
het syndroom van Kawasaki en thrombotische thrombocytopenische purpura. Om inzicht te 
krijgen in een mogelijke rol van cytokines in de Pathogenese van D+ HUS, werden de 
spiegels van tumor necrosis factor α (TNFa), vrij circulerende TNF receptoren (sTNFR55 
en STNFR75), interleukine-10 (IL-1 /3) en interleukine-6 (IL-6) bepaald in het plasma van 
patientjes met HUS bij opname en in de controle groepen van patientjes met chronisch 
nierfalcn (CRF) en gezonde kinderen. De resultaten zijn beschreven in hoofdstuk 3. TNFa 
en IL-1/3 waren niet verhoogd in het plasma van HUS patientjes vergeleken met de controle 
groepen. Echter plasma spiegels van IL-6 waren significant hoger in de HUS patientjes met 
extra-renale manifestaties (277 ± 103 pg/ml) vergeleken met de spiegels van HUS patientjes 
zonder extra-renale manifestaties (milde vorm) en de beide controle groepen (< 30 pg/ml). 
Hoewel de exacte functie van IL-6 in HUS niet bekend is en de alhier onderzochte groep 
klein is, blijkt uit deze studie dat IL-6 geassocieerd is met de ernstige vorm van HUS. 
Plasma spiegels van sTNFR55 en sTNFR75 waren significant verhoogd in alle HUS 
patientjes in vergelijking met de sTNFR spiegels in gezonde kinderen. Echter hoge sTNFR 
spiegels werden ook aangetroffen in het plasma van patientjes met CRF. Plasma spiegels van 
sTNFR dienen voorzichtig te worden geïnterpreteerd indien er sprake is van een verstoorde 
nierfunctie. 
Activatie van het fibrinolytische systeem leidt tot afbraak van fibrine en vervolgens tot 
desintegratie van een stolsel. De vaatwand speelt een belangrijke rol in de produktie van de 
fibrinolytische parameters. Beschadiging van de endotheelcellen leidt tot een verstoring in 
het evenwicht tussen het stolling- en het fibrinolytische systeem. In HUS wordt de 
endotheelschade met name gezien in de nier' glomerulaire endotheelcellen laten los van de 
basaal-membraan en thrombi en fibrine deposities worden aangetroffen in het lumen ал de 
glomerulaire capillairen. In hoofdstuk 4 worden de plasma spiegels van fibrinolytische 
parameters en van Willebrand factor bij patientjes met D+ HUS beschreven. Tevens werd 
het effect van verocytotoxine-1 (VT-l)op de humane endotheelcellen onderzocht. De spiegels 
van tissue plasminogeen activator (t-PA), diens remmer de plasminogeen-activator inhibitor 
type 1 (PAI-1), von Willebrand factor (vWF) en de fibrin- en fibnnogeen degradatie 
Produkten waren significant verhoogd in het plasma afgenomen bij opname. In de 
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convalescente fase, twee tot drie weken na opname, werden geen verhoogde plasma-waarden 
van t-PA, PAI-1 en vWF spiegels gevonden. Intraveneuze toediening van DDAVP bij 
opname gaf geen verandering van de t-PA, urokinase (u-ΡΑ) en vWF concentratie in het 
bloed, echter DDAVP-toediening twee weken na opname het een toename zien in de t-PA 
secretie. De verhoogde fibnnolytische parameters en vWF bij opname suggereren dat er in 
D + HUS, naast de hemorrhagische colitis en de gestoorde nier-functie, sprake is van een 
gegeneraliseerde activatie van het endotheel. Door middel van in vitro studies met humane 
endotheelcellen werd de rol van VT-1 in het fibnnolytische systeem onderzocht. Humane 
endotheelcellen gepreincubeerd met VT-1 gaven geen verandering in de produktie van t-PA, 
PAI-1 en vWF. Echter wanneer VT-1 gegeven werd aan met TNFa voorbeharidelde 
endotheelcellen zodat er voldoende VT-1 receptoren aanwezig waren, was er een duidelijke 
afname van zowel t-PA, PAI-1 als vWF. Deze afname was het gevolg van het inhibitoire 
effect van VT-1 op de algehele eiwit-synthese. Hoewel de uitslagen van het in vivo en in 
vitro onderzoek paradoxaal lijken, zouden ze middels de volgende hypothese verklaarbaar 
kunnen zijn: Na een periode van acute, vaak bloederige diarree is de nier het meest 
aangedane orgaan in HUS. Het is aangetoond dat de humane nier de receptor voor VT bezit 
en VT wordt mede verantwoordelijk geacht voor de endotheelschade in de glomeruli. Deze 
schade leidt tot het ontstaan van fibrine deposities en thrombus vorming. Het in deze situatie 
ontstane thrombine, ontstekingsmediatoren en activatie van leucocyten kunnen er toe leiden 
dat het endotheel distaal van de aangedane gebieden geactiveerd wordl. 
In hoofdstuk 5 werd het effect van verocytotoxine in humane endotheelcellen verder 
onderzocht. Een toename in de gevoeligheid voor VT-1 werd gezien wanneer humane 
endotheelcellen werden gepreincubeerd met TNFa. Binding-studies met P,I-VT-1 lieten zien 
dat deze preincubatie met TNFa zorgde voor een toename in de 13,I-VT-1 binding aan 
endotheelcellen. Het effect van TNFa was concentratie afhankelijk en verzadigbaar bij 
ongeveer 10 nmol/1 VT-1. Analyse van de Scatchard plot wees uit dat de affiniteit van VT-1 
voor de endotheelcellen niet veranderde, maar dat TNFa een tien- tot honderdvoudige 
toename in specifieke VT-1 receptoren per cel induceerde Niet alleen TNFa, maar ook IL-1, 
lymphotoxine en lipopolysaccharide lieten een toename zien in VT-1 binding. Deze toename 
in VT-1 binding was het gevolg van een toename in de functionele receptor van VT, het 
glycosphmgolipide globotnaosylceramide (GbOse3cer). De novo eiwitsynthese was nodig 
voor deze inductie van GbOsejCer door TNFa. Uit deze studie bleek, dat TNFa een (of 
meer) enzym(en) indiceert, die noodzakelijk zijn voor de synthese van de VT-1 receptor, 
GbOsejCer. Tevens laten deze in vitro data zien dat naast VT-1, ontstekingsmediatoren een 
belangrijke rol zouden kunnen spelen in de Pathogenese van HUS. 
De biosynthese van glycosphingolipiden geschiedt door dat geactiveerde suikers, 
gebonden aan nucleotiden, worden gekoppeld aan het ceramide. Glycosyltransferases zijn 
nodig voor deze overdracht. De data in hoofdstuk 6 laten zien dat de inductie van GbOse3cer 
door TNFa en IL-1 geschiedde door een stijging in galactose bevattende glycosphingolipiden 
ten gevolge van een toename in galactosyl transferase activiteit(en). Humane veneuze 
endotheelcellen geïsoleerd uit de navelstreng (HUVEC) hebben twee TNFa receptoren, een 
55 kDa receptor (TNFR-p55) en een 75 kDa receptor (TNFR-p75) Beide receptoren zijn 
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aanwezig in ongestimuleerde endotheelcellen In dit hoofdstuk laten we zien dal activalie van 
de TNFR-p55 door TNFa voldoende is voor de inductie van de VT-1 receptor GbOse,cer 
Een rol voor de TNFR-p75 kon worden aangetoond bij lage TNFa concentraties en 
gedurende de eerste 8 tot 10 uur van de incubatie periode Proteïne kinase С activiteit was 
niet noodzakelijk voor de inductie van GbOse,cer door TNFa in de humane endotheelcellen. 
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ABBREVIATIONS 
BSA 
DDAVP 
D + HUS 
D- HUS 
EHEC 
EIA 
ELISA 
EPEC 
FVT 
GbOscjCer 
HUS 
HUVEC 
HSA 
IL-1 
IL-6 
LPS 
PAI-1 
PBS 
PKC 
PMA 
SEM 
SD 
SLT 
TLC 
sTNFR 
TNF 
TNFR 
t-PA 
TTP 
u-PA 
VT 
VTEC 
VT/PECS 
vWF 
bovine serum albumin 
l-desamino-8-argimne vasopressin 
diarrhea-associated hemolytic uremic syndrome 
diarrhea-negative hemolytic uremic syndrome 
enterohemorrhagic Escherichia colt 
enzyme immunoassay 
enzyme linked immunosorbent assay 
enteropathogenic Escherichia coll 
free verocytotoxin 
globotnaosylceramide 
hemolytic uremic syndrome 
human umbilical vein endothelial cells 
human serum albumin 
interleukin-1 
interleukin-6 
lipopolysacchande 
plasminogen activator inhibitor type I 
phosphate buffered saline 
protein kinase С 
phorbol myristate acetate 
standard error to the mean 
standard deviation 
shiga-like toxin 
thin layer chromatography 
soluble tumor necrosis factor receptor 
tumor necrosis factor 
tumor necrosis factor receptor 
tissue-type plasminogen activator 
trombotic thrombocytopenic purpura 
urokinase 
verocytotoxin 
verocytotoxin-producing Escherichia coli 
verocytotoxin detection in polymyxin В extracts of colony sweeps 
von Willebrand factor 
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waren we niet altijd samen (maar toch ook weer wel), is ondenkbaar. 
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begon zij de studie Geneeskunde aan de Katholieke Universiteit te Nijmegen. Het doctoraal 
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met de gemeenschap van Pikin Guerero samengewerkt aan de opbouw van een school en een 
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onderzoeker in dienst van de afdeling Kindergeneeskunde van het Academisch Ziekenhuis 
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epidemiologische onderzoek voortgezet op de afdeling Medische Microbiologie, Sint Radboud 
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Financíele ondersteuning werd in het eerste jaar verkregen van het Ter Meulen Fonds van 
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De auteur is getrouwd met Ivo de Blaauw. 
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ïngen 
1 Onderzoek naar serologische antistoffen tegen lipopolysacchanden van 
verocytotoxine-producerende E coli stammen is de gevoeligste methode voor het 
vaststellen van een infectie door verocytotoxine-produrende E coli in het 
hemolytisch uremisch syndroom (Hoofdstuk 2) 
2 De activering van het fibnnolytische systeem vastgesteld in plasma van patiënten 
met HUS is niet het gevolg van een direct effect van verocytotoxine op 
endotheelcellen (Hoofdstuk 4) 
3 Cytokines, zoals tumor necrosis factor α en interleukine 1, induceren de receptor 
van verocytotoxine in humane endotheelcellen geïsoleerd uit de navelstreng 
(Hoofdstuk 5) 
4 De door tumor necrosis lactor a geïnduceerde expressie van verocytotoxine 
receptoren is niet afhankelijk van proteïne kinase С activiteit (Hoofdstuk 6) 
5 In tegenstelling tot patiënten met de X gebonden vorm van renale diabetes 
insipidus vertonen patiënten met de autosomaal recessieve vorm een normale 
stijging van weefsel plasminogeen activator antigeen na het toedienen van 1 
desamino-8-D Vasopressine (A van Lieburg, aangeboden voor publicatie) 
6 Kinderen behandeld met continue pentonaal dialyse hebben een toename van de 
gastro-oesophageale reflux (M Smeulders, aangeboden voor publicatie) 
7 Ook zonder gen-technologie is het mogelijk vernieuwend onderzoek te verrichten 
8 Het door de wereld passief toe laten van oorlogsmisdaden, zoals bijvoorbeeld in 
Bosnie, maakt het onmogelijk om onschuldigen te vinden die de misdadigers 
kunnen berechten 
9 Het tegenhouden van immigratie valt niet te verdedigen als de slachtoffers worden 
genegeerd en het Westen van mening blijft dat alle voordelen van het huidige 
beleid alleen voor onszelf zijn (W Tims, de Volkskrant 11 oktober 1994) 
10 Een kant van het ontwikkelingsbeleid is naar Nederlandse problemen te kijken met 
de ogen van mensen uit andere landen (J Pronk, Internationale Samenwerkjng, 
oktober 1993) 
11 Het is een restant van het kolonialisme om te denken dat mensenrechten, 
feminisme, filosofie, wetenschap en dergelijke, Westerse uitvindingen zijn 
Het zijn verworvenheden van de mensheid (Nawal El Saadawi) 
12 De mensen die zich schuldig voelen bij het genieten van het eten van een bonbon, 
zijn de oorspronkelijke betekenis van het woord vergeten 
Stellingen behorende bij het proefschrift "The hemolytic uremic syndrome in childhood 
A study of epidemiology and pathophysiology" 
Nijmegen, 17 november 1994 Nicole van de Kar 
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